0001493152-23-000793.txt : 20230106 0001493152-23-000793.hdr.sgml : 20230106 20230106160552 ACCESSION NUMBER: 0001493152-23-000793 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20230106 DATE AS OF CHANGE: 20230106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELECTIS HEALTH, INC. CENTRAL INDEX KEY: 0000727346 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 870340206 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15415 FILM NUMBER: 23515110 BUSINESS ADDRESS: STREET 1: 8480 E. ORCHARD ROAD STREET 2: SUITE 4900 CITY: GREENWOOD VILLAGE STATE: CO ZIP: 80111 BUSINESS PHONE: 720-680-0808 MAIL ADDRESS: STREET 1: 8480 E. ORCHARD ROAD STREET 2: SUITE 4900 CITY: GREENWOOD VILLAGE STATE: CO ZIP: 80111 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL HEALTHCARE REIT, INC. DATE OF NAME CHANGE: 20131004 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL CASINOS INC DATE OF NAME CHANGE: 19950413 FORMER COMPANY: FORMER CONFORMED NAME: MORGRO CHEMICAL CO DATE OF NAME CHANGE: 19920703 10-Q 1 form10-q.htm
0000727346 false Q3 --12-31 0000727346 2022-01-01 2022-09-30 0000727346 2023-01-06 0000727346 2022-09-30 0000727346 2021-12-31 0000727346 us-gaap:SeriesAPreferredStockMember 2022-09-30 0000727346 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000727346 us-gaap:SeriesDPreferredStockMember 2022-09-30 0000727346 us-gaap:SeriesDPreferredStockMember 2021-12-31 0000727346 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-09-30 0000727346 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0000727346 2021-01-01 2021-09-30 0000727346 2022-07-01 2022-09-30 0000727346 2021-07-01 2021-09-30 0000727346 GBCS:RentalMember 2022-01-01 2022-09-30 0000727346 GBCS:RentalMember 2021-01-01 2021-09-30 0000727346 GBCS:RentalMember 2022-07-01 2022-09-30 0000727346 GBCS:RentalMember 2021-07-01 2021-09-30 0000727346 us-gaap:HealthCareMember 2022-01-01 2022-09-30 0000727346 us-gaap:HealthCareMember 2021-01-01 2021-09-30 0000727346 us-gaap:HealthCareMember 2022-07-01 2022-09-30 0000727346 us-gaap:HealthCareMember 2021-07-01 2021-09-30 0000727346 GBCS:HealthcareGrantRevenueMember 2022-01-01 2022-09-30 0000727346 GBCS:HealthcareGrantRevenueMember 2021-01-01 2021-09-30 0000727346 GBCS:HealthcareGrantRevenueMember 2022-07-01 2022-09-30 0000727346 GBCS:HealthcareGrantRevenueMember 2021-07-01 2021-09-30 0000727346 GBCS:ManagementFeeRevenueMember 2022-01-01 2022-09-30 0000727346 GBCS:ManagementFeeRevenueMember 2021-01-01 2021-09-30 0000727346 GBCS:ManagementFeeRevenueMember 2022-07-01 2022-09-30 0000727346 GBCS:ManagementFeeRevenueMember 2021-07-01 2021-09-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-12-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-12-31 0000727346 us-gaap:CommonStockMember 2021-12-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000727346 us-gaap:RetainedEarningsMember 2021-12-31 0000727346 us-gaap:NoncontrollingInterestMember 2021-12-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-03-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-03-31 0000727346 us-gaap:CommonStockMember 2022-03-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000727346 us-gaap:RetainedEarningsMember 2022-03-31 0000727346 us-gaap:NoncontrollingInterestMember 2022-03-31 0000727346 2022-03-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-06-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-06-30 0000727346 us-gaap:CommonStockMember 2022-06-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000727346 us-gaap:RetainedEarningsMember 2022-06-30 0000727346 us-gaap:NoncontrollingInterestMember 2022-06-30 0000727346 2022-06-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2020-12-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2020-12-31 0000727346 us-gaap:CommonStockMember 2020-12-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000727346 us-gaap:RetainedEarningsMember 2020-12-31 0000727346 us-gaap:NoncontrollingInterestMember 2020-12-31 0000727346 2020-12-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-03-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-03-31 0000727346 us-gaap:CommonStockMember 2021-03-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000727346 us-gaap:RetainedEarningsMember 2021-03-31 0000727346 us-gaap:NoncontrollingInterestMember 2021-03-31 0000727346 2021-03-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-06-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-06-30 0000727346 us-gaap:CommonStockMember 2021-06-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000727346 us-gaap:RetainedEarningsMember 2021-06-30 0000727346 us-gaap:NoncontrollingInterestMember 2021-06-30 0000727346 2021-06-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-03-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-03-31 0000727346 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000727346 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000727346 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000727346 2022-01-01 2022-03-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-04-01 2022-06-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-04-01 2022-06-30 0000727346 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000727346 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000727346 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0000727346 2022-04-01 2022-06-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-07-01 2022-09-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-07-01 2022-09-30 0000727346 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000727346 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000727346 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-03-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-03-31 0000727346 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000727346 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000727346 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000727346 2021-01-01 2021-03-31 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-04-01 2021-06-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-04-01 2021-06-30 0000727346 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000727346 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000727346 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000727346 2021-04-01 2021-06-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-07-01 2021-09-30 0000727346 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000727346 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000727346 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2022-09-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2022-09-30 0000727346 us-gaap:CommonStockMember 2022-09-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000727346 us-gaap:RetainedEarningsMember 2022-09-30 0000727346 us-gaap:NoncontrollingInterestMember 2022-09-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0000727346 us-gaap:PreferredStockMember us-gaap:SeriesDPreferredStockMember 2021-09-30 0000727346 us-gaap:CommonStockMember 2021-09-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000727346 us-gaap:RetainedEarningsMember 2021-09-30 0000727346 us-gaap:NoncontrollingInterestMember 2021-09-30 0000727346 2021-09-30 0000727346 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-06-30 0000727346 srt:RestatementAdjustmentMember 2022-01-01 2022-06-30 0000727346 GBCS:AdjustedMember 2022-01-01 2022-06-30 0000727346 srt:ScenarioPreviouslyReportedMember GBCS:RentalMember 2022-01-01 2022-06-30 0000727346 srt:RestatementAdjustmentMember GBCS:RentalMember 2022-01-01 2022-06-30 0000727346 GBCS:AdjustedMember GBCS:RentalMember 2022-01-01 2022-06-30 0000727346 srt:ScenarioPreviouslyReportedMember us-gaap:HealthCareMember 2022-01-01 2022-06-30 0000727346 srt:RestatementAdjustmentMember us-gaap:HealthCareMember 2022-01-01 2022-06-30 0000727346 GBCS:AdjustedMember us-gaap:HealthCareMember 2022-01-01 2022-06-30 0000727346 srt:ScenarioPreviouslyReportedMember GBCS:HealthcareGrantRevenueMember 2022-01-01 2022-06-30 0000727346 srt:RestatementAdjustmentMember GBCS:HealthcareGrantRevenueMember 2022-01-01 2022-06-30 0000727346 GBCS:AdjustedMember GBCS:HealthcareGrantRevenueMember 2022-01-01 2022-06-30 0000727346 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-03-31 0000727346 srt:RestatementAdjustmentMember 2022-01-01 2022-03-31 0000727346 GBCS:AdjustedMember 2022-01-01 2022-03-31 0000727346 srt:ScenarioPreviouslyReportedMember us-gaap:HealthCareMember 2022-01-01 2022-03-31 0000727346 srt:RestatementAdjustmentMember us-gaap:HealthCareMember 2022-01-01 2022-03-31 0000727346 GBCS:AdjustedMember us-gaap:HealthCareMember 2022-01-01 2022-03-31 0000727346 srt:ScenarioPreviouslyReportedMember 2022-03-31 0000727346 srt:RestatementAdjustmentMember 2022-03-31 0000727346 GBCS:AdjustedMember 2022-03-31 0000727346 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000727346 srt:RestatementAdjustmentMember 2021-01-01 2021-12-31 0000727346 GBCS:AdjustedMember 2021-01-01 2021-12-31 0000727346 srt:ScenarioPreviouslyReportedMember us-gaap:HealthCareMember 2021-01-01 2021-12-31 0000727346 srt:RestatementAdjustmentMember us-gaap:HealthCareMember 2021-01-01 2021-12-31 0000727346 GBCS:AdjustedMember us-gaap:HealthCareMember 2021-01-01 2021-12-31 0000727346 srt:ScenarioPreviouslyReportedMember 2022-06-30 0000727346 srt:RestatementAdjustmentMember 2022-06-30 0000727346 GBCS:AdjustedMember 2022-06-30 0000727346 2022-01-01 2022-06-30 0000727346 us-gaap:LandMember 2022-09-30 0000727346 us-gaap:LandMember 2021-12-31 0000727346 us-gaap:LandImprovementsMember 2022-09-30 0000727346 us-gaap:LandImprovementsMember 2021-12-31 0000727346 us-gaap:BuildingImprovementsMember 2022-09-30 0000727346 us-gaap:BuildingImprovementsMember 2021-12-31 0000727346 GBCS:FurnitureFixturesAndEquipmentMember 2022-09-30 0000727346 GBCS:FurnitureFixturesAndEquipmentMember 2021-12-31 0000727346 GBCS:StateandMunicipalMember 2022-09-30 0000727346 GBCS:StateandMunicipalMember 2021-12-31 0000727346 GBCS:SeniorSecuredPromissoryNotesMember 2022-09-30 0000727346 GBCS:SeniorSecuredPromissoryNotesMember 2021-12-31 0000727346 GBCS:SeniorSecuredPromissoryNotesRelatedPartiesMember 2022-09-30 0000727346 GBCS:SeniorSecuredPromissoryNotesRelatedPartiesMember 2021-12-31 0000727346 GBCS:FixedRateMortgageLoansMember 2022-09-30 0000727346 GBCS:FixedRateMortgageLoansMember 2021-12-31 0000727346 GBCS:VariableRateMortgageLoansMember 2022-09-30 0000727346 GBCS:VariableRateMortgageLoansMember 2021-12-31 0000727346 GBCS:OtherDebtSubordinatedSecuredMember 2022-09-30 0000727346 GBCS:OtherDebtSubordinatedSecuredMember 2021-12-31 0000727346 GBCS:OtherDebtSubordinatedSecuredRelatedPartiesMember 2022-09-30 0000727346 GBCS:OtherDebtSubordinatedSecuredRelatedPartiesMember 2021-12-31 0000727346 GBCS:OtherDebtSubordinatedSecuredSellerFinancingMember 2022-09-30 0000727346 GBCS:OtherDebtSubordinatedSecuredSellerFinancingMember 2021-12-31 0000727346 GBCS:FixedRateMember 2022-09-30 0000727346 GBCS:FixedRateMember 2022-01-01 2022-09-30 0000727346 GBCS:VariableRateMember 2022-09-30 0000727346 GBCS:VariableRateMember 2022-01-01 2022-09-30 0000727346 GBCS:SeniorSecuredNotesMember srt:MinimumMember 2022-09-30 0000727346 GBCS:SeniorSecuredNotesMember srt:MaximumMember 2021-12-31 0000727346 GBCS:SeniorSecuredNotesMember 2022-01-01 2022-09-30 0000727346 stpr:AR GBCS:MortgageLoansMember 2022-09-30 0000727346 stpr:AR GBCS:MortgageLoansMember 2021-12-31 0000727346 stpr:GA GBCS:MortgageLoansMember 2022-09-30 0000727346 stpr:GA GBCS:MortgageLoansMember 2021-12-31 0000727346 stpr:OH GBCS:MortgageLoansMember 2022-09-30 0000727346 stpr:OH GBCS:MortgageLoansMember 2021-12-31 0000727346 stpr:OK GBCS:MortgageLoansMember 2022-09-30 0000727346 stpr:OK GBCS:MortgageLoansMember 2021-12-31 0000727346 GBCS:MortgageLoansMember 2022-09-30 0000727346 GBCS:MortgageLoansMember 2021-12-31 0000727346 GBCS:MortgageLoansMember 2022-01-01 2022-09-30 0000727346 GBCS:FirstMortgageLoanMember 2022-01-01 2022-09-30 0000727346 us-gaap:SecondMortgageMember 2022-01-01 2022-09-30 0000727346 GBCS:FirstMortgageLoanMember 2021-07-01 2021-07-31 0000727346 us-gaap:SecondMortgageMember 2021-07-01 2021-07-31 0000727346 GBCS:ThirdMortgageLoanMember 2021-07-01 2021-07-31 0000727346 2021-07-01 2021-07-31 0000727346 2021-07-31 0000727346 GBCS:GoodwillNursingHomeMember GBCS:OtherDebtMember 2022-09-30 0000727346 GBCS:GoodwillNursingHomeMember GBCS:OtherDebtMember 2021-12-31 0000727346 GBCS:GoodwillNursingHomeMember GBCS:OtherDebtMember 2022-01-01 2022-09-30 0000727346 GBCS:GoodwillNursingHomeOneMember GBCS:OtherDebtMember 2022-09-30 0000727346 GBCS:GoodwillNursingHomeOneMember GBCS:OtherDebtMember 2021-12-31 0000727346 GBCS:GoodwillNursingHomeOneMember GBCS:OtherDebtMember 2022-01-01 2022-09-30 0000727346 GBCS:HigherCallNursingCenterMember GBCS:OtherDebtMember 2022-09-30 0000727346 GBCS:HigherCallNursingCenterMember GBCS:OtherDebtMember 2021-12-31 0000727346 GBCS:HigherCallNursingCenterMember GBCS:OtherDebtMember 2022-01-01 2022-09-30 0000727346 GBCS:OtherDebtMember 2022-09-30 0000727346 GBCS:OtherDebtMember 2021-12-31 0000727346 GBCS:TenPercentageSeniorSecuredPromissoryNoteOneMember 2022-09-30 0000727346 GBCS:TenPercentageSeniorSecuredPromissoryNoteOneMember 2021-12-31 0000727346 GBCS:TenPercentageSeniorSecuredPromissoryNoteOneMember 2022-01-01 2022-09-30 0000727346 GBCS:ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember 2022-09-30 0000727346 GBCS:ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember 2021-12-31 0000727346 GBCS:ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember 2022-01-01 2022-09-30 0000727346 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-09-30 0000727346 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-09-30 0000727346 us-gaap:DividendDeclaredMember 2022-01-01 2022-09-30 0000727346 us-gaap:DividendDeclaredMember 2021-01-01 2021-09-30 0000727346 us-gaap:WarrantMember 2022-09-30 0000727346 us-gaap:WarrantMember 2021-12-31 0000727346 us-gaap:WarrantMember 2022-01-01 2022-09-30 0000727346 us-gaap:WarrantMember 2021-01-01 2021-12-31 0000727346 GBCS:MrCliffordNeumanMember 2022-09-30 0000727346 GBCS:MrCliffordNeumanMember 2021-12-31 0000727346 GBCS:MrCliffordNeumanMember 2022-01-01 2022-09-30 0000727346 GBCS:MrCliffordNeumanMember 2021-01-01 2021-12-31 0000727346 us-gaap:GoodwillMember 2022-01-01 2022-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure GBCS:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

 QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2022

 

OR

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

 

For the transition period from _______ to ______

 

Commission file number 0-15415

 

Selectis Health, Inc.

(Exact name of Registrant as specified in its Charter)

 

Utah   87-0340206
(State or other jurisdiction of   I.R.S. Employer
incorporation or organization)   Identification number

 

8480 E Orchard Rd, Ste 4900,    
Greenwood Village, CO   80111
(Address of principal executive offices)   (Zip Code)

 

Issuer’s telephone number: (720) 680-0808

 

Check whether the Issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the last 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer Smaller Reporting Company

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

 

As of January 06, 2023, the Registrant had 3,067,059 shares of its Common Stock outstanding.

 

 

 

 
 

 

INDEX

 

    Page
    No.
  PART I — FINANCIAL INFORMATION  
     
Item 1. Condensed Consolidated Financial Statements (Unaudited) 3
     
  Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021 3
     
  Condensed Consolidated Statements of Operations for the Nine and Three Months Ended September 30, 2022, and 2021 (Unaudited) 4
     
  Condensed Consolidated Statements of Changes in Equity for the Nine and Three Months Ended September 30, 2022, and September 30, 2021 (Unaudited) 5 
     
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2022 and 2021 (Unaudited) 6
     
  Notes to Condensed Consolidated Financial Statements (Unaudited) 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 24
     
Item 4. Controls and Procedures 24
     
  PART II - OTHER INFORMATION  
     
Item 1. Legal Proceedings 24
     
Item 1A. Risk Factors 31
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32
     
Item 3. Defaults Upon Senior Securities 32
     
Item 4. Mine Safety Disclosures 32
     
Item 5. Other Information 32
     
Item 6. Exhibits 32

 

2

 

 

PART 1. FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Financial Statements (Unaudited)

 

SELECTIS HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   September 30, 2022   December 31, 2021 
    Unaudited       
ASSETS          
Current Assets          
Cash  $1,928,472   $3,939,445 
Accounts Receivable, Net of allowance   3,064,919    3,506,719 
Prepaid Expenses and Other   462,868    498,015 
Investments in Debt Securities   24,387    24,387 
Total Current Assets   5,480,646    7,968,566 
           
Long Term Assets          
Restricted Cash   831,687    853,656 
Property and Equipment, Net   36,006,716    37,024,592 
Goodwill   1,076,908    1,076,908 
Total Assets  $43,395,957   $46,923,722 
           
LIABILITIES AND EQUITY          
Liabilities          
Accounts Payable and Accrued Liabilities  $2,478,953   $4,363,917 
Accounts Payable – Related Parties   -    21,571 
Dividends Payable   7,500    7,500 
Short term debt – Related Parties, Net of discount of $0 and $3,234, respectively   150,000    150,000 
Current Maturities of Long Term Debt, Net of Discount of $1,184 and $1,714, respectively   2,049,750    6,312,562 
Other Current Liability   -    931,446 
Total Current Liabilities   4,686,203    11,786,996 
           
Debt- Related Parties   750,000    750,000 
Debt, Net of discount of $933,737 and $452,593, respectively   34,528,330    31,054,962 
Lease Security Deposit   253,899    229,582 
Total Liabilities  $40,218,432   $43,821,540 
           
Commitments and Contingencies   -    - 
Equity          
Preferred Stock:          
Series A - No Dividends, $2.00 Stated Value, Non-Voting; 2,000,000 Shares Authorized, 200,500 Shares Issued and Outstanding   401,000    401,000 
Series D - 8% Cumulative, Convertible, $10.00 Stated Value, Non-Voting; 1,000,000 Shares Authorized, 375,000 Shares Issued and Outstanding   375,000    375,000 
Common Stock - $0.05 Par Value; 800,000,000 Shares Authorized, 3,054,588 and 2,998,362 Shares Issued and Outstanding at September 31, 2022 and December 31, 2021, respectively   152,728    150,168 
Additional Paid-In Capital   13,793,300    13,494,394 
Accumulated Deficit   (11,544,503)   (11,318,380)
Total Selectis Health, Inc. Stockholders’ Equity   3,177,525    3,102,182 
Total Liabilities and Equity  $43,395,957   $46,923,722 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

3

 

 

SELECTIS HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

   2022   2021   2022   2021 
   Nine Months Ended   Three Months Ended 
   September 30,   September 30, 
   2022   2021   2022   2021 
                 
Revenue                    
Rental Revenue  $469,938   $933,360   $158,875   $155,071 
Healthcare Revenue   26,438,806    17,431,882    9,135,306    6,939,841 
Healthcare Grant Revenue   2,891,463    504,550    287,804    - 
Management Fee Revenue   -    224,143    -    224,143 
Total Revenue   29,800,207    19,093,935    9,581,985    7,319,055 
Expenses                    
Property Taxes, Insurance and Other Operating   21,192,559    12,613,896    7,227,718    4,413,930 
General and Administrative   5,329,475    4,732,115    1,970,890    1,721,292 
Provision for Bad Debts   783,524    28,275    252,050    12,142 
Depreciation   1,348,645    1,286,279    453,608    435,013 
Total Expenses   28,654,203    18,660,565    9,904,266    6,582,377 
Income (Loss) from Operations   1,146,004    433,370    (322,281)   736,678 
Other (Income) Expense                    
Loss (Gain) on Extinguishment of Debt   46,466    -    -    - 
Interest Expense, net   1,438,629    1,680,540    722,226    486,816 
Gain on Forgiveness of PPP Loan   -    (675,598)   -    - 
Other Income   (135,468)   (548,933)   (53,582)   (51,856)
Lease Termination Expense   -    450,427    -    354,710 
Total Other Expense   1,349,627    906,436    668,644    789,670 
Net Loss   (203,623)   (473,066)   (990,925)   (52,992)
Net Loss Attributable to Noncontrolling Interests   -    (10,650)   -    - 
Net Loss Attributable to Selectis Health, Inc.   (203,623)   (483,716)   (990,925)   (52,992)
Series D Preferred Dividends   (22,500)   (22,500)   (7,500)   (7,500)
Net Loss Attributable to Common Stockholders  $(226,123)  $(506,216)  $(998,425)  $(60,492)
Per Share Data:                    
Net Loss per Share Attributable to Common Stockholders:                    
Basic  $(0.07)  $(0.18)  $(0.33)  $(0.02)
Diluted  $(0.07)  $(0.18)  $(0.33)  $(0.02)
Weighted Average Common Shares Outstanding:                    
Basic   3,053,970    2,741,186    3,054,588    2,824,560 
Diluted   3,053,970    2,741,186    3,054,588    2,824,560 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4

 

 

SELECTIS HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(UNAUDITED)

 

                                                  
   Series A Preferred Stock   Series D Preferred Stock   Common Stock   Additional       Non-   Selectis Health, Inc. 
   Number
of Shares
  Amount   Number
of Shares
  Amount   Number
of Shares
   Amount   Paid-In
Capital
   Accumulated
Deficit
   Controlling
Interests
   Stockholders’
Equity
 
                                                  
Balance, December 31, 2021   200,500   $401,000    375,000   $375,000    2,998,362   $150,168   $13,494,394   $(11,318,380)             -   $3,102,182 
Series D Preferred Dividends   -     -     -     -     -     -     -     (7,500)   -     (7,500)
Common shares issued for debt   -    -    -    -    56,226    2,560    252,440    -    -    255,000 
Loss on Forgiveness of Debt   -    -    -    -    -    -    46,466    -    -    46,466 
Net Income   -    -    -    -    -    -    -    37,090    -    37,090 
Balance, March 31, 2022 as adjusted   200,500   $401,000    375,000   $375,000    3,054,588   $152,728   $13,793,300   $(11,288,790)   -   $3,433,238 
Series D Preferred Dividends   -     -     -     -     -     -     -     (7,500)   -     (7,500)
Net Income   -    -    -    -    -    -    -    750,212    -    750,212 
Balance, June 30, 2022 as adjusted   200,500   $401,000    375,000   $375,000    3,054,588   $152,728   $13,793,300   $(10,546,078)   -   $4,175,950 
Series D Preferred Dividends   -     -     -     -     -     -     -     (7,500)   -     (7,500)
Net Loss   -    -    -    -    -    -    -    (990,925)   -    (990,925)
Balance, September 30, 2022   200,500   $401,000    375,000   $375,000    3,054,588   $152,728   $13,793,300   $(11,544,503)   -   $3,177,525 

 

   Series A Preferred Stock   Series D Preferred Stock   Common Stock   Additional       Non-   Selectis Health, Inc. 
   Number
of Shares
   Amount   Number
of Shares
   Amount   Number
of Shares
   Amount   Paid-In
Capital
   Accumulated
Deficit
   Controlling
Interests
   Stockholders’
Equity
 
                                         
Balance, December 31, 2020   200,500   $401,000    375,000   $375,000    2,686,638   $134,332   $11,540,052   $(9,036,400)   (198,045)  $3,215,939 
Series D Preferred Dividends   -    -    -    -    -    -    -    (7,500)   -    (7,500)
Net Income   -    -    -    -    -    -    -    248,056    10,650    258,706 
Balance, March 31, 2021   200,500   $401,000    375,000   $375,000    2,686,638   $134,332   $11,540,052   $(8,795,844)   (187,395)  $3,467,145 
Series D Preferred Dividends   -    -    -    -    -    -    -    (7,500)   -    (7,500)
Share Based Compensation – Restricted Stock Awards   -    -    -    -    3,000    150    18,750    -    -    18,900 
Cashless Exercise of Warrants   -    -    -    -    2,857    143    (143)   -    -    - 
Purchase of Non-Controlling Interest   -    -    -    -    -    -    (247,395)   -    187,395    (60,000)
Net Income   -    -    -    -    -    -    -    (678,780)   -    (678,780)
Balance, June 30, 2021   200,500   $401,000    375,000   $375,000    2,692,495   $134,625   $11,311,264   $(9,482,124)   -   $2,739,765 
Series D Preferred Dividends   -    -    -    -    -              (7,500)   -    (7,500)
Issuance of common stock for cash   -    -    -    -    150,000    7,500    706,125    -    -    713,625 
Cashless Exercise of Warrants   -    -    -    -    16,667    833    (833)   -    -    - 
Cashless Exercise of Stock Options   -    -    -    -    31,200    1,560    (1,560)   -    -    - 
Net Income   -    -    -    -    -    -    -    (52,992)   -    (52,992)
Balance, September 30, 2021   200,500   $401,000    375,000   $375,000    2,890,362   $144,518   $12,041,996   $(9,542,616)   -   $3,392,898 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

5

 

 

SELECTIS HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   2022   2021 
   Nine Months Ended September 30, 
   2022   2021 
Cash Flows From Operating Activities:          
Net Income (Loss)  $(203,623)  $(473,066)
Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by (Used in) Operating Activities:          
Gain on Forgiveness from PPP Loan   -    (675,598)
Other Income from Partial Settlement of Debt   (40,346)   (520,221)
Depreciation and Amortization   1,348,645    1,286,279 
Amortization of Deferred Loan Costs and Debt Discount   -   157,291 
Provision for Bad Debt   783,524    28,275 
Stock Based Compensation   -    18,900 
Changes in Operating Assets and Liabilities, Net of Assets and Liabilities Acquired:          
Accounts and Rents Receivable   (341,724)   (2,535,412)
Prepaid Expenses and Other Assets   616,540    853,451 
Accounts Payable and Accrued Liabilities   (2,837,981)   248,337 
Lease Security Deposits   24,317    7,000 
Cash Used in Operating Activities   (650,648)   (1,604,764)
           
Cash Flows From Investing Activities:          
Capital Expenditures for Property and Equipment   (330,769)   (493,689)
Cash Used in Investing Activities   (330,769)   (493,689)
           
Cash Flows From Financing Activities:          
Proceeds from Issuance of Debt, Non-Related Party   -    9,134,102 
Payments on Debt, Non-Related Party   (1,075,491)   (8,023,719)
Dividends Paid on Preferred Stock   

(22,500

)   (30,000)
Proceeds from stock offering   -    713,625 
Purchase of Non-Controlling Interest   -    (60,000)
Debt Discount – Warrants RP   46,466    - 
Cash (Used in) Provided by Financing Activities   (1,051,525)   1,734,008 
           
Net Decrease in Cash, Cash Equivalents and Restricted Cash   (2,032,942)   (364,445)
Cash and Cash Equivalents and Restricted Cash at Beginning of the Period   4,793,101    3,978,303 
Cash and Cash Equivalents and Restricted Cash at End of the Period  $2,760,159   $3,613,858 
           
Supplemental Disclosure of Cash Flow Information          
Cash Paid for Interest   

1,438,629

    1,680,540 
Cash   1,928,472    2,791,585 
Restricted Cash   831,687    822,273 
Total Cash and Cash Equivalents and Restricted Cash   2,760,159    3,613,858 
           
Supplemental Schedule of Non-Cash Investing and Financing Activities          
Dividends Declared on Series D Preferred Stock  $22,500   $22,500 
Issuance of common stock for cashless exercise of warrants   -    976 
Issuance of common stock for cashless exercise of options   -    1,560 
Financing of Insurance Premiums   581,393    507,433 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

6

 

 

SELECTIS HEALTH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Organization and Description of the Business

 

Selectis Health, Inc (“Selectis” or “we” or the “Company”) owns and operates, through wholly-owned subsidiaries Assisted Living Facilities, Independent Living Facilities, and Skilled Nursing Facilities across the South and Southeastern portions of the US. In 2019 the Company shifted from leasing long-term care facilities to third-party, independent operators towards an owner operator model.

 

Prior to the Company changing its name to Selectis Health, Inc., the Company was known as Global Healthcare REIT, Inc. from September 30, 2013, to May 2021. Prior to this, the Company was known as Global Casinos, Inc. Global Casinos, Inc. operated two gaming casinos which were split-off and sold on September 30, 2013. Simultaneous with the split-off and sale of the gaming operations, the Company acquired West Paces Ferry Healthcare REIT, Inc. (“WPF”). WPF was merged into the Company in 2019.

 

We acquire, develop, lease, manage, and dispose of healthcare real estate, provide financing to healthcare providers, and provide healthcare operations through our wholly-owned subsidiaries. Our portfolio is comprised of investments in the following three healthcare segments: (i) senior housing (including independent and assisted living), (ii) post-acute/skilled nursing, and (iii) bonds securing senior housing communities. We will make investments within our healthcare segments using the following six investment products: (i) direct ownership of properties, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management, (v) the Housing and Economic Recovery Act of 2008 (“RIDEA”), which represents investments in senior housing operations utilizing the structure permitted by RIDEA and (xi) owning healthcare operations.

 

Management’s Liquidity Plans

 

On August 27, 2014, FASB issued ASU 2014-05, Disclosure of Uncertainties about an Entity’s ability to Continue as a Going Concern, which requires management to assess a company’s ability to continue as a going concern within one year from financial statement issuance and to provide related footnote disclosures in certain circumstances.

 

For the nine months ended September 30, 2022, the Company had negative operating cash flows of $0.7 million and a net working capital of $0.8 million. Management believes that the Company has the ability to meet its obligations for the next twelve months from the date of these financial statements. This is, in part due to refinancing debt to more favorable terms, and the optimization of our operations in our current facilities. Based on management’s projections we expect to generate positive cash flows positive cash flows from its continued operations.

 

7

 

 

The focus on opportunities within our current portfolio and future properties to acquire and operate, the settlement, refinance, and continued service of debt obligations, the potential funds generated from stock sales and other initiatives contributing to additional working capital should alleviate any substantial doubt about the Company’s ability to continue as a going concern as defined by ASU 2014-05. However, we cannot predict, with certainty, the outcome of our actions to generate liquidity and the failure to do so could negatively impact our future operations.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and in conjunction with the rules and regulations of the Securities Exchange Commission. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary to make the consolidated financial statements not misleading have been included. Operating results for the nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the entire year. The unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission.

 

In May 2021, the board of directors of the Company approved a one-for-ten reverse stock split of the Company’s issued and outstanding shares of common stock. On September 21, 2021, the Company filed Amendment No. 1 to its Second Amended and Restated Articles of Incorporation reflecting the reverse split and name change. This took effect on September 22, 2021 upon approval from FINRA. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto, and elsewhere in this Form 10-Q, have been retroactively adjusted to give effect to the reverse stock split as if such reverse stock split occurred on the first day of the first period presented.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Recently Issued Accounting Pronouncements

 

The Financial Accounting Standards Board and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2022. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term.

 

Reclassification

 

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. Certain intercompany revenues and expenses were included in revenue and general and administration expenses. These reclassifications had no effect on the previously reported net income.

 

Revisions to Previously Issued Financial Statements

 

For the six months ending June 30, 2022, the Company identified an error related to the accounting guidance for intercompany revenues and expenses. For the six months ending June 30, 2022 the Company recorded $869,249 of intercompany revenues to healthcare revenue and $869,249 of intercompany expenses in general and administrative expenses.

 

The Company assessed the materiality of this error on prior period financial statements in accordance with the SEC Staff Accounting Bulletin Number 99, Materiality, and ASC 250-10, Accounting Changes and Error Corrections. The error did not have any effect on the Company’s previously reported Condensed Consolidated Statements of Cash Flows and Condensed Consolidated Statements of Shareholder’s Deficit. The Company determined that this error was not material to the financial statements for the six months ended June 30, 2022. The Company decided to correct this immaterial error as revision to previously issued financial statement and has revised the June 30, 2022 financial statements presented herein.

 

The below tables summarize the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations for the six months ended June 30, 2022:

 

   As previously reported   Revision adjustments   As revised 
   Six Months Ended 
   June 30, 2022 
   As previously reported   Revision adjustments   As revised 
Revenue               
Rental Revenue  $311,063   $-   $311,063 
Healthcare Revenue   18,642,051    (869,249)   17,772,802 
Healthcare Grant Revenue   2,603,659    -    2,603,659 
Total Revenue   21,556,773    (869,249)   20,987,524 
Expenses               
Property Taxes, Insurance and Other Operating   13,964,841         13,964,841 
General and Administrative   4,227,834    (869,249)   3,358,585 
Provision for Bad Debts   531,474         531,474 
Depreciation and Amortization   895,037         895,037 
Total Expenses   19,619,186    (869,249)   18,749,937 
Income from Operations   1,937,587         1,937,587 
Other (Income) Expense               
Loss (Gain) on Extinguishment of Debt   46,466         46,466 
Interest Expense, net   716,403         716,403 
Gain on Forgiveness of PPP Loan   -         - 
Other Income   (81,886)        (81,886)
Lease Termination Expense   -         - 
Total Other (Income) Expense   680,983         680,983 
Net Income (Loss)  $1,256,604        $1,256,604 

  

During the preparation of the nine months ending September 30, 2022, financial statements management became aware of misstatements in the financial statements of $191,589 and $469,302 of healthcare revenue and accounts receivable reported during the three and six month periods ended March 31, 2022 and June 30, 2022, respectively.

 

The Company determined that cash payments received from a Medicare B bad debt reimbursement program were recorded directly to revenue rather than a reduction to the account receivable account to which the receivables were recorded, causing both revenue and receivables to be overstated at each reporting periods.

 

The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended March 31, 2022:

 

   Reported   Revision adjustments   Adjusted 
Three months ended March 31, 2022
   Reported   Revision adjustments   Adjusted 
P&L Analysis               
Total Revenue  $10,091,006   $(191,589)  $9,899,417 
Healthcare Revenue   9,367,854    

(191,589

)   9,176,265 
Operating Income   615,396    (191,589)   423,807 
Net Income   228,679    (191,589)   37,090 
EPS   0.07         0.01 
WASO   3,052,769         3,052,769 
                
Balance Sheet Analysis               
Accounts Receivable  $4,168,272   $

(191,589

)  $3,976,683 
Current Assets   7,474,534    

(191,589

)   7,282,945 
Total Assets   46,086,051    

(191,589

)   45,894,462 
Working Capital   38,478,308    

(191,589

)   38,286,719 
Accumulated Deficit   (11,089,701)  (191,589)   (11,281,290)
Total Equity   3,632,327    

(191,589

)   3,440,738 

 

The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended June 30, 2022:

 

   YTD Reported   Revision adjustment   YTD Adjusted   QTD Reported   Revision adjustment   QTD Adjusted 
Three and six months ended June 30, 2022
   YTD Reported   Revision adjustment   YTD Adjusted   QTD Reported   Revision adjustment   QTD Adjusted 
P&L analysis                              
Total Revenue  $20,687,524   $

(469,302

)  $20,218,222   $10,596,518   $

(277,713

)  $10,318,805 
Healthcare Revenue   17,772,802    (469,302)   17,303,500    8,404,948    (277,713)   8,127,235 
Operating Income   1,937,587    

(469,302

)   1,468,285    1,321,651    

(277,713

)   1,043,938 
Net Income   1,256,604    (469,302)   787,302    1,027,925    

(277,713

)   750,212 
EPS   0.42         0.26    0.34         0.25 
WASO   2,998,361         2,998,361    3,054,627         3,054,627 
                               
Balance Sheet analysis                              
Accounts Receivable  $5,167,862   $

(469,302

)  $4,698,560                
Current Assets   8,789,109    

(469,302

)   8,319,807                
Total Assets   47,014,470    

(469,302

)   46,545,168                
Working Capital   32,534,605    

(469,302

)   32,065,303                
Accumulated Deficit   (10,061,776)   (469,302)   (10,531,078)               
Total Equity   4,660,252    

(469,302

)   4,190,950                

 

8

 

 

Earnings per Share

 

Basic earnings per share are based on the weighted-average number of shares of common stock outstanding. FASB ASC Topic 260, “Earnings per Share”, requires the Company to include additional shares in the computation of earnings per share, assuming dilution.

 

Diluted earnings per share are based on the assumption that all dilutive options and warrants were converted or exercised by applying the treasury stock method and that all convertible preferred stock were converted into common shares by applying the if-converted method. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period or at the time of issuance, if later, and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, the preferred dividends applicable to convertible preferred stock are added back to the numerator. The convertible preferred stock is assumed to have been converted at the beginning of the period or at time of issuance, if later, and the resulting common shares are included in the denominator.

 

We calculate basic earnings per share by dividing net income attributable to common stockholders (the “numerator”) by the weighted average number of common shares outstanding (the “denominator”) during the reporting period. Diluted earnings per share is calculated similarly but reflects the potential impact of outstanding options, warrants and other commitments to issue common stock, including shares issuable upon the conversion of convertible preferred stock outstanding, except where the impact would be anti-dilutive.

 

The following table sets forth the computation of basic and diluted earnings per share:

 

   2022   2021   2022   2021 
   Nine Months Ended   Three Months Ended 
   September 30,   September 30, 
   2022   2021   2022   2021 
Numerator for basic earnings per share:                    
Net Income (Loss) Attributable to Selectis Health, Inc.   (203,623)   (483,716)   (990,925)   (52,992)
Series D Preferred Dividends   (22,500)   (22,500)   (7,500)   (7,500)
Net Income (Loss) Attributable to Common Stockholders - Basic   (226,123)   (506,216)   (998,425)   (60,492)
                     
Numerator for diluted earnings per share:                    
Net Income (Loss) Attributable to Common Stockholders   (226,123)   (506,216)   (998,425)   (60,492)
Series D Preferred Dividends   22,500    22,500    7,500    7,500 
Net Income (Loss) Attributable to Common Stockholders - Diluted   (203,623)   (483,716)   (990,925)   (52,992)
                     
Denominator for basic earnings per share:                    
Weighted Average Common Shares Outstanding   3,053,970    2,741,186    3,054,588    2,824,560 
                     
Denominator for diluted earnings per share:                    
Weighted Average Common Shares Outstanding - Basic   3,053,970    2,741,186    3,054,588    2,824,560 
Effect of dilutive securities:                    
Conversion of preferred shares   -    -    -    - 
Exercise of warrants   -    -    -    - 
Weighted Average Common Shares Outstanding - Diluted   3,053,970    2,741,186    3,054,588    2,824,560 
                     
Net Income (Loss) per Share Attributable to Common Stockholders:                    
Basic   (0.07)   (0.18)   (0.33)   (0.02)
Diluted   (0.07)   (0.18)   (0.33)   (0.02)

 

9

 

 

Fair Value Measurements

 

The Company utilizes the methods of fair value measurement as described in ASC 820 to value its financial assets and liabilities. As defined in ASC 820, fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

 

Level 1 – Quoted market prices in active markets for identical assets or liabilities at the measurement date.

 

Level 2 – Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data.

 

Level 3 – Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments.

 

A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

 

The Company has no financial assets or financial liabilities that are required to be measured at fair value on a recurring basis as of September 30, 2022.

 

Our consolidated balance sheets include the following financial instruments: cash and cash equivalents, accounts receivable, restricted cash, accounts payable, debt and lease security deposit. We consider the carrying values of our short-term financial instruments to approximate fair value because they generally expose the Company to limited credit risk, because of the short period of time between origination of the financial assets and liabilities and their expected settlement, or because of their proximity to acquisition date fair values. The carrying value of debt approximates fair value based on borrowing rates currently available for debt of similar terms and maturities.

 

Upon acquisition of real estate properties, the Company determines the total purchase price of each property and allocates this price based on the fair value of the tangible assets and intangible assets, if any, acquired and any liabilities assumed based on Level 3 inputs. These Level 3 inputs can include comparable sales values, discount rates, and capitalization rates from a third-party appraisal or other market sources.

 

 

10

 

 

3. PROPERTY AND EQUIPMENT, NET

 

The gross carrying amount and accumulated depreciation of the Company’s property and equipment as of September 30, 2022, and December 31, 2021, are as follows:

 

   September 30, 2022   December 31, 2021 
         
Land  $1,778,250   $1,778,250 
Land Improvements   329,055    329,055 
Buildings and Improvements   43,230,535    44,574,401 
Furniture, Fixtures and Equipment   2,436,932    2,322,297 

Property and Equipment, gross

   47,774,772    49,004,003 
           
Less Accumulated Depreciation   (11,768,056)   (10,419,411)
           

Property and Equipment, net

  $36,006,716   $37,024,592 

 

   2022   2021 
   For the Nine Months Ended September 30, 
   2022   2021 
         
Depreciation Expense (excluding Intangible Assets)  $1,348,645   $1,286,279 

 

4. INVESTMENTS IN DEBT SECURITIES

 

At September 30, 2022 and December 31, 2021, the Company held investments in debt securities that were classified as held-to-maturity and carried at amortized costs. Held-to-maturity securities consisted of the following:

 

   September 30, 2022   December 31, 2021 
            
States and Municipalities  $24,387   $24,387 

 

Contractual maturity of held-to-maturity securities at September 30, 2022, is $24,387, all due in one year or less, and total value of securities at their respective maturity dates is $24,387. Actual maturities may differ from contractual maturities because some borrowers have the right to call or prepay obligations with or without call or prepayment penalties.

 

11

 

 

5. DEBT AND DEBT - RELATED PARTIES

 

The following is a summary of the Company’s debt outstanding as of September 30, 2022, and December 31, 2021:

 

   September 30, 2022   December 31, 2021 
Senior Secured Promissory Notes  $1,025,000   $1,305,000 
Senior Secured Promissory Notes - Related Parties   750,000    750,000 
Fixed-Rate Mortgage Loans   30,695,361    31,407,503 
Variable-Rate Mortgage Loans   4,919,504    5,063,841 
Other Debt, Subordinated Secured   

741,000

    

741,000

 
Other Debt, Subordinated Secured - Related Parties   150,000    150,000 
Other Debt, Subordinated Secured - Seller Financing   65,361    93,251 
Debt Instrument, Gross   38,346,641    39,510,595 
Unamortized Discount and Debt Issuance Costs   (868,561)   (1,243,071)
           
Debt Instrument, Net of Discount  $37,478,080   $38,267,524 
As presented in the Consolidated Balance Sheets:          
           
Current Maturities of Long Term Debt, Net  $2,049,750   $6,312,562 
Short term debt – Related Parties, Net   150,000    150,000 
Debt, Net   34,528,330    31,054,962 
Debt – Related Parties, Net   750,000    750,000 

 

The weighted average interest rate and term of our fixed rate debt are 4.03% and 16.33 years, respectively, as of September 30, 2022. The weighted average interest rate and term of our variable rate debt are 5.90% and 16.11 years, respectively, as of September 30, 2022.

 

Corporate Senior and Senior Secured Promissory Notes

 

As of September 30, 2022, and December 31, 2021, the senior secured notes are subject to annual interest ranging from 10% to 11% and initially matured on October 31, 2021. These notes were extended to June 30, 2023 and as consideration the Company modified the outstanding warrants to extend the life and additional 1.67 years. As a result of the warrant modification, the Company recorded the incremental increase in fair value of $844,425 as a debt discount which will be amortized over the new life of the loans.

 

12

 

 

Mortgage Loans and Lines of Credit Secured by Real Estate

 

Mortgage loans and other debts such as line of credit here are collateralized by all assets of each nursing home property and an assignment of its rents. Collateral for certain mortgage loans includes the personal guarantee of Christopher Brogdon, formerly but no longer a related party, or corporate guarantees. Mortgage loans for the periods presented consisted of the following:

 

   Number of   Total Face   Total Principal Outstanding as of 
State  Properties   Amount   September 30, 2022   December 31, 2021 
Arkansas(1)   1   $5,000,000   $3,937,978   $4,058,338 
Georgia(2)   5   $17,765,992   $16,156,093   $16,581,232 
Ohio   1   $3,000,000   $2,728,599   $2,728,599 
Oklahoma(3)   6   $13,331,325   $12,792,194   $12,895,890 
    13   $39,097,317   $35,614,825   $36,264,059 

 

(1)The mortgage loan collateralized by this property is 80% guaranteed by the USDA and requires an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year. Guarantors under the mortgage loan include Christopher Brogdon. Mr. Brogdon has assumed operations of the facility and is making payments of principal and interest on the loan on our behalf in lieu of paying rent on the facility to us. During the nine months ended September 30, 2022, the Company recognized other income of $118,716 for repayments on the loan.
  
(2)The Company has refinanced two of its mortgages that would have matured in June and October of 2021 amounting to $2,961,167 and $3,289,595, to extend their maturity dates to May 2024 for both.
  
(3)The Company refinanced all three mortgages in July 2021, that would have matured in June and July of 2021 amounting to $2,065,969, $750,000, and $500,000, to extend their maturity dates to June, 2027 for all three. Additionally, the Company has refinanced the primary mortgage at the Southern Hills Campus, for 35 years at 2.38%

 

Subordinated, Corporate and Other Debt

 

Other debt due at September 30, 2022 and December 31, 2021 includes unsecured notes payable issued to entities controlled by the Company used to facilitate the acquisition of the nursing home properties.

 

       Principal Outstanding at   Stated Interest   
Property  Face Amount   September 30, 2022   December 31, 2021   Rate  Maturity Date
Goodwill Nursing Home (1)  $2,030,000   $741,000   $741,000   13% Fixed  December 31, 2019
Goodwill Nursing Home - Related Party (1)  $150,000   $150,000   $150,000   13% Fixed  December 31, 2019
Higher Call Nursing Center (2)  $150,000   $65,361   $93,251   8% Fixed  April 1, 2024
                      
        $956,361   $984,251       

 

13

 

 

Our corporate debt at September 30, 2022, and December 31, 2021 includes unsecured notes and notes secured by all assets of the Company not serving as collateral for other notes.

 

       Principal Outstanding at   Stated Interest   
Series  Face Amount   September 30, 2022   December 31,2021   Rate  Maturity Date
                   
10% Senior Secured Promissory Notes   1,670,000    1,025,000    1,305,000   10.0% Fixed  June 30, 2024
11% Senior Secured Promissory Notes – Related Party   975,000    750,000    750,000   10.0% Fixed  June 30, 2024
                      
        $1,025,000   $2,055,000       

 

6. STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

During the nine months ended September 30, 2022 and 2021, the Company paid $15,000 and $30,000 respectively for Series D preferred stock dividends. Dividends of $22,500 were declared during the nine months ended September 30, 2022 and September 30, 2021. All quarterly dividends previously declared have been paid.

 

Common Stock

 

For the nine months ended September 30, 2022, the Company did not issue nor did it pay dividends on common stock.

 

14

 

 

Common Stock Warrants

 

As of September 30, 2022, and December 31, 2021, the Company had 206,000, of outstanding warrants to purchase common stock at a weighted average exercise price of $5.00, respectively, and weighted average remaining term of 0.19 years and 0.93 years, respectively. The aggregate intrinsic value of common stock warrants outstanding as of September 30, 2022, and December 31, 2021 was $360,052 and $355,877, respectively. Activity for the nine months ended September 30, 2022, related to common stock warrants is as follows:

 

   September 30, 2022 
   Number of   Weighted Average 
   Warrants   Exercise Price 
         
Beginning Balance   206,000   $5 
Exercised   -    - 
Expired   -             - 
           
Ending Balance   206,000   $5 

 

7. OTHER CURRENT LIABILITY

 

During the year ended December 31, 2021 the Company received an overpayment from Medicare of $931,446. Beginning in February, 2022 payments were recouped to satisfy the overpayment. As of September 30, 2022, this liability has been satisfied.

 

8. RELATED PARTIES

 

Clifford Neuman, a former member of the Company’s Board of Directors, provided legal services to the Company. As of September 30, 2022, and December 31, 2021, the Company owed Mr. Neuman for legal services rendered $5,640 and $21,571, respectively. During the nine months ended September 30, 2022 the Company has paid Mr. Neuman $64,433 for legal services. During the year ended December 31, 2021 the Company paid Mr. Neuman $158,392 for legal services.

 

8. FACILITY LEASES

 

The following table summarizes our leasing arrangements related to the Company’s healthcare facilities at September 30, 2022:

 

   Monthly Lease       
Facility  Income (1)   Lease Expiration  Renewal Option if any
Goodwill (1)  $48,125   February 1, 2027  Term may be extended for one additional five-year term.

 

(1) The lease became effective on February 1, 2017, and the facility began generating rental revenue thereafter.

 

Future cash payments for rent to be received during the initial terms of the leases for the next five years and thereafter are as follows:

 

Years Ending September 30,    
2022  $156,870 
2023   635,026 
2024   643,401 
2025   651,954 
2026   660,665 
2027 and Thereafter   55,116 
      
Total  $2,803,032 

 

15

 

 

9. LEGAL PROCEEDINGS

 

The Company and/or its affiliated subsidiaries are or were involved in the following litigation:

 

Bailey v. GL Nursing, LLC, et. Al in the Circuit Court of Lonoke County, Arkansas, 23rd Circuit, 43CV-19-151.

 

In April 2019, the Company’s wholly-owned subsidiary was named as a co-defendant in the action arising out of a claimed personal injury suffered by the plaintiff while a resident of the skilled nursing home owned, but not operated, by GL Nursing. As of this date, we have engaged legal counsel, but no further information is known regarding the merits of the claim. After initial inquiry, it does not appear that the lease operator of the facility had in effect general liability insurance covering the GL Nursing, as landlord, as required by the operating lease.

 

As we simply were the owners of the property and not the operators, we believe that primary responsibility, if any, falls with the operator at the time. Under the terms of the lease, the operator has a duty to indemnify the Company, a claim which we intend to assert.

 

While it is too early to assess the Company’s exposure, we believe at this time that the likelihood of an adverse outcome is remote.

 

Thomas v. Edwards Redeemer Property Holdings, LLC, et.al., District Court for Oklahoma County, Oklahoma, Case No. CJ 2016-2160.

 

This action arises from a personal injury claim brought by heirs of a former resident of our Edwards Redeemer facility, filed in April 2016. We are entitled to indemnification from the lease operator and should be covered under the lease operator’s general liability policy. As we are not the operators of the facility and believe we have indemnity coverage, we believe we have no exposure. The lease operator’s insurance carrier is providing a defense and indemnity and, as a result, we believe the likelihood of a material adverse result is remote.

 

Edwards Redeemer Property Holdings LLC v. Edwards Redeemer Healthcare & Rehab, LLC, District Court of Oklahoma County, State of Oklahoma, Case No. CJ-19-5883.

 

This action was brought by us against the former lease operator for breaching the lease agreement, removing all the patients, and closing the facility. On October 17, 2019, the Court entered an Order Appointing a Receiver. We have entered into a Settlement Agreement and Release with the Receiver and an Operations Transfer Agreement pursuant to which our newly formed subsidiary will acquire the assets and operations of the facility. In March 2021, the Court approved the Settlement Agreement and Operations Transfer Agreement, the skilled nursing license was assigned to the Company’s wholly-owned subsidiary Park Place Health, LLC and the Company reopened the facility under the name Park Place Health. This matter is considered resolved.

 

Oliphant v. Global Eastman, LLC, et.al., State Court of Cobb County, State of Georgia, Civil Action No. 20-A-3983

 

This is a personal injury lawsuit against various defendants arising out of the death of a patient of the Eastman Healthcare & Rehab Center (the “Facility”). At all relevant times, the Facility was owned by the Company’s wholly owned subsidiary Dodge NH, LLC and leased to Eastman Health & Rehab LLC, an affiliate of Cadence Healthcare, as lease operator. Neither the Company nor any affiliate of the Company had any involvement in patient care at the time of the incident for which complaint was made. The Company relies upon well-settled Georgia law that a landlord has no liability for patient care. The landlord is Dodge NH, LLC. Global Eastman, LLC was not formed as a legal entity during the period of the incident and did not assume the past liabilities as part of the OTA with the receivership of Eastman Healthcare & Rehab LLC which was effective July 1, 2020. Global Eastman LLC was formed on November 21, 2019. Plaintiff has dismissed these claims with prejudice, and the Company has filed a Motion to be awarded attorney’s fees and costs.

 

In the matter of Austin.

 

On December 23, 2020, we received written notice from an attorney of the intent to assert an action for damages against Dodge NH, LLC, which is our subsidiary that owns the nursing facility in Eastman Georgia. The action arises from the shooting death outside of the facility of a woman that worked for our cleaning contractor that cleaned the nursing home. The woman was shot by her former boyfriend who then committed suicide. The incident occurred in December 2019 when the facility was operated by a third-party operator who was in receivership. We do not believe there is any basis in law or fact to hold the owner of the real estate liable, and as a result management has concluded that the likelihood of a material adverse result is remote.

 

In re: Providence HR, LLC v. CRM of Warrenton, LLC, United States Bankruptcy Court, Middle District of Georgia, Macon Division, Case No. 21-50201

 

In re: ALT/WARR, LLC v. CRM of Sparta, LLC, United States Bankruptcy Court, Middle District of Georgia, Macon Division, Case No. 21-50200

 

16

 

 

These are companion cases arising out of the Company’s election to terminate the operating leases on the Company’s two facilities in Warrenton and Sparta, Georgia. The Company served a Notice of Termination on each facility and in response the lease operators filed voluntary petitions under Chapter 11 of the US Bankruptcy Code. The Company filed Motions for Relief from Stay which was heard by the Court on March 22, 2021. By Order of the Court, the hearing was continued to May 25, 2021. The Court entered an interim Order requiring the lease operators to comply with their leases, including payment of rent, pending the next hearing. In June 2021, the Court entered an Order approving a Lease Termination Agreement, Operations Transfer Agreement and Interim Management Agreement which had been negotiated by the Company and the two operating tenants, CRM of Warrenton, LLC and CRM of Sparta, LLC. The Lease Termination Agreement and Operations Transfer Agreement became effective upon the granting of a new License by the State of Georgia for the Warrenton and Sparta facilities to two newly formed wholly owned operating subsidiaries of the Company: Selectis Sparta, LLC and Selectis Warrenton, LLC.

 

High Street Nursing, LLC v. Ohio Department of Health, Court of Common Pleas, Franklin County, Ohio, Case No. 21 CV 6559.

 

The Company brought this action through its wholly owned subsidiary High Street Nursing, LLC (“High Street”) against the Ohio Department of Health (ODH) to prevent the Department of Health from revoking the state issued license covering the Meadowview skilled nursing facility located in Seville, Ohio. The facility is owned by High Street and was leased to a third-party operator who abandoned the facility. The Department of Health is trying to revoke the license of the former operator and has refused our request to transfer the license to a new operator controlled by the Company. Our Motion for Temporary Injunction was denied by the Court. We have subsequently filed a Motion for Preliminary and Permanent Injunction which is pending. Our claims against the Department of Health are based upon our property interests in the facility and raise issues of unlawful condemnation and eminent domain. No prediction can be made regarding the outcome of this matter; but the Company will pursue the ODH to the fullest extent.

 

In the Matter of Hunter

 

The Company received a spoliation letter from an attorney dated October 8, 2021, advising of the intent to assert a personal injury claim against our operating subsidiary Glen Eagle Health & Rehab, LLC which operates our skilled nursing facility in Abbeville, Georgia. We have been provided no further information, but after reviewing the information we believe at this time that the likelihood of an adverse outcome is remote.

 

Edwards Redeemer Property Holdings, LLC, et.al. v. Buildstrong Roofing and Construction, Inc.,et.al. District Court of and for Tulsa County, Oklahoma, Case No. CJ-202

 

This Company brought this action against a contractor that performed work at our Park Place facility in Oklahoma City and our Southern Hills SNF in Tulsa. The claims are based upon negligence and breach of contract for subpar work due to defects in materials, workmanship and Buildstrong not providing services for which they received payment. The case is pending.

 

Tara Gaspar, et.al v. GL Nursing, LLC, et.al., Circuit Court of Lonoke County, Arkansas, Civil Division, Case. No. 43CV-21-864.

 

This case is a personal injury action in which our subsidiary GL Nursing, LLC was joined as a defendant because it is the owner of the property leased to an operating tenant. The action is based upon quality of care over which we had no control. We believe that our risk of a material adverse outcome is remote.

 

10. SUBSEQUENT EVENTS

 

Effective October 4, 2022, the Company changed its independent registered public accountants by engaging Marcum LLP as the company’s independent registered public accounting firm for the year ended December 31, 2022. Marcum LLP will also review the Company’s interim report as of and for the period ended September 30, 2022. Haynie & Company had previously served as the Company’s independent registered public accountants for the year ended December 31, 2021.

 

Effective October 17, 2022, Clifford Neuman resigned as a director and Andy Sink was appointed to fill the vacancy created by Mr. Neuman’s resignation. It was determined that Mr. Neuman did not qualify as an “independent” director within the meaning of Nasdaq regulations; and Mr. Neuman agreed to resign from the Board to facilitate the Company’s efforts to up list to the Nasdaq Stock Market.

 

17

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our interim financial statements and notes thereto contained elsewhere in this report. This section contains forward-looking statements, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Forward-looking statements that were true at the time made may ultimately prove to be incorrect or false. We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise. All forward-looking statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.

 

Our actual future results and trends may differ materially from expectations depending on a variety of factors discussed in our filings with the SEC. These factors include without limitation:

 

strategic business relationships;
  
statements about our future business plans and strategies;
  
anticipated operating results and sources of future revenue;
  
our organization’s growth;
  
adequacy of our financial resources;
  
development of markets;
  
competitive pressures;
  
changing economic conditions;
  
expectations regarding competition from other companies
  
the duration and scope of the COVID-19 pandemic
  
the impact of the COVID-19 pandemic on occupancy rates and on the operations of the Company’s facilities and its operators/tenants.
  
Actions governments take in response to the COVID-19 pandemic, including the introduction of public health measures and other regulations affecting our properties and our operations and the operations of our operators/tenants.
  
The effects of health and safety measures adopted by us and our operators/tenants in response to the COVID-19 pandemic.
  
Increased operational costs because of health and safety measures related to COVID-19.
  
The impact of the COVID-19 pandemic on the business and financial conditions of our operators/tenants and their ability to pay rent.
  
Disruptions to our property acquisition and disposition activities due to economic uncertainty caused by COVID-19.
  
General economic uncertainty in key markets as a result of the COVID-19 pandemic and a worsening of global economic conditions or low levels of economic growth.

 

18

 

 

macroeconomic conditions, such as a prolonged period of weak economic growth, and volatility in capital markets;
  
changes in national and local economic conditions in the real estate and healthcare markets specifically;
  
legislative and regulatory changes impacting the healthcare industry, including the implementation of the healthcare reform legislation enacted in 2010;
  
the availability of debt and equity capital;
  
changes in interest rates;
  
competition in the real estate industry; and,
  
the supply and demand for operating properties in our market areas.

 

Properties

 

As of September 30, 2022, we owned thirteen (13) long-term care facilities including a campus of three buildings in Tulsa, OK. The following table provides summary information regarding these facilities at September 30, 2022:

 

               Total Square Feet   # of Beds 
               Operating   Leased         
          Leased   Square   Square   Operating   Leased 
State  Properties   Operations   Operations   Feet   Feet   Beds   Beds 
Arkansas   1    -    1    -    40,737    -    141 
Georgia   5    4    1    78,197    46,199    454    100 
Ohio   1    1    -    27,500    -    99    - 
Oklahoma   6    6    -    162,976    -    351    - 
Total   13    11    2    268,673    86,936    904    241 

 

Results of Operations

 

The following discussion of the financial condition, results of operations, cash flows, and changes in our financial position should be read in conjunction with our interim consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q.

 

Results of Operations – Nine Months Ended September 30, 2022, Compared to the Nine Months Ended September 30, 2021

 

Rental revenues for the nine months ended September 30, 2022, and 2021 totaled $469,938 and $933,360. The Company also had healthcare revenue of $26,438,806 for the nine months ended September 30, 2022, compared to $17,431,882 for the nine months ended September 30, 2021. Due to our concerted effort to focus on healthcare operations, our healthcare revenues are increasing. As we assume operations and purchase more facilities, we anticipate this trend to continue. As a result of this, our rental income will likely continue to decrease.

 

19

 

 

General and administrative expenses were $5,329,475 and $4,732,115 for the nine months ended September 30, 2022 and 2021. To support the healthcare operations management has increased our corporate support to continue to aid the facilities in delivering world class care.

 

Property taxes, insurance, and other operating expenses totaled $21,192,559 and $12,613,896 for the nine months ended September 30, 2022 and 2021, respectively. This increase can be attributed to the Company operating additional facilities compared to the previous year. Expenses related to the provision for bad debt was $783,524 for the nine months ended September 30, 2022, and $28,275 for the nine months ended September 30, 2021. This increase is due to the Company’s growth in healthcare revenue and new bad debt policy which has increased the provision for bad debt expense.

 

Depreciation and amortization expense totaled $1,348,645 and $1,286,279 for the nine months ended September 30, 2022, and 2021 respectively. This increase is related to an increase in our plant, property, and equipment, compared to the same period in the prior year

 

The Company had $1,438,629 of interest expense for the nine months ended September 30, 2022, and $1,680,540 interest expense for the nine months ended September 30, 2021. This decrease is related to the refinancing mortgages during the year ended December 31, 2021.

 

The Company had $135,468 of other income for the nine months ended September 30, 2022, and $548,933 for the nine months ended September 30, 2021 Management is recording the principal reduction payments made by the operator for the Arkansas facility as other income. We will continue to record this as the operator continues to satisfy the debt.

 

Results of Operations – Three Months Ended September 30, 2022, Compared to the Three Months Ended September 30, 2021

 

Rental revenues for the three months ended September 30, 2022, and 2021 totaled $158,875 and $155,071. The Company also had healthcare revenue of $9,135,306 for the three months ended September 30, 2022, compared to $6,939,841 for the three months ended September 30, 2021. Due to our concerted effort to focus on healthcare operations, our healthcare revenues are increasing. As we assume operations and purchase more facilities, we anticipate this trend to continue. As a result of this, our rental income will likely continue to decrease.

 

20

 

 

General and administrative expenses were $1,970,890 and $1,721,292 for the three months ended September 30, 2022 and 2021. To support the healthcare operations management has increased our corporate support to continue to aid the facilities in delivering world class care.

 

Property taxes, insurance, and other operating expenses totaled $7,227,718 and $4,413,930 for the three months ended September 30, 2022 and 2021, respectively. This increase can be attributed to the Company operating additional facilities compared to the previous year.

 

Expenses related to the provision for bad debt was $252,050 for the three months ended September 30, 2022, and $12,142 for the three months ended September 30, 2021. This increase is due to the Company’s growth in healthcare revenue and new bad debt policy which has increased the provision for bad debt expense.

 

Depreciation and amortization expense totaled $453,608 and $435,013 for the three months ended September 30, 2022, and 2021 respectively.

 

The Company had $722,226 of interest expense for the three months ended September 30, 2022, and $486,816 interest expense for the three months ended September 30, 2021. This increase is related to the refinancing of mortgages during the year ended December 31, 2021.

 

The Company had $53,582 of other income for the three months ended September 30, 2022, and $51,856 of other expense for the three months ended September 30, 2021 Management is recording the principal reduction payments made by the operator for the Arkansas facility as other income. We will continue to record this as the operator continues to satisfy the debt.

 

Liquidity and Capital Resources

 

Throughout its history, the Company has experienced shortages in working capital and has relied, from time to time, upon sales of debt and equity securities to meet cash demands generated by our acquisition activities.

 

At September 30, 2022, the Company had cash of $1,928,472 and restricted cash of $831,687. Our restricted cash is to be spent on insurance, taxes, repairs, and capital expenditures associated with Providence of Sparta Nursing Home or Warrenton Health and Rehab. Our liquidity is expected to increase from potential equity and debt offerings and decrease as net offering proceeds are expended in connection with our various property improvement projects. Our continuing short-term liquidity requirements consisting primarily of operating expenses and debt service requirements, excluding balloon payments at maturity, are expected to be achieved from healthcare operations, rental revenues received, and existing cash on hand. We have successfully refinanced all five mortgage that matured in the 2021 fiscal year.

 

Cash used in operating activities was $650,648 for the nine months ended September 30, 2022, compared to cash used in operating activities of $1,604,764 for the nine months ended September 30, 2021. Healthcare revenue was adversely affected by COVID-19 which increased costs and decreased our census.

 

Cash used in investing activities was $330,769 for the nine months ended September 30, 2022, compared to cash used in investing activities of $493,689 for the nine months ended September 30, 2021.

 

Cash used in financing activities was $1,051,525 for the nine months ended September 30, 2022 compared to cash provided by financing activities of $1,734,008 for the nine months ended September 30, 2021. This resulted from proceeds from a PPP loan during the nine months ended September 30, 2021.

 

In accordance with ASU 2014-15 management believes the Company has sufficient liquidity and capital resources to maintain ongoing operations. This is, in part due to refinancing debt to more favorable terms, and the optimization of our operations in many of our current facilities.

 

21

 

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that we consider material.

 

Critical Accounting Policies

 

Set forth below is a summary of the accounting policies that management believes are critical to the preparation of the consolidated financial statements. Certain of these accounting policies are particularly important for an understanding of the financial position and results of operations presented in the consolidated financial statements set forth elsewhere in this report. These policies require the application of judgment and assumptions by management and, as a result, are subject to a degree of uncertainty. Actual results could differ as a result of such judgment and assumptions.

 

Impairment of Long-Lived Assets

 

When circumstances indicate the carrying value of property may not be recoverable, the Company reviews the asset for impairment. This review is based on an estimate of the future undiscounted cash flows, excluding interest charges, expected to result from the property’s use and eventual disposition. This estimate considers factors such as expected future operating income, market and other applicable trends and residual value, as well as the effects of leasing demand, competition and other factors. If impairment exists, due to the inability to recover the carrying amount of the property, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair value of the property. Estimated fair value is determined with the assistance from independent valuation specialists using recent sales of similar assets, market conditions and projected cash flows of properties using standard industry valuation techniques.

 

Goodwill

 

Goodwill represents the excess of the cost of an acquired business over the amounts assigned to its net assets. Goodwill is not amortized but is tested for impairment at a reporting unit level on an annual basis or when an event occurs, or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Events or changes in circumstances that may trigger interim impairment reviews include significant changes in business climate, operating results, planned investments in the reporting unit, or an expectation that the carrying amount may not be recoverable, among other factors.

 

22

 

 

The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events and circumstances, the Company determines it is more likely than not that the fair value of the reporting unit is greater than its carrying amount, an impairment test is unnecessary. If an impairment test is necessary, the Company will estimate the fair value of its related reporting units. If the carrying value of a reporting unit exceeds its fair value, the goodwill of that reporting unit is determined to be impaired, and the Company will proceed with recording an impairment charge equal to the excess of the carrying value over the related fair value.

 

Revenue Recognition

 

The Company’s leases may be subject to annual escalations of the minimum monthly rent required under each lease. The accompanying consolidated financial statements reflect rental income on a straight-line basis over the term of each lease. Cumulative adjustments associated with the straight-line rent requirement are reflected in Prepaid Expenses and Other in the consolidated balance sheets and totaled $177,716 and $336,931 as of September 30, 2022, and 2021, respectively.

 

Rent receivables and unbilled deferred rent receivables are carried net of an allowance for uncollectible amounts. An allowance is maintained for estimated losses resulting from the inability of certain tenants to meet the contractual obligations under their lease agreements. The Company also maintains an allowance for deferred rent lease receivables arising from the straight-line recognition of rents. Such allowances are charged to net against rental incomes.

 

When the lessee is the owner of any improvements, any lessee improvement allowance that is funded by the Company is treated as a lease incentive and amortized as a reduction of revenue over the lease term. As of September 30, 2022, and 2021, there were no deferred lease incentives recorded.

 

For our healthcare operations, we recognize revenue in accordance with ASC 606 whereby we apply the following steps:

 

a.Step 1: Identify the contract(s) with a customer
b.Step 2: Identify the performance obligations in the contract
c.Step 3: Determine the transaction price
d.Step 4: Allocate the transaction price to the performance obligations in the contract
e.Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation

 

In accordance with ASC 606, estimated uncollectable amounts due from patients are generally considered implicit price concessions that are a direct reduction to net operating revenues.

 

Recently Adopted Accounting Pronouncements

 

None.

 

Recently Issued Accounting Pronouncements

 

The Financial Accounting Standards Board and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2022. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term.

 

23

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, as appropriate, to allow timely decisions regarding required disclosure. Management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures, which, by their nature, can provide only reasonable assurance regarding management’s control objectives.

 

Our management, including our CEO and CFO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Report. Based on this evaluation, our CEO and CFO concluded that the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were not effective due to material weakness in our internal controls over financial reporting due to lack of segregation of duties, a limited corporate governance structure and insufficient formal management review process over certain financial and accounting reports resulting in misreporting of healthcare revenue and expenses. In light of the material weaknesses described above, we performed additional analysis deemed necessary to ensure that our unaudited interim financial statements were prepared in accordance with U.C. generally accepted accounting principles. Accordingly, management believes that the financial statements included in this Quarterly Report on Form 10-Q present fairly in all material respects our financial position, results of operations and cash flows for the periods presented. The Company plans to implement multi-level review in 2023, and management intends to work internally and with various third-parties to ensure we have the proper controls in place going forward.

 

There was no change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the quarter ended September 30, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II

OTHER INFORMATION

 

Item 1. Legal Proceedings

 

The Company and/or its affiliated subsidiaries are or were involved in the following litigation:

 

Bailey v. GL Nursing, LLC, et. al in the Circuit Court of Lonoke County, Arkansas, 23rd Circuit, 43CV-19-151.

 

In April 2019, the Company’s wholly-owned subsidiary was named as a co-defendant in the action arising out of a claimed personal injury suffered by the plaintiff while a resident of the skilled nursing home owned, but not operated, by GL Nursing. As of this date, we have engaged legal counsel, but no further information is known regarding the merits of the claim. After initial inquiry, it does not appear that the lease operator of the facility had in effect general liability insurance covering the GL Nursing, as landlord, as required by the operating lease.

 

As we simply were the owners of the property and not the operators, we believe that primary responsibility, if any, falls with the operator at the time. Under the terms of the lease, the operator has a duty to indemnify the Company, a claim which we intend to assert.

 

While it is too early to assess the Company’s exposure, we believe at this time that the likelihood of an adverse outcome is remote.

 

Thomas v. Edwards Redeemer Property Holdings, LLC, et.al., District Court for Oklahoma County, Oklahoma, Case No. CJ 2016-2160.

 

This action arises from a personal injury claim brought by heirs of a former resident of our Edwards Redeemer facility, filed in April 2016. We are entitled to indemnification from the lease operator and should be covered under the lease operator’s general liability policy. As we are not the operators of the facility and believe we have indemnity coverage, we believe we have no exposure. The lease operator’s insurance carrier is providing a defense and indemnity and, as a result, we believe the likelihood of a material adverse result is remote.

 

Edwards Redeemer Property Holdings LLC v. Edwards Redeemer Healthcare & Rehab, LLC, District Court of Oklahoma County, State of Oklahoma, Case No. CJ-19-5883.

 

This action was brought by us against the former lease operator for breaching the lease agreement, removing all the patients, and closing the facility. On October 17, 2019, the Court entered an Order Appointing a Receiver. We have entered into a Settlement Agreement and Release with the Receiver and an Operations Transfer Agreement pursuant to which our newly formed subsidiary will acquire the assets and operations of the facility. In March 2021, the Court approved the Settlement Agreement and Operations Transfer Agreement, the skilled nursing license was assigned to the Company’s wholly-owned subsidiary Park Place Health, LLC and the Company reopened the facility under the name Park Place Health. This matter is considered resolved.

 

24

 

 

Oliphant v. Global Eastman, LLC, et.al., State Court of Cobb County, State of Georgia, Civil Action No. 20-A-3983

 

This is a personal injury lawsuit against various defendants arising out of the death of a patient of the Eastman Healthcare & Rehab Center (the “Facility”). At all relevant times, the Facility was owned by the Company’s wholly owned subsidiary Dodge NH, LLC and leased to Eastman Health & Rehab LLC, an affiliate of Cadence Healthcare, as lease operator. Neither the Company nor any affiliate of the Company had any involvement in patient care at the time of the incident for which complaint was made. The Company relies upon well-settled Georgia law that a landlord has no liability for patient care. The landlord is Dodge NH, LLC. Global Eastman, LLC was not formed as a legal entity during the period of the incident and did not assume the past liabilities as part of the OTA with the receivership of Eastman Healthcare & Rehab LLC which was effective July 1, 2020. Global Eastman LLC was formed on November 21, 2019. Plaintiff has dismissed these claims with prejudice, and the Company has filed a Motion to be awarded attorney’s fees and costs.

 

In the matter of Austin.

 

On December 23, 2020, we received written notice from an attorney of the intent to assert an action for damages against Dodge NH, LLC, which is our subsidiary that owns the nursing facility in Eastman Georgia. The action arises from the shooting death outside of the facility of a woman that worked for our cleaning contractor that cleaned the nursing home. The woman was shot by her former boyfriend who then committed suicide. The incident occurred in December 2019 when the facility was operated by a third-party operator who was in receivership. We do not believe there is any basis in law or fact to hold the owner of the real estate liable, and as a result management has concluded that the likelihood of a material adverse result is remote.

 

In re: Providence HR, LLC v. CRM of Warrenton, LLC, United States Bankruptcy Court, Middle District of Georgia, Macon Division, Case No. 21-50201

 

In re: ALT/WARR, LLC v. CRM of Sparta, LLC, United States Bankruptcy Court, Middle District of Georgia, Macon Division, Case No. 21-50200

 

These are companion cases arising out of the Company’s election to terminate the operating leases on the Company’s two facilities in Warrenton and Sparta, Georgia. The Company served a Notice of Termination on each facility and in response the lease operators filed voluntary petitions under Chapter 11 of the US Bankruptcy Code. The Company filed Motions for Relief from Stay which was heard by the Court on March 22, 2021. By Order of the Court, the hearing was continued to May 25, 2021. The Court entered an interim Order requiring the lease operators to comply with their leases, including payment of rent, pending the next hearing. In June 2021, the Court entered an Order approving a Lease Termination Agreement, Operations Transfer Agreement and Interim Management Agreement which had been negotiated by the Company and the two operating tenants, CRM of Warrenton, LLC and CRM of Sparta, LLC. The Lease Termination Agreement and Operations Transfer Agreement became effective upon the granting of a new License by the State of Georgia for the Warrenton and Sparta facilities to two newly formed wholly owned operating subsidiaries of the Company: Selectis Sparta, LLC and Selectis Warrenton, LLC.

 

High Street Nursing, LLC v. Ohio Department of Health, Court of Common Pleas, Franklin County, Ohio, Case No. 21 CV 6559.

 

The Company brought this action through its wholly owned subsidiary High Street Nursing, LLC (“High Street”) against the Ohio Department of Health (ODH) to prevent the Department of Health from revoking the state issued license covering the Meadowview skilled nursing facility located in Seville, Ohio. The facility is owned by High Street and was leased to a third-party operator who abandoned the facility. The Department of Health is trying to revoke the license of the former operator and has refused our request to transfer the license to a new operator controlled by the Company. Our Motion for Temporary Injunction was denied by the Court. We have subsequently filed a Motion for Preliminary and Permanent Injunction which is pending. Our claims against the Department of Health are based upon our property interests in the facility and raise issues of unlawful condemnation and eminent domain. No prediction can be made regarding the outcome of this matter; but the Company will pursue the ODH to the fullest extent.

 

In the Matter of Hunter

 

The Company received a spoliation letter from an attorney dated October 8, 2021, advising of the intent to assert a personal injury claim against our operating subsidiary Glen Eagle Health & Rehab, LLC which operates our skilled nursing facility in Abbeville, Georgia. We have been provided no further information, but after reviewing the information we believe at this time that the likelihood of an adverse outcome is remote.

 

Edwards Redeemer Property Holdings, LLC, et.al. v. Buildstrong Roofing and Construction, Inc.,et.al. District Court of and for Tulsa County, Oklahoma, Case No. CJ-202

 

This Company brought this action against a contractor that performed work at our Park Place facility in Oklahoma City and our Southern Hills SNF in Tulsa. The claims are based upon negligence and breach of contract for subpar work due to defects in materials, workmanship and Buildstrong not providing services for which they received payment. The case is pending.

 

Tara Gaspar, et.al v. GL Nursing, LLC, et.al., Circuit Court of Lonoke County, Arkansas, Civil Division, Case. No. 43CV-21-864.

 

This case is a personal injury action in which our subsidiary GL Nursing, LLC was joined as a defendant because it is the owner of the property leased to an operating tenant. The action is based upon quality of care over which we had no control. We believe that our risk of a material adverse outcome is remote.

 

25

 

 

Item 2. COVID-19 Pandemic

 

In December 2019, a novel strain of coronavirus (“COVID-19”) emerged in China. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 a pandemic. The outbreak has now spread to the United States and infections have been reported globally.

 

Starting in March 2020, the COVID-19 pandemic, and measures to prevent its spread began to affect us in a number of ways. In our operating portfolio, occupancy trended lower in the second half of the month as government policies and implementation of infection control best practices began to materially limit or close communities to new resident move-ins. In addition, starting in mid-March, operating costs began to rise materially, including for services, labor and personal protective equipment and other supplies, as our operators took appropriate actions to protect residents and caregivers.

 

The Centers for Disease Control & Prevention (“CDC”) provides final confirmation of the cases. The Company is engaging in aggressive mitigation efforts in accordance with CDC and state Department of Health guidelines to protect the health and safety of residents while respecting their rights. Employees at all of our facilities are taking several precautions as they care for residents, including, among other things, monitoring themselves for symptoms upon leaving and returning home, and upon arriving at and leaving the skilled nursing facility. They are also wearing masks and other personal protective equipment while caring for residents. Additionally, as of the date of this Report, all of our facilities have reported occurrences of COVID-19 in both staff and residents. We have implemented aggressive vaccination programs at all of our facilities but have not imposed mandates. As of the date of this Report, the vast majority of our staff and residents have been vaccinated.

 

The federal government, as well as state and local governments, have implemented or announced programs to provide financial and other support to businesses affected by the COVID-19 pandemic, some of which benefit or could benefit our company, tenants, operators, borrowers, and managers. While these government assistance programs are not expected to fully offset the negative financial impact of the pandemic, and there can be no assurance that these programs will continue or the extent to which they will be expanded, we are monitoring them closely and have been in active dialogue with our tenants, operators, borrowers, and managers regarding ways in which these programs could benefit them or us.

 

The COVID-19 pandemic is rapidly evolving. The information in this Report is based on data currently available to us and will likely change as the pandemic progresses. As COVID-19 continues to spread throughout areas in which we operate, we believe the outbreak has the potential to have a material negative impact on our operating results and financial condition. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our operators, employees and vendors, and impact on the facilities we manage, all of which are uncertain and cannot be predicted. Given these uncertainties, we cannot reasonably estimate the related impact to our business, operating results, and financial condition.

 

We expect the trends highlighted above with respect to the impact of the COVID-19 pandemic to continue and, in some cases, accelerate. The extent of the COVID-19 pandemic’s continued effect on our operational and financial performance will depend on future developments, including the duration, spread and intensity of the outbreak, the pace at which jurisdictions across the country re-open and restrictions begin to lift, the availability of government financial support to our business, tenants, and operators and whether a resurgence of the outbreak occurs. Due to these uncertainties, we are not able at this time to estimate the ultimate impact of the COVID-19 pandemic on our business, results of operations, financial condition, and cash flows but it could be material.

 

26

 

 

Recent Developments Related to COVID-19

 

In addition to experiencing outbreaks of positive cases and deaths of residents and employees during the pandemic, we and our operators have been required to, and continue to, adapt their operations rapidly throughout the pandemic to manage the spread of the COVID-19 virus as well as the implementation of new treatments and vaccines, and to implement new requirements relating to infection control, personal protective equipment (“PPE”), quality of care, visitation protocols, staffing levels, and reporting, among other regulations, throughout the pandemic. Many of our controlled and third-party operators have reported incurring significant cost increases as a result of the COVID-19 pandemic, with dramatic increases for facilities with positive cases. We believe these increases primarily stem from elevated labor costs, including increased use of overtime and bonus pay, as well as a significant increase in both the cost and usage of PPE, testing equipment and processes and supplies, as well as implementation of new infection control protocols and vaccination programs. In addition, we are experiencing declines, in some cases that are material, in occupancy levels as a result of the pandemic, which declines on average appear to be stabilizing. We believe these declines may be in part due to COVID-19 related fatalities at the facilities, the delay of SNF placement and/or utilization of alternative care settings for those with lower level of care needs, the suspension and/or postponement of elective hospital procedures, fewer discharges from hospitals to SNFs and higher hospital readmittances from SNFs.

 

While substantial government support, primarily through the federal CARES Act in the U.S. and distribution of PPE, vaccines and testing equipment by federal and state governments, has been allocated to SNFs and to a lesser extent to ALFs, further government support will likely be needed to continue to offset these impacts. It is unclear whether and to what extent such government support will continue to be sufficient and timely to offset these impacts. In particular, it remains unclear as to whether unallocated funds under the Provider Relief Fund will be distributed to our operators in any meaningful way, whether additional funds will be added to the Provider Relief Fund or otherwise allocated to health care operators or our operators, or whether additional Medicaid funds under the recently enacted American Rescue Plan Act of 2021 (the “American Rescue Plan Act”) in the U.S. will ultimately support reimbursement to our operators. Further, to the extent the cost and occupancy impacts on our operators continue or accelerate and are not offset by continued government relief that is sufficient and timely, we anticipate that the operating results of certain of our operators would be materially and adversely affected, some may be unwilling or unable to pay their contractual obligations to us in full or on a timely basis and we may be unable to restructure such obligations on terms as favorable to us as those currently in place.

 

There are a number of uncertainties we face as we consider the potential impact of COVID-19 on our business, including how long census disruption and elevated COVID-19 costs will last, the impact of vaccination programs and participation levels in those programs in reducing the spread of COVID-19 in our facilities, and the extent to which funding support from the federal government and the states will continue to offset these incremental costs as well as lost revenues. Notwithstanding vaccination programs, we expect that heightened clinical protocols for infection control within facilities will continue for some period; however, we do not know if future reimbursement rates or equipment provided by governmental agencies will be sufficient to cover the increased costs of enhanced infection control and monitoring.

 

While we continue to believe that longer term demographics will drive increasing demand for needs-based skilled nursing care, we expect the uncertainties to our business described above to persist at least for the near term until we can gain more information as to the level of costs our operators will continue to experience and for how long, and the level of additional governmental support that will be available to them, the potential support our operators may request from us and the future demand for needs-based skilled nursing care and senior living facilities. We continue to monitor the impact of occupancy declines at many of our operators, and it remains uncertain whether and when demand and occupancy levels will return to pre-COVID-19 levels.

 

27

 

 

Government Regulation and Reimbursement

 

The healthcare industry is heavily regulated. We are subject to extensive and complex federal, state and local healthcare laws and regulations. These laws and regulations are subject to frequent and substantial changes resulting from the adoption of new legislation, rules and regulations, and administrative and judicial interpretations of existing law. The ultimate timing or effect of these changes, which may be applied retroactively, cannot be predicted. Changes in laws and regulations impacting our operators, in addition to regulatory non-compliance by our operators, can have a significant effect on the operations and financial condition of our operators, which in turn may adversely impact us. There is the potential that we may be subject directly to healthcare laws and regulations because of the broad nature of some of these regulations, such as the Anti-kickback Statute and False Claims Act, among others.

 

The U.S. Department of Health and Human Services (“HHS”) declared a public health emergency on January 31, 2020, following the World Health Organization’s decision to declare COVID-19 a public health emergency of international concern. This declaration, which has been extended, allows HHS to provide temporary regulatory waivers and new reimbursement rules designed to equip providers with flexibility to respond to the COVID-19 pandemic by suspending various Medicare patient coverage criteria and documentation and care requirements, including, for example, suspension of the three-day prior hospital stay coverage requirement and expanding the list of approved services which may be provided via telehealth. These regulatory actions could contribute to a change in census volumes and skilled nursing mix that may not otherwise have occurred. It remains uncertain when federal and state regulators will resume enforcement of those regulations which are waived or otherwise not being enforced during the public health emergency due to the exercise of enforcement discretion.

 

These temporary changes to regulations and reimbursement, as well as emergency legislation, including the CARES Act enacted on March 27, 2020, and discussed below, continue to have a significant impact on our operations and financial condition. The extent of the COVID-19 pandemic’s effect on the Company’s and our operators’ operational and financial performance will depend on future developments, including the sufficiency and timeliness of additional governmental relief, the duration, spread and intensity of the outbreak, the impact of new vaccine distributions on our operators and their populations, as well as the difference in how the pandemic may impact SNFs in contrast to ALFs, all of which developments and impacts are uncertain and difficult to predict. Due to these uncertainties, we are not able at this time to estimate the effect of these factors on our business; however, the adverse impact on our business, results of operations, financial condition and cash flows could be material.

 

A significant portion of our revenue is derived from government-funded reimbursement programs, consisting primarily of Medicare and Medicaid. As federal and state governments continue to focus on healthcare reform initiatives, efforts to reduce costs by government payors will likely continue. Significant limits on the scope of services reimbursed and/or reductions of reimbursement rates could therefore have a material adverse effect on our results of operations and financial condition. Additionally, new and evolving payor and provider programs that are tied to quality and efficiency could adversely impact our tenants’ and operators’ liquidity, financial condition or results of operations, and there can be no assurance that payments under any of these government health care programs are currently, or will be in the future, sufficient to fully reimburse the property operators for their operating and capital expenses.

 

28

 

 

The following is a discussion of recent developments regarding certain U.S. laws and regulations generally applicable to our operators, and in certain cases, to us, and their impact.

 

Reimbursement Changes Related to COVID-19:

 

U.S. Federal Stimulus Funds, through the CARES Act and Provider Relief Fund, appropriating $178 Billion to Health Care Providers. In response to the pandemic, Congress enacted a series of economic stimulus and relief measures throughout 2020 and 2021. On March 18, 2020, the Families First Coronavirus Response Act was enacted in the U.S., providing a temporary 6.2% increase to each qualifying state and territory’s Medicaid Federal Medical Assistance Percentage (“FMAP”) effective January 1, 2020. The temporary FMAP increase will extend through the last day of the calendar quarter in which the public health emergency terminates. States will make individual determinations about how this additional Medicaid reimbursement will be applied to SNFs, if at all.

 

In a further response to the pandemic, the CARES Act authorized approximately $178 Billion to be distributed through the Public Health and Social Services Emergency Fund (“Provider Relief Fund”) to reimburse eligible healthcare providers for health care related expenses or lost revenues that are attributable to coronavirus. The Provider Relief Fund is administered under the broad authority and discretion of HHS and recipients are not required to repay distributions received to the extent they are used in compliance with applicable requirements.

 

HHS began distributing Provider Relief Fund grants in April 2020 and has made grants available to various provider groups in three general phases. In May 2020, HHS announced that approximately $9.5 Billion in targeted distributions would be made available to eligible skilled nursing facilities, approximately $2.5 Billion of which were composed of performance-based incentive payments tied to a facility’s infection rate. Approximately $8.5 billion in additional funds were added to the Provider Relief Fund through the American Rescue Plan Act enacted on March 11, 2021; however, these funds are limited to rural providers and suppliers.

 

HHS continues to evaluate and provide allocations of, and issue regulations and guidance regarding, grants made under the CARES Act and related legislation. There are substantial uncertainties regarding the extent to which our operators will receive funds which have not been allocated, whether additional funds will be allocated to the Provider Relief Fund, health care providers or senior care providers and whether additional payments will be distributed to providers, the financial impact of receiving any of these funds on their operations or financial condition, and whether operators will be able to meet the compliance requirements associated with the funds. HHS continues to evaluate and provide allocations of, and issue regulation and guidance regarding, grants made under the CARES Act.

 

The CARES Act and related legislation also made other forms of financial assistance available to healthcare providers, which have the potential to impact our operators to varying degrees. This assistance includes Medicare and Medicaid payment adjustments and an expansion of the Medicare Accelerated and Advance Payment Program, which made available accelerated payments of Medicare funds in order to increase cash flow to providers. These payments are loans that providers must repay. Additionally, CMS suspended Medicare sequestration payment adjustments, which would have otherwise reduced payments to Medicare providers by 2%, from May 1, 2020, through December 31, 2021, but also extended sequestration through 2030. While not limited to healthcare providers, the CARES Act additionally provided payroll tax relief for employers, allowing them to defer payment of employer Social Security taxes that are otherwise owed for wage payments made after March 27, 2020, through December 31, 2020 to December 31, 2021 with respect to 50% of the payroll taxes owed, with the remaining 50% deferred until December 31, 2022.

 

29

 

 

Quality of Care Initiatives and Additional Requirements Related to COVID-19:

 

In addition to COVID-19 reimbursement changes, several regulatory initiatives announced in 2020 and the first quarter of 2021 focused on addressing quality of care in long-term care facilities, including those related to COVID-19 testing and infection control protocols, vaccine protocols, staffing levels, reporting requirements, and visitation policies, as well as increased inspection of nursing homes. For example, recent updates to the Nursing Home Care website and the Five Star Quality Rating System include revisions to the inspection process, adjustment of staffing rating thresholds and the implementation of new quality measures. Although the American Rescue Plan Act did not allocate specific funds to SNF or assisted living facility providers, approximately $200 million was allocated to quality improvement organizations to provide infection control and vaccination uptake support to SNFs.

 

On June 16, 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis announced the launch of an investigation into the COVID-19 response of nursing homes and the use of federal funds by nursing homes during the pandemic. The Select Subcommittee continued to be active throughout the remainder of 2020 and the first quarter of 2021. In March 2021, the Oversight Subcommittee of the House Ways and Means Committee held a hearing on examining the impact of private equity in the U.S. health care system, including the impact on quality of care provided within the skilled nursing industry. These hearings could result in legislation imposing additional requirements on our operators.

 

Reimbursement Generally:

 

Medicaid. The American Rescue Plan Act contains several provisions designed to increase coverage, expand benefits, and adjust federal financing for state Medicaid programs. For example, the American Rescue Plan Act increases the FMAP by 10 percentage points for state home and community-based services expenditures beginning April 1, 2021, through March 31, 2022 in an effort to assist seniors and people with disabilities to receive services safely in the community rather than in nursing homes and other congregate care settings. As a condition for receiving the FMAP increase, states must enhance, expand, or strengthen their Medicaid home and community-based services program during this period. These potential enhancements to Medicaid reimbursement funding may be offset in certain states by state budgetary concerns, the ability of the state to allocate matching funds and to comply with the new requirements, the potential for increased enrollment in Medicaid due to unemployment and declines in family incomes resulting from the COVID-19 pandemic, and the potential allocation of state Medicaid funds available for reimbursement away from SNFs in favor of home and community-based programs. Since our operators’ profit margins on Medicaid patients are generally relatively low, more than modest reductions in Medicaid reimbursement or an increase in the percentage of Medicaid patients has in the past and may in the future adversely affect our operators’ results of operations and financial condition, which in turn could adversely impact us.

 

Department of Justice and Other Enforcement Actions:

 

SNFs are under intense scrutiny for ensuring the quality of care being rendered to residents and appropriate billing practices conducted by the facility. The Department of Justice (“DOJ”) has historically used the False Claims Act to civilly pursue nursing homes that bill the federal government for services not rendered or care that is grossly substandard. In 2020, the DOJ launched a National Nursing Home Initiative to coordinate and enhance civil and criminal enforcement actions against nursing homes with grossly substandard deficiencies. Such enforcement activities are unpredictable and may develop over lengthy periods of time. An adverse resolution of any of these enforcement activities or investigations incurred by our operators may involve injunctive relief and/or substantial monetary penalties, either or both of which could have a material adverse effect on their reputation, business, results of operations and cash flows.

 

30

 

 

Item 1A. Risk Factors

 

COVID

 

The COVID-19 pandemic has subjected our business, operations, and financial condition to a number of risks including the risks described in greater detail in the Management’s Discussion and Analysis section of this Report, including, but not limited to, those discussed below:

 

Risks Related to Revenue: Our revenues and our operators’ revenues are dependent, in part, on occupancy. In addition to the impact of increases in mortality rates on occupancy of our operating facilities, the ongoing COVID-19 pandemic has prevented prospective occupants and their families from visiting our facilities and limited the ability of new occupants to move into our facilities due to heightened move-in criteria and screening. Although the ongoing impact of the pandemic on occupancy remain uncertain, occupancy of our operating and triple-net properties could further decrease. Such a decrease could affect the net operating income of our operating properties and the ability of our triple-net operators to make contractual payments to us.
  
Risks Related to Operator and Tenant Financial Condition: In addition to the risk of decreased revenue from tenant and operator payments, the impact of the COVID-19 pandemic creates a heightened risk of tenant and operator, bankruptcy or insolvency due to factors such as decreased occupancy, medical practice disruptions resulting from stay-at-home orders, increased health and safety and labor expenses or litigation resulting from developments related to the COVID-19 pandemic. Although our operating lease agreements provide us with the right to evict a tenant, demand immediate payment of rent and exercise other remedies, the bankruptcy and insolvency laws afford certain rights to a party that has filed for bankruptcy or reorganization. A tenant, operator, in bankruptcy or subject to insolvency proceedings may be able to limit or delay our ability to collect unpaid rent in the case of a lease. In addition, if a lease is rejected in a tenant bankruptcy, our claim against the tenant may be limited by applicable provisions of the bankruptcy law. We may be required to fund certain expenses (e.g., real estate taxes and maintenance) to preserve the value of an investment property, avoid the imposition of liens on a property and/or transition a property to a new tenant. In some past instances, we have terminated our lease with a tenant and relet the property to another tenant; however, our ability to do so may be severely limited under current conditions due to the industry and macroeconomic effects of the COVID-19 pandemic. If we cannot transition a leased property to a new tenant because of the COVID-19 pandemic or for other reasons, we may take possession of that property, which may expose us to certain successor liabilities. Publicity about the operator’s financial condition and insolvency proceedings, particularly considering ongoing publicity related to the COVID-19 pandemic, may also negatively impact their and our reputations, decreasing customer demand and revenues. Should such events occur, our revenue and operating cash flow may be adversely affected.
  
Risks Related to Operations: Across all of our properties, we and our operators have incurred increased operational costs as a result of the introduction of public health measures and other regulations affecting our properties and our operations, as well additional health and safety measures adopted by us and our operators related to the COVID-19 pandemic, including increases in labor and property cleaning expenses and expenditures related to our efforts to procure PPE and supplies on behalf of our operators. Such operational costs may increase in the future based on the duration and severity of the pandemic or the introduction of additional public health regulations. Operators and tenants are also subject to risks arising from the unique pressures on seniors housing and medical practice employees during the COVID-19 pandemic. As a result of difficult conditions and stresses related to the COVID-19 pandemic, employee morale and productivity may suffer and additional pay, such as hazard pay, may not be sufficient to retain key operator and tenant employees. In addition, our operations or those of our operators or tenants may be adversely impacted if a significant number of our employees or those of our operators or tenants’ contract COVID-19. Although we continue to undertake extensive efforts to ensure the safety of our properties, employees and residents and to provide operator support in this regard, the impact of the COVID-19 pandemic on our facilities could result in additional operational costs and reputational and litigation risk to us and our operators. As a result of the COVID-19 pandemic, operator and tenant cost of insurance is expected to increase and such insurance may not cover certain claims related to COVID-19. Our exposure to COVID-19 related litigation risk may be increased if the operators or tenants of the relevant facilities are subject to bankruptcy or insolvency. In addition, we are facing increased operational challenges and costs resulting from logistical challenges such as supply chain interruptions, business closures and restrictions on the movement of people.
  
Risks Related to Property Acquisitions and Dispositions: As a result of uncertainty regarding the length and severity of the COVID-19 pandemic and the impact of the pandemic on our business and related industries, our investments in and acquisitions of senior housing and health care properties, as well as our ability to transition or sell properties with profitable results, may be limited. We have a significant development portfolio and have not experienced significant delays or disruptions but may in the future. Such disruptions to acquisition, disposition and development activity may negatively impact our long-term competitive position.
  
Risks Related to Liquidity: The COVID-19 pandemic and related public health measures implemented by governments worldwide has had severe global macroeconomic impacts and has resulted in significant financial market volatility. An extended period of volatility or a downturn in the financial markets could result in increased cost of capital. If our access to capital is restricted or our borrowing costs increase as a result of developments in financial markets relating to the pandemic, our operations and financial condition could be adversely impacted. In addition, a prolonged period of decreased revenue and limited acquisition and disposition activity operations could adversely affect our financial condition and long-term growth prospects and there can also be no assurance that we will not face credit rating downgrades. Future downgrades could adversely affect our cost of capital, liquidity, competitive position and access to capital markets.

 

The events and consequences discussed in these risk factors could, in circumstances we may not be able to accurately predict, recognize or control, have a material adverse effect on our business, growth, reputation, prospects, financial condition, operating results, cash flows, liquidity, ability to pay dividends and stock price. As the COVID-19 pandemic continues to adversely affect our operating and financial results, it may also have the effect of heightening many of the other risks described in this Report.

 

31

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None, except as previously disclosed.

 

Item 3. Defaults Upon Senior Securities

 

None, except as disclosed in this Report.

 

Item 4. Mine Safety Disclosures

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

31.1   Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002*
31.2   Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002*
32.1   Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
32.2   Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.INS   Inline XBRL Instance Document**
101.SCH   Inline XBRL Schema Document**
101.CAL   Inline XBRL Calculation Linkbase Document**
101.LAB   Inline XBRL Label Linkbase Document**
101.PRE   Inline XBRL Presentation Linkbase Document**
101.DEF   Inline XBRL Definition Linkbase Document**
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* filed herewith

** furnished, not filed

 

32

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SELECTIS HEALTH, INC
     
Date: January 06, 2023 By: /s/ Lance Baller
    Lance Baller, Chief Executive Officer
    (Principal Executive Officer)
     
Date: January 06, 2023 By: /s/ Mary Lucus
    Mary Lucus, Chief Financial Officer
    (Principal Accounting Officer)

 

33

 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Lance Baller, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Selectis Health, Inc.
   
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 06, 2023 /s/ Lance Baller
  Lance Baller, Chief Executive Officer (Principal Executive Officer)

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION

 

I, Mary Lucus, certify that:

 

1.I have reviewed this Quarterly Report on Form 10-Q of Selectis Health, Inc/ f/k/a Global Healthcare REIT, Inc.
   
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
   
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
   
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
   
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
   
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: January 06, 2023 /s/ Mary Lucus
  Interim Chief Financial Officer (Principal Accounting Officer)

 


 

 

EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Selectis Health, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lance Baller, Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Date: January 06, 2023

 

/s/ Lance Baller  
Lance Baller, Chief Executive Officer  
(Principal Executive Officer)  

 

 

 

EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

Selectis Health, Inc.

Certification Pursuant to

18 U.S.C. Section 1350

(as Adopted Pursuant to Section 906 of

the Sarbanes-Oxley Act Of 2002)

 

In connection with the Annual Report of Selectis Health, Inc. (the “Company”) on Form 10-Q for the quarter period ended September 30, 2022, as filed with the Securities and Exchange Commission (the “Report”), I, Mary Lucus, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: January 06, 2023

 

/s/ Mary Lucus  
Mary Lucus  
Interim Chief Financial Officer (Principal Accounting Officer)  

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Selectis Health, Inc. f/k/a Global Healthcare REIT, Inc. and will be retained by Selectis Health, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 

 

EX-101.SCH 6 gbcs-20220930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - INVESTMENTS IN DEBT SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - DEBT AND DEBT - RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - OTHER CURRENT LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - FACILITY LEASES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INVESTMENTS IN DEBT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - DEBT AND DEBT - RELATED PARTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - STOCKHOLDERS’ EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - FACILITY LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF RESTATEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - INVESTMENTS IN DEBT SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF DEBT INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF MORTGAGE LOAN DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF MORTGAGE LOAN DEBT (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF OTHER DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - DEBT AND DEBT - RELATED PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - OTHER CURRENT LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - RELATED PARTIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF LEASING ARRANGEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 gbcs-20220930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 gbcs-20220930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 gbcs-20220930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series D Preferred Stock [Member] Product and Service [Axis] Rental [Member] Health Care [Member] Healthcare Grant Revenue [Member] Management Fee Revenue [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Revision of Prior Period [Axis] Previously Reported [Member] Revision of Prior Period, Adjustment [Member] Adjusted [Member] Long-Lived Tangible Asset [Axis] Land [Member] Land Improvements [Member] Building Improvements [Member] Furniture Fixtures And Equipment [Member] Debt Security Category [Axis] State and Municipal [Member] Long-Term Debt, Type [Axis] Senior Secured Promissory Notes [Member] Senior Secured Promissory Notes Related Parties [Member] Fixed Rate Mortgage Loans [Member] Variable Rate Mortgage Loans [Member] Other Debt Sub ordinated Secured [Member] Other Debt Subordinated Secured Related Parties [Member] Other Debt Subordinated Secured Seller Financing [Member] Variable Rate [Axis] Fixed Rate [Member] Variable Rate [Member] Senior Secured Notes [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Geographical [Axis] ARKANSAS Debt Instrument [Axis] Mortgage Loans [Member] GEORGIA OHIO OKLAHOMA Financial Instrument [Axis] First Mortgage Loan [Member] Second Mortgage [Member] Third Mortgage Loan [Member] Related Party [Axis] Goodwill Nursing Home [Member] Other Debt [Member] Goodwill Nursing Home - Related Party [Member] Higher Call Nursing Center [Member] 10% Senior Secured Promissory Note One [Member] 11% Senior Secured Promissory Notes Related Party [Member] Dividends [Axis] Dividend Declared [Member] Warrant [Member] Mr Clifford Neuman [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Goodwill [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS Current Assets Cash Accounts Receivable, Net of allowance Prepaid Expenses and Other Investments in Debt Securities Total Current Assets Long Term Assets Restricted Cash Property and Equipment, Net Goodwill Total Assets LIABILITIES AND EQUITY Liabilities Accounts Payable and Accrued Liabilities Accounts Payable – Related Parties Dividends Payable Short term debt – Related Parties, Net of discount of $0 and $3,234, respectively Current Maturities of Long Term Debt, Net of Discount of $1,184 and $1,714, respectively Other Current Liability Total Current Liabilities Debt- Related Parties Debt, Net of discount of $933,737 and $452,593, respectively Lease Security Deposit Total Liabilities Commitments and Contingencies Equity Preferred Stock value: Common Stock - $0.05 Par Value; 800,000,000 Shares Authorized, 3,054,588 and 2,998,362 Shares Issued and Outstanding at September 31, 2022 and December 31, 2021, respectively Additional Paid-In Capital Accumulated Deficit Total Selectis Health, Inc. Stockholders’ Equity Total Liabilities and Equity Debt discount of related parties Long term debt, net of discount, current Long term debt, net of discount, non current Dividend, preferred stock Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Revenue Total Revenue Expenses Property Taxes, Insurance and Other Operating General and Administrative Provision for Bad Debts Depreciation Total Expenses Income (Loss) from Operations Other (Income) Expense Loss (Gain) on Extinguishment of Debt Interest Expense, net Gain on Forgiveness of PPP Loan Other Income Lease Termination Expense Total Other Expense Net Loss Net Loss Attributable to Noncontrolling Interests Net Loss Attributable to Selectis Health, Inc. Series D Preferred Dividends Net Loss Attributable to Common Stockholders Net Loss per Share Attributable to Common Stockholders: Basic Diluted Weighted Average Common Shares Outstanding: Basic Diluted Beginning balance, value Beginning balance, shares Series D Preferred Dividends Common shares issued for debt Common shares issued for debt, shares Loss on Forgiveness of Debt Net Income (Loss) Share Based Compensation – Restricted Stock Awards Share Based Compensation - Restricted Stock Awards, shares Cashless Exercise of Warrants Cashless Exercise of Warrants, shares Purchase of Non-Controlling Interest Issuance of common stock for cash Issuance of common stock for cash, shares Cashless Exercise of Stock Options Cashless Exercise of Stock Options, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by (Used in) Operating Activities: Gain on Forgiveness from PPP Loan Other Income from Partial Settlement of Debt Depreciation and Amortization Amortization of Deferred Loan Costs and Debt Discount Provision for Bad Debt Stock Based Compensation Changes in Operating Assets and Liabilities, Net of Assets and Liabilities Acquired: Accounts and Rents Receivable Prepaid Expenses and Other Assets Accounts Payable and Accrued Liabilities Lease Security Deposits Cash Used in Operating Activities Cash Flows From Investing Activities: Capital Expenditures for Property and Equipment Cash Used in Investing Activities Cash Flows From Financing Activities: Proceeds from Issuance of Debt, Non-Related Party Payments on Debt, Non-Related Party Dividends Paid on Preferred Stock Proceeds from stock offering Purchase of Non-Controlling Interest Debt Discount – Warrants RP Cash (Used in) Provided by Financing Activities Net Decrease in Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents and Restricted Cash at Beginning of the Period Cash and Cash Equivalents and Restricted Cash at End of the Period Supplemental Disclosure of Cash Flow Information Cash Paid for Interest Cash Restricted Cash Total Cash and Cash Equivalents and Restricted Cash Supplemental Schedule of Non-Cash Investing and Financing Activities Dividends Declared on Series D Preferred Stock Issuance of common stock for cashless exercise of warrants Issuance of common stock for cashless exercise of options Financing of Insurance Premiums Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT, NET Investments, Debt and Equity Securities [Abstract] INVESTMENTS IN DEBT SECURITIES Debt Disclosure [Abstract] DEBT AND DEBT - RELATED PARTIES Equity [Abstract] STOCKHOLDERS’ EQUITY Other Liabilities Disclosure [Abstract] OTHER CURRENT LIABILITY Related Party Transactions [Abstract] RELATED PARTIES Leases [Abstract] FACILITY LEASES Commitments and Contingencies Disclosure [Abstract] LEGAL PROCEEDINGS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principles of Consolidation Recently Issued Accounting Pronouncements Reclassification Earnings per Share Fair Value Measurements SCHEDULE OF RESTATEMENT SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE SCHEDULE OF PROPERTY PLANT AND EQUIPMENT SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES SCHEDULE OF DEBT INSTRUMENTS SCHEDULE OF MORTGAGE LOAN DEBT SCHEDULE OF OTHER DEBT SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY SCHEDULE OF LEASING ARRANGEMENTS SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE Net Cash Provided by (Used in) Operating Activities Working capital deficit Schedule of Product Information [Table] Product Information [Line Items] Total Revenue Loss (Gain) on Extinguishment of Debt Gain on Forgiveness of PPP Loan Other Income Total Other (Income) Expense Healthcare Revenue Operating Income Net Income EPS WASO Accounts receivable Current Assets Assets Working Capital Total Equity Net Income (Loss) per Share Attributable to Common Stockholders: Net Income (Loss) Attributable to Selectis Health, Inc. Series D Preferred Dividends Numerator for diluted earnings per share: Net Income (Loss) Attributable to Common Stockholders Series D Preferred Dividends Net Income (Loss) Attributable to Common Stockholders - Diluted Denominator for diluted earnings per share: Weighted Average Common Shares Outstanding Weighted Average Common Shares Outstanding - Basic Effect of dilutive securities: Conversion of preferred shares Exercise of warrants Weighted Average Common Shares Outstanding - Diluted Misstatement adjustment amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and Equipment, gross Less Accumulated Depreciation Property and Equipment, net Depreciation Expense (excluding Intangible Assets) Held-to-maturity securities Contractual maturity of held-to-maturity securities Held-to-maturity fair value Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Debt Instrument, Gross Unamortized Discount and Debt Issuance Costs Debt Instrument, Net of Discount Current Maturities of Long Term Debt, Net Short term debt – Related Parties, Net Debt, Net Debt – Related Parties, Net Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Number of Properties Face Amount Long-term Debt, Gross Mortgage loan description USDA guaranteed rate Annual renewal fee payable Repayments of First Mortgage Bond Mortgage one Maturity date Debt instrument term Interest rate Debt, Face Amount Debt, Principal Outstanding Debt, Interest Rate Debt, Maturity Date Debt weighted average interest rate Debt instrument interest rate Debt maturity date Debt instrument extended maturity date Incremental increase in fair value of debt discount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of Warrants, Beginning Balance Weighted Average Exercise Price, Beginning Balance Number of Warrants, Exercised Weighted Average Exercise Price, Exercised Number of Warrants, Expired Weighted Average Exercise Price, Expired Number of Warrants, Ending Balance Weighted Average Exercise Price, Ending Balance Schedule of Stock by Class [Table] Class of Stock [Line Items] Preferred stock, dividend paid Warrants to purchase common stock Weighted average exercise price Common stock warrants term Aggregate intrinsic value of common stock warrants outstanding Other current liability Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Due to related party Repayments of related party debt Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Monthly lease income Lease expiration date Lease renewal option 2022 2023 2024 2025 2026 2027 and Thereafter Total Debt discount of related parties . Management Fee Revenue [Member] Lease termination expense. Loss on Forgiveness of Debt, net Cashless exercise of warrants. Cashless exercise of warrants shares. Gain on forgiveness from PPP Loan. Other income from partial settlement of debt. Dividends declared on series D preferred stock. Issuance of common stock for cashless exercise of warrants. Financing of insurance premiums. Working capital deficit. Preferred stock dividends and other adjustments basic. Net income loss attributable to diluted gross. Preferred stock dividends and other adjustments diluted. Denominator for diluted earnings per share [Abstract] Effect of dilutive securities. Exercise of warrants. State and Municipal [Member] Fixed Rate [Member] Variable Rate [Member] Senior Secured Notes [Member] Incremental increase in fair value of debt discount. Mortgage Loans [Member] OH [Member] OK [Member] USDA guaranteed rate. Annual renewal fee payable. Mortgage one. Mortgage two. Mortgage three. Schedule Of Other Debt [Table Text Block] Goodwill Nursing Home [Member] Represents the amount of long-term and short-term debt outstanding, less the amount of unamortized discount, as of the indicated date. Goodwill Nursing Home - Related Party [Member] Higher Call Nursing Center [Member] 10% Senior Secured Promissory Note One [Member] Eleven Percentage Senior Secured Promissory Notes Related Party [Member] Weighted average exercise price for warrant. Schedule of Leasing Arrangements [Table Text Block] Lease Renewal Option. Lessee operating lease liability payments due year four and thereafter. Mortgage loan description. Conversion of preferred shares. Debt Discount - Warrants RP. Less Impairment. Other Debt Current Note Payables [Member] Debt instrument extended maturity date. First Mortgage Loan [Member] Third Mortgage Loan [Member] Mr Clifford Neuman [Member] Weighted average exercise price of non options equity instruments exercises. Weighted average exercise price of non options equity instruments outstanding. Weighted average exercise price of non options equity instruments expirations. Weighted average number of diluted shares outstanding except effect of dilutive securities. Rental [Member] Healthcare Grant Revenue [Member] Gain on forgiveness of Loan. Healthcare revenue. Working capital. Adjustment error. Total revenue percent. Healthcare revenue percent. Operating income percent. Net income percent. Earning per share percent. Accounts receivable percent. Current assets percent. Total assets percent. Working capital percent. Total Equity percent. Accumulated deficit percent. Misstaement adjustment error amount. Operating income. Allonge And Modifiction Agreement [Member] Global Healthcare REIT Inc [Member] Premium Payment Percentage Goodwill Hunting LLC [Member] Gain on purchase of notes payable Two Investors [Member] Weighted average common shares outstanding diluted effect of dilutive securities Debt long term and short term combined net amount. Other Debt Sub ordinated Secured [Member] Adjusted [Member] Assets, Current Liabilities, Current Liabilities [Default Label] Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) GainOnForgivenessFromPaycheckProtectionProgramLoan Nonoperating Income (Expense) Net Income (Loss) Attributable to Noncontrolling Interest Preferred Stock Dividends and Other Adjustments Net Income (Loss) Available to Common Stockholders, Basic Weighted Average Number of Shares Outstanding, Diluted Shares, Outstanding Dividends, Preferred Stock, Stock OtherIncomeFromPartialSettlementOfDebt Increase (Decrease) in Receivables Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Repayments of Other Long-Term Debt Payments for Repurchase of Redeemable Noncontrolling Interest Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Restricted Cash and Cash Equivalents, Current Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Working capital deficit Revenues PreferredStockDividendsAndOtherAdjustmentsDiluted Net Income (Loss) Available to Common Stockholders, Diluted Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Debt Instrument, Unamortized Discount (Premium), Net DebtLongtermAndShorttermCombinedNetAmount Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice Lessee, Operating Lease, Liability, to be Paid EX-101.PRE 10 gbcs-20220930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover - shares
9 Months Ended
Sep. 30, 2022
Jan. 06, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2022  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 0-15415  
Entity Registrant Name Selectis Health, Inc.  
Entity Central Index Key 0000727346  
Entity Tax Identification Number 87-0340206  
Entity Incorporation, State or Country Code UT  
Entity Address, Address Line One 8480 E Orchard Rd  
Entity Address, Address Line Two Ste 4900  
Entity Address, City or Town Greenwood Village  
Entity Address, State or Province CO  
Entity Address, Postal Zip Code 80111  
City Area Code 720  
Local Phone Number 680-0808  
Entity Current Reporting Status No  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   3,067,059
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current Assets    
Cash $ 1,928,472 $ 3,939,445
Accounts Receivable, Net of allowance 3,064,919 3,506,719
Prepaid Expenses and Other 462,868 498,015
Investments in Debt Securities 24,387 24,387
Total Current Assets 5,480,646 7,968,566
Long Term Assets    
Restricted Cash 831,687 853,656
Property and Equipment, Net 36,006,716 37,024,592
Goodwill 1,076,908 1,076,908
Total Assets 43,395,957 46,923,722
Liabilities    
Accounts Payable and Accrued Liabilities 2,478,953 4,363,917
Accounts Payable – Related Parties 21,571
Dividends Payable 7,500 7,500
Short term debt – Related Parties, Net of discount of $0 and $3,234, respectively 150,000 150,000
Current Maturities of Long Term Debt, Net of Discount of $1,184 and $1,714, respectively 2,049,750 6,312,562
Other Current Liability 931,446
Total Current Liabilities 4,686,203 11,786,996
Debt- Related Parties 750,000 750,000
Debt, Net of discount of $933,737 and $452,593, respectively 34,528,330 31,054,962
Lease Security Deposit 253,899 229,582
Total Liabilities 40,218,432 43,821,540
Commitments and Contingencies
Equity    
Common Stock - $0.05 Par Value; 800,000,000 Shares Authorized, 3,054,588 and 2,998,362 Shares Issued and Outstanding at September 31, 2022 and December 31, 2021, respectively 152,728 150,168
Additional Paid-In Capital 13,793,300 13,494,394
Accumulated Deficit (11,544,503) (11,318,380)
Total Selectis Health, Inc. Stockholders’ Equity 3,177,525 3,102,182
Total Liabilities and Equity 43,395,957 46,923,722
Series A Preferred Stock [Member]    
Equity    
Preferred Stock value: 401,000 401,000
Series D Preferred Stock [Member]    
Equity    
Preferred Stock value: $ 375,000 $ 375,000
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Debt discount of related parties $ 0 $ 3,234
Long term debt, net of discount, current 1,184 1,714
Long term debt, net of discount, non current $ 933,737 $ 452,593
Common stock, par value $ 0.05 $ 0.05
Common stock, shares authorized 800,000,000 800,000,000
Common stock, shares issued 3,054,588 2,998,362
Common stock, shares outstanding 3,054,588 2,998,362
Series A Preferred Stock [Member]    
Dividend, preferred stock $ 0 $ 0
Preferred stock, par value $ 2.00 $ 2.00
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 200,500 200,500
Preferred stock, shares outstanding 200,500 200,500
Series D Preferred Stock [Member]    
Preferred stock, par value $ 10.00 $ 10.00
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 375,000 375,000
Preferred stock, shares outstanding 375,000 375,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue        
Total Revenue $ 9,581,985 $ 7,319,055 $ 29,800,207 $ 19,093,935
Expenses        
Property Taxes, Insurance and Other Operating 7,227,718 4,413,930 21,192,559 12,613,896
General and Administrative 1,970,890 1,721,292 5,329,475 4,732,115
Provision for Bad Debts 252,050 12,142 783,524 28,275
Depreciation 453,608 435,013 1,348,645 1,286,279
Total Expenses 9,904,266 6,582,377 28,654,203 18,660,565
Income (Loss) from Operations (322,281) 736,678 1,146,004 433,370
Other (Income) Expense        
Loss (Gain) on Extinguishment of Debt 46,466
Interest Expense, net 722,226 486,816 1,438,629 1,680,540
Gain on Forgiveness of PPP Loan (675,598)
Other Income (53,582) (51,856) (135,468) (548,933)
Lease Termination Expense 354,710 450,427
Total Other Expense 668,644 789,670 1,349,627 906,436
Net Loss (990,925) (52,992) (203,623) (473,066)
Net Loss Attributable to Noncontrolling Interests (10,650)
Net Loss Attributable to Selectis Health, Inc. (990,925) (52,992) (203,623) (483,716)
Series D Preferred Dividends (7,500) (7,500) (22,500) (22,500)
Net Loss Attributable to Common Stockholders $ (998,425) $ (60,492) $ (226,123) $ (506,216)
Net Loss per Share Attributable to Common Stockholders:        
Basic $ (0.33) $ (0.02) $ (0.07) $ (0.18)
Diluted $ (0.33) $ (0.02) $ (0.07) $ (0.18)
Weighted Average Common Shares Outstanding:        
Basic 3,054,588 2,824,560 3,053,970 2,741,186
Diluted 3,054,588 2,824,560 3,053,970 2,741,186
Rental [Member]        
Revenue        
Total Revenue $ 158,875 $ 155,071 $ 469,938 $ 933,360
Health Care [Member]        
Revenue        
Total Revenue 9,135,306 6,939,841 26,438,806 17,431,882
Healthcare Grant Revenue [Member]        
Revenue        
Total Revenue 287,804 2,891,463 504,550
Management Fee Revenue [Member]        
Revenue        
Total Revenue $ 224,143 $ 224,143
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($)
Preferred Stock [Member]
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series D Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 401,000 $ 375,000 $ 134,332 $ 11,540,052 $ (9,036,400) $ (198,045) $ 3,215,939
Beginning balance, shares at Dec. 31, 2020 200,500 375,000 2,686,638        
Series D Preferred Dividends (7,500) (7,500)
Net Income (Loss) 248,056 10,650 258,706
Ending balance, value at Mar. 31, 2021 $ 401,000 $ 375,000 $ 134,332 11,540,052 (8,795,844) (187,395) 3,467,145
Ending balance, shares at Mar. 31, 2021 200,500 375,000 2,686,638        
Beginning balance, value at Dec. 31, 2020 $ 401,000 $ 375,000 $ 134,332 11,540,052 (9,036,400) (198,045) 3,215,939
Beginning balance, shares at Dec. 31, 2020 200,500 375,000 2,686,638        
Net Income (Loss)             (473,066)
Ending balance, value at Sep. 30, 2021 $ 401,000 $ 375,000 $ 144,518 12,041,996 (9,542,616) 3,392,898
Ending balance, shares at Sep. 30, 2021 200,500 375,000 2,890,362        
Beginning balance, value at Mar. 31, 2021 $ 401,000 $ 375,000 $ 134,332 11,540,052 (8,795,844) (187,395) 3,467,145
Beginning balance, shares at Mar. 31, 2021 200,500 375,000 2,686,638        
Series D Preferred Dividends (7,500) (7,500)
Net Income (Loss) (678,780) (678,780)
Share Based Compensation – Restricted Stock Awards $ 150 18,750 18,900
Share Based Compensation - Restricted Stock Awards, shares     3,000        
Cashless Exercise of Warrants $ 143 (143)
Cashless Exercise of Warrants, shares     2,857        
Purchase of Non-Controlling Interest (247,395) 187,395 (60,000)
Ending balance, value at Jun. 30, 2021 $ 401,000 $ 375,000 $ 134,625 11,311,264 (9,482,124) 2,739,765
Ending balance, shares at Jun. 30, 2021 200,500 375,000 2,692,495        
Series D Preferred Dividends     (7,500) (7,500)
Net Income (Loss) (52,992) (52,992)
Cashless Exercise of Warrants $ 833 (833)
Cashless Exercise of Warrants, shares     16,667        
Issuance of common stock for cash $ 7,500 706,125 713,625
Issuance of common stock for cash, shares     150,000        
Cashless Exercise of Stock Options $ 1,560 (1,560)
Cashless Exercise of Stock Options, shares     31,200        
Ending balance, value at Sep. 30, 2021 $ 401,000 $ 375,000 $ 144,518 12,041,996 (9,542,616) 3,392,898
Ending balance, shares at Sep. 30, 2021 200,500 375,000 2,890,362        
Beginning balance, value at Dec. 31, 2021 $ 401,000 $ 375,000 $ 150,168 13,494,394 (11,318,380) 3,102,182
Beginning balance, shares at Dec. 31, 2021 200,500 375,000 2,998,362        
Series D Preferred Dividends (7,500) (7,500)
Common shares issued for debt $ 2,560 $ 252,440 $ 255,000
Common shares issued for debt, shares     56,226        
Loss on Forgiveness of Debt 46,466 46,466
Net Income (Loss) $ 37,090 $ 37,090
Ending balance, value at Mar. 31, 2022 $ 401,000 $ 375,000 $ 152,728 13,793,300 (11,288,790) 3,433,238
Ending balance, shares at Mar. 31, 2022 200,500 375,000 3,054,588        
Beginning balance, value at Dec. 31, 2021 $ 401,000 $ 375,000 $ 150,168 13,494,394 (11,318,380) 3,102,182
Beginning balance, shares at Dec. 31, 2021 200,500 375,000 2,998,362        
Ending balance, value at Jun. 30, 2022 $ 401,000 $ 375,000 $ 152,728 13,793,300 (10,546,078) 4,175,950
Ending balance, shares at Jun. 30, 2022 200,500 375,000 3,054,588        
Beginning balance, value at Dec. 31, 2021 $ 401,000 $ 375,000 $ 150,168 13,494,394 (11,318,380) 3,102,182
Beginning balance, shares at Dec. 31, 2021 200,500 375,000 2,998,362        
Net Income (Loss)             (203,623)
Ending balance, value at Sep. 30, 2022 $ 401,000 $ 375,000 $ 152,728 13,793,300 (11,544,503) 3,177,525
Ending balance, shares at Sep. 30, 2022 200,500 375,000 3,054,588        
Beginning balance, value at Mar. 31, 2022 $ 401,000 $ 375,000 $ 152,728 13,793,300 (11,288,790) 3,433,238
Beginning balance, shares at Mar. 31, 2022 200,500 375,000 3,054,588        
Series D Preferred Dividends (7,500) (7,500)
Net Income (Loss) 750,212 750,212
Ending balance, value at Jun. 30, 2022 $ 401,000 $ 375,000 $ 152,728 13,793,300 (10,546,078) 4,175,950
Ending balance, shares at Jun. 30, 2022 200,500 375,000 3,054,588        
Series D Preferred Dividends (7,500) (7,500)
Net Income (Loss) (990,925) (990,925)
Ending balance, value at Sep. 30, 2022 $ 401,000 $ 375,000 $ 152,728 $ 13,793,300 $ (11,544,503) $ 3,177,525
Ending balance, shares at Sep. 30, 2022 200,500 375,000 3,054,588        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Cash Flows From Operating Activities:        
Net Income (Loss) $ (990,925) $ (52,992) $ (203,623) $ (473,066)
Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by (Used in) Operating Activities:        
Gain on Forgiveness from PPP Loan (675,598)
Other Income from Partial Settlement of Debt     (40,346) (520,221)
Depreciation and Amortization 453,608 435,013 1,348,645 1,286,279
Amortization of Deferred Loan Costs and Debt Discount     157,291
Provision for Bad Debt 252,050 12,142 783,524 28,275
Stock Based Compensation     18,900
Changes in Operating Assets and Liabilities, Net of Assets and Liabilities Acquired:        
Accounts and Rents Receivable     (341,724) (2,535,412)
Prepaid Expenses and Other Assets     616,540 853,451
Accounts Payable and Accrued Liabilities     (2,837,981) 248,337
Lease Security Deposits     24,317 7,000
Cash Used in Operating Activities     (650,648) (1,604,764)
Cash Flows From Investing Activities:        
Capital Expenditures for Property and Equipment     (330,769) (493,689)
Cash Used in Investing Activities     (330,769) (493,689)
Cash Flows From Financing Activities:        
Proceeds from Issuance of Debt, Non-Related Party     9,134,102
Payments on Debt, Non-Related Party     (1,075,491) (8,023,719)
Dividends Paid on Preferred Stock     (22,500) (30,000)
Proceeds from stock offering     713,625
Purchase of Non-Controlling Interest     (60,000)
Debt Discount – Warrants RP     46,466
Cash (Used in) Provided by Financing Activities     (1,051,525) 1,734,008
Net Decrease in Cash, Cash Equivalents and Restricted Cash     (2,032,942) (364,445)
Cash and Cash Equivalents and Restricted Cash at Beginning of the Period     4,793,101 3,978,303
Cash and Cash Equivalents and Restricted Cash at End of the Period 2,760,159 3,613,858 2,760,159 3,613,858
Supplemental Disclosure of Cash Flow Information        
Cash Paid for Interest     1,438,629 1,680,540
Cash 1,928,472 2,791,585 1,928,472 2,791,585
Restricted Cash 831,687 822,273 831,687 822,273
Total Cash and Cash Equivalents and Restricted Cash $ 2,760,159 $ 3,613,858 2,760,159 3,613,858
Supplemental Schedule of Non-Cash Investing and Financing Activities        
Dividends Declared on Series D Preferred Stock     22,500 22,500
Issuance of common stock for cashless exercise of warrants     976
Issuance of common stock for cashless exercise of options     1,560
Financing of Insurance Premiums     $ 581,393 $ 507,433
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.4
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Organization and Description of the Business

 

Selectis Health, Inc (“Selectis” or “we” or the “Company”) owns and operates, through wholly-owned subsidiaries Assisted Living Facilities, Independent Living Facilities, and Skilled Nursing Facilities across the South and Southeastern portions of the US. In 2019 the Company shifted from leasing long-term care facilities to third-party, independent operators towards an owner operator model.

 

Prior to the Company changing its name to Selectis Health, Inc., the Company was known as Global Healthcare REIT, Inc. from September 30, 2013, to May 2021. Prior to this, the Company was known as Global Casinos, Inc. Global Casinos, Inc. operated two gaming casinos which were split-off and sold on September 30, 2013. Simultaneous with the split-off and sale of the gaming operations, the Company acquired West Paces Ferry Healthcare REIT, Inc. (“WPF”). WPF was merged into the Company in 2019.

 

We acquire, develop, lease, manage, and dispose of healthcare real estate, provide financing to healthcare providers, and provide healthcare operations through our wholly-owned subsidiaries. Our portfolio is comprised of investments in the following three healthcare segments: (i) senior housing (including independent and assisted living), (ii) post-acute/skilled nursing, and (iii) bonds securing senior housing communities. We will make investments within our healthcare segments using the following six investment products: (i) direct ownership of properties, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management, (v) the Housing and Economic Recovery Act of 2008 (“RIDEA”), which represents investments in senior housing operations utilizing the structure permitted by RIDEA and (xi) owning healthcare operations.

 

Management’s Liquidity Plans

 

On August 27, 2014, FASB issued ASU 2014-05, Disclosure of Uncertainties about an Entity’s ability to Continue as a Going Concern, which requires management to assess a company’s ability to continue as a going concern within one year from financial statement issuance and to provide related footnote disclosures in certain circumstances.

 

For the nine months ended September 30, 2022, the Company had negative operating cash flows of $0.7 million and a net working capital of $0.8 million. Management believes that the Company has the ability to meet its obligations for the next twelve months from the date of these financial statements. This is, in part due to refinancing debt to more favorable terms, and the optimization of our operations in our current facilities. Based on management’s projections we expect to generate positive cash flows positive cash flows from its continued operations.

 

 

The focus on opportunities within our current portfolio and future properties to acquire and operate, the settlement, refinance, and continued service of debt obligations, the potential funds generated from stock sales and other initiatives contributing to additional working capital should alleviate any substantial doubt about the Company’s ability to continue as a going concern as defined by ASU 2014-05. However, we cannot predict, with certainty, the outcome of our actions to generate liquidity and the failure to do so could negatively impact our future operations.

 

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and in conjunction with the rules and regulations of the Securities Exchange Commission. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary to make the consolidated financial statements not misleading have been included. Operating results for the nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the entire year. The unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission.

 

In May 2021, the board of directors of the Company approved a one-for-ten reverse stock split of the Company’s issued and outstanding shares of common stock. On September 21, 2021, the Company filed Amendment No. 1 to its Second Amended and Restated Articles of Incorporation reflecting the reverse split and name change. This took effect on September 22, 2021 upon approval from FINRA. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto, and elsewhere in this Form 10-Q, have been retroactively adjusted to give effect to the reverse stock split as if such reverse stock split occurred on the first day of the first period presented.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Recently Issued Accounting Pronouncements

 

The Financial Accounting Standards Board and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2022. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term.

 

Reclassification

 

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. Certain intercompany revenues and expenses were included in revenue and general and administration expenses. These reclassifications had no effect on the previously reported net income.

 

Revisions to Previously Issued Financial Statements

 

For the six months ending June 30, 2022, the Company identified an error related to the accounting guidance for intercompany revenues and expenses. For the six months ending June 30, 2022 the Company recorded $869,249 of intercompany revenues to healthcare revenue and $869,249 of intercompany expenses in general and administrative expenses.

 

The Company assessed the materiality of this error on prior period financial statements in accordance with the SEC Staff Accounting Bulletin Number 99, Materiality, and ASC 250-10, Accounting Changes and Error Corrections. The error did not have any effect on the Company’s previously reported Condensed Consolidated Statements of Cash Flows and Condensed Consolidated Statements of Shareholder’s Deficit. The Company determined that this error was not material to the financial statements for the six months ended June 30, 2022. The Company decided to correct this immaterial error as revision to previously issued financial statement and has revised the June 30, 2022 financial statements presented herein.

 

The below tables summarize the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations for the six months ended June 30, 2022:

 

   As previously reported   Revision adjustments   As revised 
   Six Months Ended 
   June 30, 2022 
   As previously reported   Revision adjustments   As revised 
Revenue               
Rental Revenue  $311,063   $-   $311,063 
Healthcare Revenue   18,642,051    (869,249)   17,772,802 
Healthcare Grant Revenue   2,603,659    -    2,603,659 
Total Revenue   21,556,773    (869,249)   20,987,524 
Expenses               
Property Taxes, Insurance and Other Operating   13,964,841         13,964,841 
General and Administrative   4,227,834    (869,249)   3,358,585 
Provision for Bad Debts   531,474         531,474 
Depreciation and Amortization   895,037         895,037 
Total Expenses   19,619,186    (869,249)   18,749,937 
Income from Operations   1,937,587         1,937,587 
Other (Income) Expense               
Loss (Gain) on Extinguishment of Debt   46,466         46,466 
Interest Expense, net   716,403         716,403 
Gain on Forgiveness of PPP Loan   -         - 
Other Income   (81,886)        (81,886)
Lease Termination Expense   -         - 
Total Other (Income) Expense   680,983         680,983 
Net Income (Loss)  $1,256,604        $1,256,604 

  

During the preparation of the nine months ending September 30, 2022, financial statements management became aware of misstatements in the financial statements of $191,589 and $469,302 of healthcare revenue and accounts receivable reported during the three and six month periods ended March 31, 2022 and June 30, 2022, respectively.

 

The Company determined that cash payments received from a Medicare B bad debt reimbursement program were recorded directly to revenue rather than a reduction to the account receivable account to which the receivables were recorded, causing both revenue and receivables to be overstated at each reporting periods.

 

The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended March 31, 2022:

 

   Reported   Revision adjustments   Adjusted 
Three months ended March 31, 2022
   Reported   Revision adjustments   Adjusted 
P&L Analysis               
Total Revenue  $10,091,006   $(191,589)  $9,899,417 
Healthcare Revenue   9,367,854    

(191,589

)   9,176,265 
Operating Income   615,396    (191,589)   423,807 
Net Income   228,679    (191,589)   37,090 
EPS   0.07         0.01 
WASO   3,052,769         3,052,769 
                
Balance Sheet Analysis               
Accounts Receivable  $4,168,272   $

(191,589

)  $3,976,683 
Current Assets   7,474,534    

(191,589

)   7,282,945 
Total Assets   46,086,051    

(191,589

)   45,894,462 
Working Capital   38,478,308    

(191,589

)   38,286,719 
Accumulated Deficit   (11,089,701)  (191,589)   (11,281,290)
Total Equity   3,632,327    

(191,589

)   3,440,738 

 

The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended June 30, 2022:

 

   YTD Reported   Revision adjustment   YTD Adjusted   QTD Reported   Revision adjustment   QTD Adjusted 
Three and six months ended June 30, 2022
   YTD Reported   Revision adjustment   YTD Adjusted   QTD Reported   Revision adjustment   QTD Adjusted 
P&L analysis                              
Total Revenue  $20,687,524   $

(469,302

)  $20,218,222   $10,596,518   $

(277,713

)  $10,318,805 
Healthcare Revenue   17,772,802    (469,302)   17,303,500    8,404,948    (277,713)   8,127,235 
Operating Income   1,937,587    

(469,302

)   1,468,285    1,321,651    

(277,713

)   1,043,938 
Net Income   1,256,604    (469,302)   787,302    1,027,925    

(277,713

)   750,212 
EPS   0.42         0.26    0.34         0.25 
WASO   2,998,361         2,998,361    3,054,627         3,054,627 
                               
Balance Sheet analysis                              
Accounts Receivable  $5,167,862   $

(469,302

)  $4,698,560                
Current Assets   8,789,109    

(469,302

)   8,319,807                
Total Assets   47,014,470    

(469,302

)   46,545,168                
Working Capital   32,534,605    

(469,302

)   32,065,303                
Accumulated Deficit   (10,061,776)   (469,302)   (10,531,078)               
Total Equity   4,660,252    

(469,302

)   4,190,950                

 

 

Earnings per Share

 

Basic earnings per share are based on the weighted-average number of shares of common stock outstanding. FASB ASC Topic 260, “Earnings per Share”, requires the Company to include additional shares in the computation of earnings per share, assuming dilution.

 

Diluted earnings per share are based on the assumption that all dilutive options and warrants were converted or exercised by applying the treasury stock method and that all convertible preferred stock were converted into common shares by applying the if-converted method. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period or at the time of issuance, if later, and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, the preferred dividends applicable to convertible preferred stock are added back to the numerator. The convertible preferred stock is assumed to have been converted at the beginning of the period or at time of issuance, if later, and the resulting common shares are included in the denominator.

 

We calculate basic earnings per share by dividing net income attributable to common stockholders (the “numerator”) by the weighted average number of common shares outstanding (the “denominator”) during the reporting period. Diluted earnings per share is calculated similarly but reflects the potential impact of outstanding options, warrants and other commitments to issue common stock, including shares issuable upon the conversion of convertible preferred stock outstanding, except where the impact would be anti-dilutive.

 

The following table sets forth the computation of basic and diluted earnings per share:

 

   2022   2021   2022   2021 
   Nine Months Ended   Three Months Ended 
   September 30,   September 30, 
   2022   2021   2022   2021 
Numerator for basic earnings per share:                    
Net Income (Loss) Attributable to Selectis Health, Inc.   (203,623)   (483,716)   (990,925)   (52,992)
Series D Preferred Dividends   (22,500)   (22,500)   (7,500)   (7,500)
Net Income (Loss) Attributable to Common Stockholders - Basic   (226,123)   (506,216)   (998,425)   (60,492)
                     
Numerator for diluted earnings per share:                    
Net Income (Loss) Attributable to Common Stockholders   (226,123)   (506,216)   (998,425)   (60,492)
Series D Preferred Dividends   22,500    22,500    7,500    7,500 
Net Income (Loss) Attributable to Common Stockholders - Diluted   (203,623)   (483,716)   (990,925)   (52,992)
                     
Denominator for basic earnings per share:                    
Weighted Average Common Shares Outstanding   3,053,970    2,741,186    3,054,588    2,824,560 
                     
Denominator for diluted earnings per share:                    
Weighted Average Common Shares Outstanding - Basic   3,053,970    2,741,186    3,054,588    2,824,560 
Effect of dilutive securities:                    
Conversion of preferred shares   -    -    -    - 
Exercise of warrants   -    -    -    - 
Weighted Average Common Shares Outstanding - Diluted   3,053,970    2,741,186    3,054,588    2,824,560 
                     
Net Income (Loss) per Share Attributable to Common Stockholders:                    
Basic   (0.07)   (0.18)   (0.33)   (0.02)
Diluted   (0.07)   (0.18)   (0.33)   (0.02)

 

 

Fair Value Measurements

 

The Company utilizes the methods of fair value measurement as described in ASC 820 to value its financial assets and liabilities. As defined in ASC 820, fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

 

Level 1 – Quoted market prices in active markets for identical assets or liabilities at the measurement date.

 

Level 2 – Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data.

 

Level 3 – Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments.

 

A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

 

The Company has no financial assets or financial liabilities that are required to be measured at fair value on a recurring basis as of September 30, 2022.

 

Our consolidated balance sheets include the following financial instruments: cash and cash equivalents, accounts receivable, restricted cash, accounts payable, debt and lease security deposit. We consider the carrying values of our short-term financial instruments to approximate fair value because they generally expose the Company to limited credit risk, because of the short period of time between origination of the financial assets and liabilities and their expected settlement, or because of their proximity to acquisition date fair values. The carrying value of debt approximates fair value based on borrowing rates currently available for debt of similar terms and maturities.

 

Upon acquisition of real estate properties, the Company determines the total purchase price of each property and allocates this price based on the fair value of the tangible assets and intangible assets, if any, acquired and any liabilities assumed based on Level 3 inputs. These Level 3 inputs can include comparable sales values, discount rates, and capitalization rates from a third-party appraisal or other market sources.

 

 

 

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.4
PROPERTY AND EQUIPMENT, NET
9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET

3. PROPERTY AND EQUIPMENT, NET

 

The gross carrying amount and accumulated depreciation of the Company’s property and equipment as of September 30, 2022, and December 31, 2021, are as follows:

 

   September 30, 2022   December 31, 2021 
         
Land  $1,778,250   $1,778,250 
Land Improvements   329,055    329,055 
Buildings and Improvements   43,230,535    44,574,401 
Furniture, Fixtures and Equipment   2,436,932    2,322,297 

Property and Equipment, gross

   47,774,772    49,004,003 
           
Less Accumulated Depreciation   (11,768,056)   (10,419,411)
           

Property and Equipment, net

  $36,006,716   $37,024,592 

 

   2022   2021 
   For the Nine Months Ended September 30, 
   2022   2021 
         
Depreciation Expense (excluding Intangible Assets)  $1,348,645   $1,286,279 

 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.4
INVESTMENTS IN DEBT SECURITIES
9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
INVESTMENTS IN DEBT SECURITIES

4. INVESTMENTS IN DEBT SECURITIES

 

At September 30, 2022 and December 31, 2021, the Company held investments in debt securities that were classified as held-to-maturity and carried at amortized costs. Held-to-maturity securities consisted of the following:

 

   September 30, 2022   December 31, 2021 
            
States and Municipalities  $24,387   $24,387 

 

Contractual maturity of held-to-maturity securities at September 30, 2022, is $24,387, all due in one year or less, and total value of securities at their respective maturity dates is $24,387. Actual maturities may differ from contractual maturities because some borrowers have the right to call or prepay obligations with or without call or prepayment penalties.

 

 

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT AND DEBT - RELATED PARTIES
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
DEBT AND DEBT - RELATED PARTIES

5. DEBT AND DEBT - RELATED PARTIES

 

The following is a summary of the Company’s debt outstanding as of September 30, 2022, and December 31, 2021:

 

   September 30, 2022   December 31, 2021 
Senior Secured Promissory Notes  $1,025,000   $1,305,000 
Senior Secured Promissory Notes - Related Parties   750,000    750,000 
Fixed-Rate Mortgage Loans   30,695,361    31,407,503 
Variable-Rate Mortgage Loans   4,919,504    5,063,841 
Other Debt, Subordinated Secured   

741,000

    

741,000

 
Other Debt, Subordinated Secured - Related Parties   150,000    150,000 
Other Debt, Subordinated Secured - Seller Financing   65,361    93,251 
Debt Instrument, Gross   38,346,641    39,510,595 
Unamortized Discount and Debt Issuance Costs   (868,561)   (1,243,071)
           
Debt Instrument, Net of Discount  $37,478,080   $38,267,524 
As presented in the Consolidated Balance Sheets:          
           
Current Maturities of Long Term Debt, Net  $2,049,750   $6,312,562 
Short term debt – Related Parties, Net   150,000    150,000 
Debt, Net   34,528,330    31,054,962 
Debt – Related Parties, Net   750,000    750,000 

 

The weighted average interest rate and term of our fixed rate debt are 4.03% and 16.33 years, respectively, as of September 30, 2022. The weighted average interest rate and term of our variable rate debt are 5.90% and 16.11 years, respectively, as of September 30, 2022.

 

Corporate Senior and Senior Secured Promissory Notes

 

As of September 30, 2022, and December 31, 2021, the senior secured notes are subject to annual interest ranging from 10% to 11% and initially matured on October 31, 2021. These notes were extended to June 30, 2023 and as consideration the Company modified the outstanding warrants to extend the life and additional 1.67 years. As a result of the warrant modification, the Company recorded the incremental increase in fair value of $844,425 as a debt discount which will be amortized over the new life of the loans.

 

 

Mortgage Loans and Lines of Credit Secured by Real Estate

 

Mortgage loans and other debts such as line of credit here are collateralized by all assets of each nursing home property and an assignment of its rents. Collateral for certain mortgage loans includes the personal guarantee of Christopher Brogdon, formerly but no longer a related party, or corporate guarantees. Mortgage loans for the periods presented consisted of the following:

 

   Number of   Total Face   Total Principal Outstanding as of 
State  Properties   Amount   September 30, 2022   December 31, 2021 
Arkansas(1)   1   $5,000,000   $3,937,978   $4,058,338 
Georgia(2)   5   $17,765,992   $16,156,093   $16,581,232 
Ohio   1   $3,000,000   $2,728,599   $2,728,599 
Oklahoma(3)   6   $13,331,325   $12,792,194   $12,895,890 
    13   $39,097,317   $35,614,825   $36,264,059 

 

(1)The mortgage loan collateralized by this property is 80% guaranteed by the USDA and requires an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year. Guarantors under the mortgage loan include Christopher Brogdon. Mr. Brogdon has assumed operations of the facility and is making payments of principal and interest on the loan on our behalf in lieu of paying rent on the facility to us. During the nine months ended September 30, 2022, the Company recognized other income of $118,716 for repayments on the loan.
  
(2)The Company has refinanced two of its mortgages that would have matured in June and October of 2021 amounting to $2,961,167 and $3,289,595, to extend their maturity dates to May 2024 for both.
  
(3)The Company refinanced all three mortgages in July 2021, that would have matured in June and July of 2021 amounting to $2,065,969, $750,000, and $500,000, to extend their maturity dates to June, 2027 for all three. Additionally, the Company has refinanced the primary mortgage at the Southern Hills Campus, for 35 years at 2.38%

 

Subordinated, Corporate and Other Debt

 

Other debt due at September 30, 2022 and December 31, 2021 includes unsecured notes payable issued to entities controlled by the Company used to facilitate the acquisition of the nursing home properties.

 

       Principal Outstanding at   Stated Interest   
Property  Face Amount   September 30, 2022   December 31, 2021   Rate  Maturity Date
Goodwill Nursing Home (1)  $2,030,000   $741,000   $741,000   13% Fixed  December 31, 2019
Goodwill Nursing Home - Related Party (1)  $150,000   $150,000   $150,000   13% Fixed  December 31, 2019
Higher Call Nursing Center (2)  $150,000   $65,361   $93,251   8% Fixed  April 1, 2024
                      
        $956,361   $984,251       

 

 

Our corporate debt at September 30, 2022, and December 31, 2021 includes unsecured notes and notes secured by all assets of the Company not serving as collateral for other notes.

 

       Principal Outstanding at   Stated Interest   
Series  Face Amount   September 30, 2022   December 31,2021   Rate  Maturity Date
                   
10% Senior Secured Promissory Notes   1,670,000    1,025,000    1,305,000   10.0% Fixed  June 30, 2024
11% Senior Secured Promissory Notes – Related Party   975,000    750,000    750,000   10.0% Fixed  June 30, 2024
                      
        $1,025,000   $2,055,000       

 

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKHOLDERS’ EQUITY
9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

6. STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

During the nine months ended September 30, 2022 and 2021, the Company paid $15,000 and $30,000 respectively for Series D preferred stock dividends. Dividends of $22,500 were declared during the nine months ended September 30, 2022 and September 30, 2021. All quarterly dividends previously declared have been paid.

 

Common Stock

 

For the nine months ended September 30, 2022, the Company did not issue nor did it pay dividends on common stock.

 

 

Common Stock Warrants

 

As of September 30, 2022, and December 31, 2021, the Company had 206,000, of outstanding warrants to purchase common stock at a weighted average exercise price of $5.00, respectively, and weighted average remaining term of 0.19 years and 0.93 years, respectively. The aggregate intrinsic value of common stock warrants outstanding as of September 30, 2022, and December 31, 2021 was $360,052 and $355,877, respectively. Activity for the nine months ended September 30, 2022, related to common stock warrants is as follows:

 

   September 30, 2022 
   Number of   Weighted Average 
   Warrants   Exercise Price 
         
Beginning Balance   206,000   $5 
Exercised   -    - 
Expired   -             - 
           
Ending Balance   206,000   $5 

 

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.4
OTHER CURRENT LIABILITY
9 Months Ended
Sep. 30, 2022
Other Liabilities Disclosure [Abstract]  
OTHER CURRENT LIABILITY

7. OTHER CURRENT LIABILITY

 

During the year ended December 31, 2021 the Company received an overpayment from Medicare of $931,446. Beginning in February, 2022 payments were recouped to satisfy the overpayment. As of September 30, 2022, this liability has been satisfied.

 

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.4
RELATED PARTIES
9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
RELATED PARTIES

8. RELATED PARTIES

 

Clifford Neuman, a former member of the Company’s Board of Directors, provided legal services to the Company. As of September 30, 2022, and December 31, 2021, the Company owed Mr. Neuman for legal services rendered $5,640 and $21,571, respectively. During the nine months ended September 30, 2022 the Company has paid Mr. Neuman $64,433 for legal services. During the year ended December 31, 2021 the Company paid Mr. Neuman $158,392 for legal services.

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.4
FACILITY LEASES
9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
FACILITY LEASES

8. FACILITY LEASES

 

The following table summarizes our leasing arrangements related to the Company’s healthcare facilities at September 30, 2022:

 

   Monthly Lease       
Facility  Income (1)   Lease Expiration  Renewal Option if any
Goodwill (1)  $48,125   February 1, 2027  Term may be extended for one additional five-year term.

 

(1) The lease became effective on February 1, 2017, and the facility began generating rental revenue thereafter.

 

Future cash payments for rent to be received during the initial terms of the leases for the next five years and thereafter are as follows:

 

Years Ending September 30,    
2022  $156,870 
2023   635,026 
2024   643,401 
2025   651,954 
2026   660,665 
2027 and Thereafter   55,116 
      
Total  $2,803,032 

 

 

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.4
LEGAL PROCEEDINGS
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
LEGAL PROCEEDINGS

9. LEGAL PROCEEDINGS

 

The Company and/or its affiliated subsidiaries are or were involved in the following litigation:

 

Bailey v. GL Nursing, LLC, et. Al in the Circuit Court of Lonoke County, Arkansas, 23rd Circuit, 43CV-19-151.

 

In April 2019, the Company’s wholly-owned subsidiary was named as a co-defendant in the action arising out of a claimed personal injury suffered by the plaintiff while a resident of the skilled nursing home owned, but not operated, by GL Nursing. As of this date, we have engaged legal counsel, but no further information is known regarding the merits of the claim. After initial inquiry, it does not appear that the lease operator of the facility had in effect general liability insurance covering the GL Nursing, as landlord, as required by the operating lease.

 

As we simply were the owners of the property and not the operators, we believe that primary responsibility, if any, falls with the operator at the time. Under the terms of the lease, the operator has a duty to indemnify the Company, a claim which we intend to assert.

 

While it is too early to assess the Company’s exposure, we believe at this time that the likelihood of an adverse outcome is remote.

 

Thomas v. Edwards Redeemer Property Holdings, LLC, et.al., District Court for Oklahoma County, Oklahoma, Case No. CJ 2016-2160.

 

This action arises from a personal injury claim brought by heirs of a former resident of our Edwards Redeemer facility, filed in April 2016. We are entitled to indemnification from the lease operator and should be covered under the lease operator’s general liability policy. As we are not the operators of the facility and believe we have indemnity coverage, we believe we have no exposure. The lease operator’s insurance carrier is providing a defense and indemnity and, as a result, we believe the likelihood of a material adverse result is remote.

 

Edwards Redeemer Property Holdings LLC v. Edwards Redeemer Healthcare & Rehab, LLC, District Court of Oklahoma County, State of Oklahoma, Case No. CJ-19-5883.

 

This action was brought by us against the former lease operator for breaching the lease agreement, removing all the patients, and closing the facility. On October 17, 2019, the Court entered an Order Appointing a Receiver. We have entered into a Settlement Agreement and Release with the Receiver and an Operations Transfer Agreement pursuant to which our newly formed subsidiary will acquire the assets and operations of the facility. In March 2021, the Court approved the Settlement Agreement and Operations Transfer Agreement, the skilled nursing license was assigned to the Company’s wholly-owned subsidiary Park Place Health, LLC and the Company reopened the facility under the name Park Place Health. This matter is considered resolved.

 

Oliphant v. Global Eastman, LLC, et.al., State Court of Cobb County, State of Georgia, Civil Action No. 20-A-3983

 

This is a personal injury lawsuit against various defendants arising out of the death of a patient of the Eastman Healthcare & Rehab Center (the “Facility”). At all relevant times, the Facility was owned by the Company’s wholly owned subsidiary Dodge NH, LLC and leased to Eastman Health & Rehab LLC, an affiliate of Cadence Healthcare, as lease operator. Neither the Company nor any affiliate of the Company had any involvement in patient care at the time of the incident for which complaint was made. The Company relies upon well-settled Georgia law that a landlord has no liability for patient care. The landlord is Dodge NH, LLC. Global Eastman, LLC was not formed as a legal entity during the period of the incident and did not assume the past liabilities as part of the OTA with the receivership of Eastman Healthcare & Rehab LLC which was effective July 1, 2020. Global Eastman LLC was formed on November 21, 2019. Plaintiff has dismissed these claims with prejudice, and the Company has filed a Motion to be awarded attorney’s fees and costs.

 

In the matter of Austin.

 

On December 23, 2020, we received written notice from an attorney of the intent to assert an action for damages against Dodge NH, LLC, which is our subsidiary that owns the nursing facility in Eastman Georgia. The action arises from the shooting death outside of the facility of a woman that worked for our cleaning contractor that cleaned the nursing home. The woman was shot by her former boyfriend who then committed suicide. The incident occurred in December 2019 when the facility was operated by a third-party operator who was in receivership. We do not believe there is any basis in law or fact to hold the owner of the real estate liable, and as a result management has concluded that the likelihood of a material adverse result is remote.

 

In re: Providence HR, LLC v. CRM of Warrenton, LLC, United States Bankruptcy Court, Middle District of Georgia, Macon Division, Case No. 21-50201

 

In re: ALT/WARR, LLC v. CRM of Sparta, LLC, United States Bankruptcy Court, Middle District of Georgia, Macon Division, Case No. 21-50200

 

 

These are companion cases arising out of the Company’s election to terminate the operating leases on the Company’s two facilities in Warrenton and Sparta, Georgia. The Company served a Notice of Termination on each facility and in response the lease operators filed voluntary petitions under Chapter 11 of the US Bankruptcy Code. The Company filed Motions for Relief from Stay which was heard by the Court on March 22, 2021. By Order of the Court, the hearing was continued to May 25, 2021. The Court entered an interim Order requiring the lease operators to comply with their leases, including payment of rent, pending the next hearing. In June 2021, the Court entered an Order approving a Lease Termination Agreement, Operations Transfer Agreement and Interim Management Agreement which had been negotiated by the Company and the two operating tenants, CRM of Warrenton, LLC and CRM of Sparta, LLC. The Lease Termination Agreement and Operations Transfer Agreement became effective upon the granting of a new License by the State of Georgia for the Warrenton and Sparta facilities to two newly formed wholly owned operating subsidiaries of the Company: Selectis Sparta, LLC and Selectis Warrenton, LLC.

 

High Street Nursing, LLC v. Ohio Department of Health, Court of Common Pleas, Franklin County, Ohio, Case No. 21 CV 6559.

 

The Company brought this action through its wholly owned subsidiary High Street Nursing, LLC (“High Street”) against the Ohio Department of Health (ODH) to prevent the Department of Health from revoking the state issued license covering the Meadowview skilled nursing facility located in Seville, Ohio. The facility is owned by High Street and was leased to a third-party operator who abandoned the facility. The Department of Health is trying to revoke the license of the former operator and has refused our request to transfer the license to a new operator controlled by the Company. Our Motion for Temporary Injunction was denied by the Court. We have subsequently filed a Motion for Preliminary and Permanent Injunction which is pending. Our claims against the Department of Health are based upon our property interests in the facility and raise issues of unlawful condemnation and eminent domain. No prediction can be made regarding the outcome of this matter; but the Company will pursue the ODH to the fullest extent.

 

In the Matter of Hunter

 

The Company received a spoliation letter from an attorney dated October 8, 2021, advising of the intent to assert a personal injury claim against our operating subsidiary Glen Eagle Health & Rehab, LLC which operates our skilled nursing facility in Abbeville, Georgia. We have been provided no further information, but after reviewing the information we believe at this time that the likelihood of an adverse outcome is remote.

 

Edwards Redeemer Property Holdings, LLC, et.al. v. Buildstrong Roofing and Construction, Inc.,et.al. District Court of and for Tulsa County, Oklahoma, Case No. CJ-202

 

This Company brought this action against a contractor that performed work at our Park Place facility in Oklahoma City and our Southern Hills SNF in Tulsa. The claims are based upon negligence and breach of contract for subpar work due to defects in materials, workmanship and Buildstrong not providing services for which they received payment. The case is pending.

 

Tara Gaspar, et.al v. GL Nursing, LLC, et.al., Circuit Court of Lonoke County, Arkansas, Civil Division, Case. No. 43CV-21-864.

 

This case is a personal injury action in which our subsidiary GL Nursing, LLC was joined as a defendant because it is the owner of the property leased to an operating tenant. The action is based upon quality of care over which we had no control. We believe that our risk of a material adverse outcome is remote.

 

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.4
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

10. SUBSEQUENT EVENTS

 

Effective October 4, 2022, the Company changed its independent registered public accountants by engaging Marcum LLP as the company’s independent registered public accounting firm for the year ended December 31, 2022. Marcum LLP will also review the Company’s interim report as of and for the period ended September 30, 2022. Haynie & Company had previously served as the Company’s independent registered public accountants for the year ended December 31, 2021.

 

Effective October 17, 2022, Clifford Neuman resigned as a director and Andy Sink was appointed to fill the vacancy created by Mr. Neuman’s resignation. It was determined that Mr. Neuman did not qualify as an “independent” director within the meaning of Nasdaq regulations; and Mr. Neuman agreed to resign from the Board to facilitate the Company’s efforts to up list to the Nasdaq Stock Market.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and in conjunction with the rules and regulations of the Securities Exchange Commission. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary to make the consolidated financial statements not misleading have been included. Operating results for the nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the entire year. The unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission.

 

In May 2021, the board of directors of the Company approved a one-for-ten reverse stock split of the Company’s issued and outstanding shares of common stock. On September 21, 2021, the Company filed Amendment No. 1 to its Second Amended and Restated Articles of Incorporation reflecting the reverse split and name change. This took effect on September 22, 2021 upon approval from FINRA. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto, and elsewhere in this Form 10-Q, have been retroactively adjusted to give effect to the reverse stock split as if such reverse stock split occurred on the first day of the first period presented.

 

Principles of Consolidation

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

 

The Financial Accounting Standards Board and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2022. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term.

 

Reclassification

Reclassification

 

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. Certain intercompany revenues and expenses were included in revenue and general and administration expenses. These reclassifications had no effect on the previously reported net income.

 

Revisions to Previously Issued Financial Statements

 

For the six months ending June 30, 2022, the Company identified an error related to the accounting guidance for intercompany revenues and expenses. For the six months ending June 30, 2022 the Company recorded $869,249 of intercompany revenues to healthcare revenue and $869,249 of intercompany expenses in general and administrative expenses.

 

The Company assessed the materiality of this error on prior period financial statements in accordance with the SEC Staff Accounting Bulletin Number 99, Materiality, and ASC 250-10, Accounting Changes and Error Corrections. The error did not have any effect on the Company’s previously reported Condensed Consolidated Statements of Cash Flows and Condensed Consolidated Statements of Shareholder’s Deficit. The Company determined that this error was not material to the financial statements for the six months ended June 30, 2022. The Company decided to correct this immaterial error as revision to previously issued financial statement and has revised the June 30, 2022 financial statements presented herein.

 

The below tables summarize the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations for the six months ended June 30, 2022:

 

   As previously reported   Revision adjustments   As revised 
   Six Months Ended 
   June 30, 2022 
   As previously reported   Revision adjustments   As revised 
Revenue               
Rental Revenue  $311,063   $-   $311,063 
Healthcare Revenue   18,642,051    (869,249)   17,772,802 
Healthcare Grant Revenue   2,603,659    -    2,603,659 
Total Revenue   21,556,773    (869,249)   20,987,524 
Expenses               
Property Taxes, Insurance and Other Operating   13,964,841         13,964,841 
General and Administrative   4,227,834    (869,249)   3,358,585 
Provision for Bad Debts   531,474         531,474 
Depreciation and Amortization   895,037         895,037 
Total Expenses   19,619,186    (869,249)   18,749,937 
Income from Operations   1,937,587         1,937,587 
Other (Income) Expense               
Loss (Gain) on Extinguishment of Debt   46,466         46,466 
Interest Expense, net   716,403         716,403 
Gain on Forgiveness of PPP Loan   -         - 
Other Income   (81,886)        (81,886)
Lease Termination Expense   -         - 
Total Other (Income) Expense   680,983         680,983 
Net Income (Loss)  $1,256,604        $1,256,604 

  

During the preparation of the nine months ending September 30, 2022, financial statements management became aware of misstatements in the financial statements of $191,589 and $469,302 of healthcare revenue and accounts receivable reported during the three and six month periods ended March 31, 2022 and June 30, 2022, respectively.

 

The Company determined that cash payments received from a Medicare B bad debt reimbursement program were recorded directly to revenue rather than a reduction to the account receivable account to which the receivables were recorded, causing both revenue and receivables to be overstated at each reporting periods.

 

The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended March 31, 2022:

 

   Reported   Revision adjustments   Adjusted 
Three months ended March 31, 2022
   Reported   Revision adjustments   Adjusted 
P&L Analysis               
Total Revenue  $10,091,006   $(191,589)  $9,899,417 
Healthcare Revenue   9,367,854    

(191,589

)   9,176,265 
Operating Income   615,396    (191,589)   423,807 
Net Income   228,679    (191,589)   37,090 
EPS   0.07         0.01 
WASO   3,052,769         3,052,769 
                
Balance Sheet Analysis               
Accounts Receivable  $4,168,272   $

(191,589

)  $3,976,683 
Current Assets   7,474,534    

(191,589

)   7,282,945 
Total Assets   46,086,051    

(191,589

)   45,894,462 
Working Capital   38,478,308    

(191,589

)   38,286,719 
Accumulated Deficit   (11,089,701)  (191,589)   (11,281,290)
Total Equity   3,632,327    

(191,589

)   3,440,738 

 

The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended June 30, 2022:

 

   YTD Reported   Revision adjustment   YTD Adjusted   QTD Reported   Revision adjustment   QTD Adjusted 
Three and six months ended June 30, 2022
   YTD Reported   Revision adjustment   YTD Adjusted   QTD Reported   Revision adjustment   QTD Adjusted 
P&L analysis                              
Total Revenue  $20,687,524   $

(469,302

)  $20,218,222   $10,596,518   $

(277,713

)  $10,318,805 
Healthcare Revenue   17,772,802    (469,302)   17,303,500    8,404,948    (277,713)   8,127,235 
Operating Income   1,937,587    

(469,302

)   1,468,285    1,321,651    

(277,713

)   1,043,938 
Net Income   1,256,604    (469,302)   787,302    1,027,925    

(277,713

)   750,212 
EPS   0.42         0.26    0.34         0.25 
WASO   2,998,361         2,998,361    3,054,627         3,054,627 
                               
Balance Sheet analysis                              
Accounts Receivable  $5,167,862   $

(469,302

)  $4,698,560                
Current Assets   8,789,109    

(469,302

)   8,319,807                
Total Assets   47,014,470    

(469,302

)   46,545,168                
Working Capital   32,534,605    

(469,302

)   32,065,303                
Accumulated Deficit   (10,061,776)   (469,302)   (10,531,078)               
Total Equity   4,660,252    

(469,302

)   4,190,950                

 

 

Earnings per Share

Earnings per Share

 

Basic earnings per share are based on the weighted-average number of shares of common stock outstanding. FASB ASC Topic 260, “Earnings per Share”, requires the Company to include additional shares in the computation of earnings per share, assuming dilution.

 

Diluted earnings per share are based on the assumption that all dilutive options and warrants were converted or exercised by applying the treasury stock method and that all convertible preferred stock were converted into common shares by applying the if-converted method. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period or at the time of issuance, if later, and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, the preferred dividends applicable to convertible preferred stock are added back to the numerator. The convertible preferred stock is assumed to have been converted at the beginning of the period or at time of issuance, if later, and the resulting common shares are included in the denominator.

 

We calculate basic earnings per share by dividing net income attributable to common stockholders (the “numerator”) by the weighted average number of common shares outstanding (the “denominator”) during the reporting period. Diluted earnings per share is calculated similarly but reflects the potential impact of outstanding options, warrants and other commitments to issue common stock, including shares issuable upon the conversion of convertible preferred stock outstanding, except where the impact would be anti-dilutive.

 

The following table sets forth the computation of basic and diluted earnings per share:

 

   2022   2021   2022   2021 
   Nine Months Ended   Three Months Ended 
   September 30,   September 30, 
   2022   2021   2022   2021 
Numerator for basic earnings per share:                    
Net Income (Loss) Attributable to Selectis Health, Inc.   (203,623)   (483,716)   (990,925)   (52,992)
Series D Preferred Dividends   (22,500)   (22,500)   (7,500)   (7,500)
Net Income (Loss) Attributable to Common Stockholders - Basic   (226,123)   (506,216)   (998,425)   (60,492)
                     
Numerator for diluted earnings per share:                    
Net Income (Loss) Attributable to Common Stockholders   (226,123)   (506,216)   (998,425)   (60,492)
Series D Preferred Dividends   22,500    22,500    7,500    7,500 
Net Income (Loss) Attributable to Common Stockholders - Diluted   (203,623)   (483,716)   (990,925)   (52,992)
                     
Denominator for basic earnings per share:                    
Weighted Average Common Shares Outstanding   3,053,970    2,741,186    3,054,588    2,824,560 
                     
Denominator for diluted earnings per share:                    
Weighted Average Common Shares Outstanding - Basic   3,053,970    2,741,186    3,054,588    2,824,560 
Effect of dilutive securities:                    
Conversion of preferred shares   -    -    -    - 
Exercise of warrants   -    -    -    - 
Weighted Average Common Shares Outstanding - Diluted   3,053,970    2,741,186    3,054,588    2,824,560 
                     
Net Income (Loss) per Share Attributable to Common Stockholders:                    
Basic   (0.07)   (0.18)   (0.33)   (0.02)
Diluted   (0.07)   (0.18)   (0.33)   (0.02)

 

 

Fair Value Measurements

Fair Value Measurements

 

The Company utilizes the methods of fair value measurement as described in ASC 820 to value its financial assets and liabilities. As defined in ASC 820, fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

 

Level 1 – Quoted market prices in active markets for identical assets or liabilities at the measurement date.

 

Level 2 – Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data.

 

Level 3 – Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments.

 

A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

 

The Company has no financial assets or financial liabilities that are required to be measured at fair value on a recurring basis as of September 30, 2022.

 

Our consolidated balance sheets include the following financial instruments: cash and cash equivalents, accounts receivable, restricted cash, accounts payable, debt and lease security deposit. We consider the carrying values of our short-term financial instruments to approximate fair value because they generally expose the Company to limited credit risk, because of the short period of time between origination of the financial assets and liabilities and their expected settlement, or because of their proximity to acquisition date fair values. The carrying value of debt approximates fair value based on borrowing rates currently available for debt of similar terms and maturities.

 

Upon acquisition of real estate properties, the Company determines the total purchase price of each property and allocates this price based on the fair value of the tangible assets and intangible assets, if any, acquired and any liabilities assumed based on Level 3 inputs. These Level 3 inputs can include comparable sales values, discount rates, and capitalization rates from a third-party appraisal or other market sources.

 

 

 

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
SCHEDULE OF RESTATEMENT

The below tables summarize the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations for the six months ended June 30, 2022:

 

   As previously reported   Revision adjustments   As revised 
   Six Months Ended 
   June 30, 2022 
   As previously reported   Revision adjustments   As revised 
Revenue               
Rental Revenue  $311,063   $-   $311,063 
Healthcare Revenue   18,642,051    (869,249)   17,772,802 
Healthcare Grant Revenue   2,603,659    -    2,603,659 
Total Revenue   21,556,773    (869,249)   20,987,524 
Expenses               
Property Taxes, Insurance and Other Operating   13,964,841         13,964,841 
General and Administrative   4,227,834    (869,249)   3,358,585 
Provision for Bad Debts   531,474         531,474 
Depreciation and Amortization   895,037         895,037 
Total Expenses   19,619,186    (869,249)   18,749,937 
Income from Operations   1,937,587         1,937,587 
Other (Income) Expense               
Loss (Gain) on Extinguishment of Debt   46,466         46,466 
Interest Expense, net   716,403         716,403 
Gain on Forgiveness of PPP Loan   -         - 
Other Income   (81,886)        (81,886)
Lease Termination Expense   -         - 
Total Other (Income) Expense   680,983         680,983 
Net Income (Loss)  $1,256,604        $1,256,604 
 

The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended March 31, 2022:

 

   Reported   Revision adjustments   Adjusted 
Three months ended March 31, 2022
   Reported   Revision adjustments   Adjusted 
P&L Analysis               
Total Revenue  $10,091,006   $(191,589)  $9,899,417 
Healthcare Revenue   9,367,854    

(191,589

)   9,176,265 
Operating Income   615,396    (191,589)   423,807 
Net Income   228,679    (191,589)   37,090 
EPS   0.07         0.01 
WASO   3,052,769         3,052,769 
                
Balance Sheet Analysis               
Accounts Receivable  $4,168,272   $

(191,589

)  $3,976,683 
Current Assets   7,474,534    

(191,589

)   7,282,945 
Total Assets   46,086,051    

(191,589

)   45,894,462 
Working Capital   38,478,308    

(191,589

)   38,286,719 
Accumulated Deficit   (11,089,701)  (191,589)   (11,281,290)
Total Equity   3,632,327    

(191,589

)   3,440,738 

 

The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended June 30, 2022:

 

   YTD Reported   Revision adjustment   YTD Adjusted   QTD Reported   Revision adjustment   QTD Adjusted 
Three and six months ended June 30, 2022
   YTD Reported   Revision adjustment   YTD Adjusted   QTD Reported   Revision adjustment   QTD Adjusted 
P&L analysis                              
Total Revenue  $20,687,524   $

(469,302

)  $20,218,222   $10,596,518   $

(277,713

)  $10,318,805 
Healthcare Revenue   17,772,802    (469,302)   17,303,500    8,404,948    (277,713)   8,127,235 
Operating Income   1,937,587    

(469,302

)   1,468,285    1,321,651    

(277,713

)   1,043,938 
Net Income   1,256,604    (469,302)   787,302    1,027,925    

(277,713

)   750,212 
EPS   0.42         0.26    0.34         0.25 
WASO   2,998,361         2,998,361    3,054,627         3,054,627 
                               
Balance Sheet analysis                              
Accounts Receivable  $5,167,862   $

(469,302

)  $4,698,560                
Current Assets   8,789,109    

(469,302

)   8,319,807                
Total Assets   47,014,470    

(469,302

)   46,545,168                
Working Capital   32,534,605    

(469,302

)   32,065,303                
Accumulated Deficit   (10,061,776)   (469,302)   (10,531,078)               
Total Equity   4,660,252    

(469,302

)   4,190,950                
 

SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE

The following table sets forth the computation of basic and diluted earnings per share:

 

   2022   2021   2022   2021 
   Nine Months Ended   Three Months Ended 
   September 30,   September 30, 
   2022   2021   2022   2021 
Numerator for basic earnings per share:                    
Net Income (Loss) Attributable to Selectis Health, Inc.   (203,623)   (483,716)   (990,925)   (52,992)
Series D Preferred Dividends   (22,500)   (22,500)   (7,500)   (7,500)
Net Income (Loss) Attributable to Common Stockholders - Basic   (226,123)   (506,216)   (998,425)   (60,492)
                     
Numerator for diluted earnings per share:                    
Net Income (Loss) Attributable to Common Stockholders   (226,123)   (506,216)   (998,425)   (60,492)
Series D Preferred Dividends   22,500    22,500    7,500    7,500 
Net Income (Loss) Attributable to Common Stockholders - Diluted   (203,623)   (483,716)   (990,925)   (52,992)
                     
Denominator for basic earnings per share:                    
Weighted Average Common Shares Outstanding   3,053,970    2,741,186    3,054,588    2,824,560 
                     
Denominator for diluted earnings per share:                    
Weighted Average Common Shares Outstanding - Basic   3,053,970    2,741,186    3,054,588    2,824,560 
Effect of dilutive securities:                    
Conversion of preferred shares   -    -    -    - 
Exercise of warrants   -    -    -    - 
Weighted Average Common Shares Outstanding - Diluted   3,053,970    2,741,186    3,054,588    2,824,560 
                     
Net Income (Loss) per Share Attributable to Common Stockholders:                    
Basic   (0.07)   (0.18)   (0.33)   (0.02)
Diluted   (0.07)   (0.18)   (0.33)   (0.02)
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.4
PROPERTY AND EQUIPMENT, NET (Tables)
9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT

The gross carrying amount and accumulated depreciation of the Company’s property and equipment as of September 30, 2022, and December 31, 2021, are as follows:

 

   September 30, 2022   December 31, 2021 
         
Land  $1,778,250   $1,778,250 
Land Improvements   329,055    329,055 
Buildings and Improvements   43,230,535    44,574,401 
Furniture, Fixtures and Equipment   2,436,932    2,322,297 

Property and Equipment, gross

   47,774,772    49,004,003 
           
Less Accumulated Depreciation   (11,768,056)   (10,419,411)
           

Property and Equipment, net

  $36,006,716   $37,024,592 

 

   2022   2021 
   For the Nine Months Ended September 30, 
   2022   2021 
         
Depreciation Expense (excluding Intangible Assets)  $1,348,645   $1,286,279 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.4
INVESTMENTS IN DEBT SECURITIES (Tables)
9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES

At September 30, 2022 and December 31, 2021, the Company held investments in debt securities that were classified as held-to-maturity and carried at amortized costs. Held-to-maturity securities consisted of the following:

 

   September 30, 2022   December 31, 2021 
            
States and Municipalities  $24,387   $24,387 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT AND DEBT - RELATED PARTIES (Tables)
9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
SCHEDULE OF DEBT INSTRUMENTS

The following is a summary of the Company’s debt outstanding as of September 30, 2022, and December 31, 2021:

 

   September 30, 2022   December 31, 2021 
Senior Secured Promissory Notes  $1,025,000   $1,305,000 
Senior Secured Promissory Notes - Related Parties   750,000    750,000 
Fixed-Rate Mortgage Loans   30,695,361    31,407,503 
Variable-Rate Mortgage Loans   4,919,504    5,063,841 
Other Debt, Subordinated Secured   

741,000

    

741,000

 
Other Debt, Subordinated Secured - Related Parties   150,000    150,000 
Other Debt, Subordinated Secured - Seller Financing   65,361    93,251 
Debt Instrument, Gross   38,346,641    39,510,595 
Unamortized Discount and Debt Issuance Costs   (868,561)   (1,243,071)
           
Debt Instrument, Net of Discount  $37,478,080   $38,267,524 
As presented in the Consolidated Balance Sheets:          
           
Current Maturities of Long Term Debt, Net  $2,049,750   $6,312,562 
Short term debt – Related Parties, Net   150,000    150,000 
Debt, Net   34,528,330    31,054,962 
Debt – Related Parties, Net   750,000    750,000 
SCHEDULE OF MORTGAGE LOAN DEBT

   Number of   Total Face   Total Principal Outstanding as of 
State  Properties   Amount   September 30, 2022   December 31, 2021 
Arkansas(1)   1   $5,000,000   $3,937,978   $4,058,338 
Georgia(2)   5   $17,765,992   $16,156,093   $16,581,232 
Ohio   1   $3,000,000   $2,728,599   $2,728,599 
Oklahoma(3)   6   $13,331,325   $12,792,194   $12,895,890 
    13   $39,097,317   $35,614,825   $36,264,059 

 

(1)The mortgage loan collateralized by this property is 80% guaranteed by the USDA and requires an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year. Guarantors under the mortgage loan include Christopher Brogdon. Mr. Brogdon has assumed operations of the facility and is making payments of principal and interest on the loan on our behalf in lieu of paying rent on the facility to us. During the nine months ended September 30, 2022, the Company recognized other income of $118,716 for repayments on the loan.
  
(2)The Company has refinanced two of its mortgages that would have matured in June and October of 2021 amounting to $2,961,167 and $3,289,595, to extend their maturity dates to May 2024 for both.
  
(3)The Company refinanced all three mortgages in July 2021, that would have matured in June and July of 2021 amounting to $2,065,969, $750,000, and $500,000, to extend their maturity dates to June, 2027 for all three. Additionally, the Company has refinanced the primary mortgage at the Southern Hills Campus, for 35 years at 2.38%
SCHEDULE OF OTHER DEBT

       Principal Outstanding at   Stated Interest   
Property  Face Amount   September 30, 2022   December 31, 2021   Rate  Maturity Date
Goodwill Nursing Home (1)  $2,030,000   $741,000   $741,000   13% Fixed  December 31, 2019
Goodwill Nursing Home - Related Party (1)  $150,000   $150,000   $150,000   13% Fixed  December 31, 2019
Higher Call Nursing Center (2)  $150,000   $65,361   $93,251   8% Fixed  April 1, 2024
                      
        $956,361   $984,251       

SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS

       Principal Outstanding at   Stated Interest   
Series  Face Amount   September 30, 2022   December 31,2021   Rate  Maturity Date
                   
10% Senior Secured Promissory Notes   1,670,000    1,025,000    1,305,000   10.0% Fixed  June 30, 2024
11% Senior Secured Promissory Notes – Related Party   975,000    750,000    750,000   10.0% Fixed  June 30, 2024
                      
        $1,025,000   $2,055,000       

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKHOLDERS’ EQUITY (Tables)
9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY

   September 30, 2022 
   Number of   Weighted Average 
   Warrants   Exercise Price 
         
Beginning Balance   206,000   $5 
Exercised   -    - 
Expired   -             - 
           
Ending Balance   206,000   $5 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.4
FACILITY LEASES (Tables)
9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
SCHEDULE OF LEASING ARRANGEMENTS

The following table summarizes our leasing arrangements related to the Company’s healthcare facilities at September 30, 2022:

 

   Monthly Lease       
Facility  Income (1)   Lease Expiration  Renewal Option if any
Goodwill (1)  $48,125   February 1, 2027  Term may be extended for one additional five-year term.

 

(1) The lease became effective on February 1, 2017, and the facility began generating rental revenue thereafter.
SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE

Future cash payments for rent to be received during the initial terms of the leases for the next five years and thereafter are as follows:

 

Years Ending September 30,    
2022  $156,870 
2023   635,026 
2024   643,401 
2025   651,954 
2026   660,665 
2027 and Thereafter   55,116 
      
Total  $2,803,032 

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.4
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net Cash Provided by (Used in) Operating Activities $ 650,648 $ 1,604,764
Working capital deficit $ 800,000  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF RESTATEMENT (Details) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Expenses                    
Property Taxes, Insurance and Other Operating $ 7,227,718     $ 4,413,930       $ 21,192,559 $ 12,613,896  
General and Administrative 1,970,890     1,721,292       5,329,475 4,732,115  
Provision for Bad Debts 252,050     12,142       783,524 28,275  
Depreciation and Amortization 453,608     435,013       1,348,645 1,286,279  
Total Expenses 9,904,266     6,582,377       28,654,203 18,660,565  
Income (Loss) from Operations (322,281)     736,678       1,146,004 433,370  
Other (Income) Expense                    
Loss (Gain) on Extinguishment of Debt           (46,466)  
Interest Expense, net 722,226     486,816       1,438,629 1,680,540  
Other Income 53,582     51,856       135,468 548,933  
Lease Termination Expense     354,710       450,427  
Total Other (Income) Expense (668,644)     (789,670)       (1,349,627) (906,436)  
Net Income (Loss) (990,925) $ 750,212 $ 37,090 (52,992) $ (678,780) $ 258,706   (203,623) (473,066)  
Healthcare Revenue 9,581,985     7,319,055       29,800,207 19,093,935  
Net Income $ (990,925)     $ (52,992)       $ (203,623) $ (483,716)  
EPS $ (0.33)     $ (0.02)       $ (0.07) $ (0.18)  
WASO 3,054,588     2,824,560       3,053,970 2,741,186  
Accounts receivable $ 3,064,919             $ 3,064,919   $ 3,506,719
Current Assets 5,480,646             5,480,646   7,968,566
Assets 43,395,957             43,395,957   46,923,722
Accumulated Deficit (11,544,503)             (11,544,503)   (11,318,380)
Rental [Member]                    
Other (Income) Expense                    
Healthcare Revenue 158,875     $ 155,071       469,938 $ 933,360  
Health Care [Member]                    
Other (Income) Expense                    
Healthcare Revenue 9,135,306     6,939,841       26,438,806 17,431,882  
Healthcare Grant Revenue [Member]                    
Other (Income) Expense                    
Healthcare Revenue $ 287,804           $ 2,891,463 $ 504,550  
Previously Reported [Member]                    
Revenue                    
Total Revenue             $ 21,556,773      
Expenses                    
Property Taxes, Insurance and Other Operating             13,964,841      
General and Administrative             4,227,834      
Provision for Bad Debts             531,474      
Depreciation and Amortization             895,037      
Total Expenses             19,619,186      
Income (Loss) from Operations             1,937,587      
Other (Income) Expense                    
Loss (Gain) on Extinguishment of Debt             46,466      
Interest Expense, net             716,403      
Gain on Forgiveness of PPP Loan                  
Other Income             (81,886)      
Lease Termination Expense                  
Total Other (Income) Expense             680,983      
Net Income (Loss)             1,256,604      
Healthcare Revenue     10,091,006       10,596,518     20,687,524
Operating Income     615,396       1,321,651     1,937,587
Net Income     $ 228,679       $ 1,027,925     $ 1,256,604
EPS     $ 0.07       $ 0.34     $ 0.42
WASO     3,052,769       3,054,627     2,998,361
Accounts receivable   5,167,862 $ 4,168,272       $ 5,167,862      
Current Assets   8,789,109 7,474,534       8,789,109      
Assets   47,014,470 46,086,051       47,014,470      
Working Capital   32,534,605 38,478,308       32,534,605      
Accumulated Deficit   (10,061,776) (11,089,701)       (10,061,776)      
Total Equity   4,660,252 3,632,327       4,660,252      
Previously Reported [Member] | Rental [Member]                    
Revenue                    
Total Revenue             311,063      
Previously Reported [Member] | Health Care [Member]                    
Revenue                    
Total Revenue             18,642,051      
Other (Income) Expense                    
Healthcare Revenue     9,367,854       8,404,948     $ 17,772,802
Previously Reported [Member] | Healthcare Grant Revenue [Member]                    
Revenue                    
Total Revenue             2,603,659      
Revision of Prior Period, Adjustment [Member]                    
Revenue                    
Total Revenue             (869,249)      
Expenses                    
General and Administrative             (869,249)      
Total Expenses             (869,249)      
Other (Income) Expense                    
Healthcare Revenue     (191,589)       (277,713)     (469,302)
Operating Income     (191,589)       (277,713)     (469,302)
Net Income     (191,589)       (277,713)     (469,302)
Accounts receivable   (469,302) (191,589)       (469,302)      
Current Assets   (469,302) (191,589)       (469,302)      
Assets   (469,302) (191,589)       (469,302)      
Working Capital   (469,302) (191,589)       (469,302)      
Accumulated Deficit   (469,302) (191,589)       (469,302)      
Total Equity   (469,302) (191,589)       (469,302)      
Revision of Prior Period, Adjustment [Member] | Rental [Member]                    
Revenue                    
Total Revenue                  
Revision of Prior Period, Adjustment [Member] | Health Care [Member]                    
Revenue                    
Total Revenue             (869,249)      
Other (Income) Expense                    
Healthcare Revenue     (191,589)       (277,713)     (469,302)
Revision of Prior Period, Adjustment [Member] | Healthcare Grant Revenue [Member]                    
Revenue                    
Total Revenue                  
Adjusted [Member]                    
Revenue                    
Total Revenue             20,987,524      
Expenses                    
Property Taxes, Insurance and Other Operating             13,964,841      
General and Administrative             3,358,585      
Provision for Bad Debts             531,474      
Depreciation and Amortization             895,037      
Total Expenses             18,749,937      
Income (Loss) from Operations             1,937,587      
Other (Income) Expense                    
Loss (Gain) on Extinguishment of Debt             46,466      
Interest Expense, net             716,403      
Gain on Forgiveness of PPP Loan                  
Other Income             (81,886)      
Lease Termination Expense                  
Total Other (Income) Expense             680,983      
Net Income (Loss)             1,256,604      
Healthcare Revenue     9,899,417       10,318,805     20,218,222
Operating Income     423,807       1,043,938     1,468,285
Net Income     $ 37,090       $ 750,212     $ 787,302
EPS     $ 0.01       $ 0.25     $ 0.26
WASO     3,052,769       3,054,627     2,998,361
Accounts receivable   4,698,560 $ 3,976,683       $ 4,698,560      
Current Assets   8,319,807 7,282,945       8,319,807      
Assets   46,545,168 45,894,462       46,545,168      
Working Capital   32,065,303 38,286,719       32,065,303      
Accumulated Deficit   (10,531,078) (11,281,290)       (10,531,078)      
Total Equity   $ 4,190,950 3,440,738       4,190,950      
Adjusted [Member] | Rental [Member]                    
Revenue                    
Total Revenue             311,063      
Adjusted [Member] | Health Care [Member]                    
Revenue                    
Total Revenue             17,772,802      
Other (Income) Expense                    
Healthcare Revenue     $ 9,176,265       8,127,235     $ 17,303,500
Adjusted [Member] | Healthcare Grant Revenue [Member]                    
Revenue                    
Total Revenue             $ 2,603,659      
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net Income (Loss) per Share Attributable to Common Stockholders:        
Net Income (Loss) Attributable to Selectis Health, Inc. $ (990,925) $ (52,992) $ (203,623) $ (483,716)
Series D Preferred Dividends (7,500) (7,500) (22,500) (22,500)
Net Loss Attributable to Common Stockholders (998,425) (60,492) (226,123) (506,216)
Numerator for diluted earnings per share:        
Net Income (Loss) Attributable to Common Stockholders (998,425) (60,492) (226,123) (506,216)
Series D Preferred Dividends 7,500 7,500 22,500 22,500
Net Income (Loss) Attributable to Common Stockholders - Diluted $ (990,925) $ (52,992) $ (203,623) $ (483,716)
Denominator for diluted earnings per share:        
Weighted Average Common Shares Outstanding 3,054,588 2,824,560 3,053,970 2,741,186
Weighted Average Common Shares Outstanding - Basic 3,054,588 2,824,560 3,053,970 2,741,186
Conversion of preferred shares
Exercise of warrants
Weighted Average Common Shares Outstanding - Diluted 3,054,588 2,824,560 3,053,970 2,741,186
Basic $ (0.33) $ (0.02) $ (0.07) $ (0.18)
Diluted $ (0.33) $ (0.02) $ (0.07) $ (0.18)
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.4
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Mar. 31, 2022
Jun. 30, 2022
Accounting Policies [Abstract]    
Misstatement adjustment amount $ 191,589 $ 469,302
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Property, Plant and Equipment [Line Items]      
Property and Equipment, gross $ 47,774,772   $ 49,004,003
Less Accumulated Depreciation (11,768,056)   (10,419,411)
Property and Equipment, net 36,006,716   37,024,592
Depreciation Expense (excluding Intangible Assets) 1,348,645 $ 1,286,279  
Land [Member]      
Property, Plant and Equipment [Line Items]      
Property and Equipment, gross 1,778,250   1,778,250
Land Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property and Equipment, gross 329,055   329,055
Building Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Property and Equipment, gross 43,230,535   44,574,401
Furniture Fixtures And Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Property and Equipment, gross $ 2,436,932   $ 2,322,297
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
State and Municipal [Member]    
Held-to-maturity securities $ 24,387 $ 24,387
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.4
INVESTMENTS IN DEBT SECURITIES (Details Narrative) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Contractual maturity of held-to-maturity securities $ 24,387 $ 24,387
Held-to-maturity fair value   $ 24,387
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF DEBT INSTRUMENTS (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Debt Instrument, Gross $ 38,346,641 $ 39,510,595
Unamortized Discount and Debt Issuance Costs (868,561) (1,243,071)
Debt Instrument, Net of Discount 37,478,080 38,267,524
Current Maturities of Long Term Debt, Net 2,049,750 6,312,562
Short term debt – Related Parties, Net 150,000 150,000
Debt, Net 34,528,330 31,054,962
Debt – Related Parties, Net 750,000 750,000
Senior Secured Promissory Notes [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Gross 1,025,000 1,305,000
Senior Secured Promissory Notes Related Parties [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Gross 750,000 750,000
Fixed Rate Mortgage Loans [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Gross 30,695,361 31,407,503
Variable Rate Mortgage Loans [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Gross 4,919,504 5,063,841
Other Debt Sub ordinated Secured [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Gross 741,000 741,000
Other Debt Subordinated Secured Related Parties [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Gross 150,000 150,000
Other Debt Subordinated Secured Seller Financing [Member]    
Debt Instrument [Line Items]    
Debt Instrument, Gross $ 65,361 $ 93,251
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF MORTGAGE LOAN DEBT (Details) - Mortgage Loans [Member]
Sep. 30, 2022
USD ($)
Integer
Dec. 31, 2021
USD ($)
Short-Term Debt [Line Items]    
Number of Properties | Integer 13  
Face Amount $ 39,097,317  
Long-term Debt, Gross $ 35,614,825 $ 36,264,059
ARKANSAS    
Short-Term Debt [Line Items]    
Number of Properties | Integer [1] 1  
Face Amount [1] $ 5,000,000  
Long-term Debt, Gross [1] $ 3,937,978 4,058,338
GEORGIA    
Short-Term Debt [Line Items]    
Number of Properties | Integer [2] 5  
Face Amount [2] $ 17,765,992  
Long-term Debt, Gross [2] $ 16,156,093 16,581,232
OHIO    
Short-Term Debt [Line Items]    
Number of Properties | Integer 1  
Face Amount $ 3,000,000  
Long-term Debt, Gross $ 2,728,599 2,728,599
OKLAHOMA    
Short-Term Debt [Line Items]    
Number of Properties | Integer [3] 6  
Face Amount [3] $ 13,331,325  
Long-term Debt, Gross [3] $ 12,792,194 $ 12,895,890
[1] The mortgage loan collateralized by this property is 80% guaranteed by the USDA and requires an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year. Guarantors under the mortgage loan include Christopher Brogdon. Mr. Brogdon has assumed operations of the facility and is making payments of principal and interest on the loan on our behalf in lieu of paying rent on the facility to us. During the nine months ended September 30, 2022, the Company recognized other income of $118,716 for repayments on the loan.
[2] The Company has refinanced two of its mortgages that would have matured in June and October of 2021 amounting to $2,961,167 and $3,289,595, to extend their maturity dates to May 2024 for both.
[3] The Company refinanced all three mortgages in July 2021, that would have matured in June and July of 2021 amounting to $2,065,969, $750,000, and $500,000, to extend their maturity dates to June, 2027 for all three. Additionally, the Company has refinanced the primary mortgage at the Southern Hills Campus, for 35 years at 2.38%
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF MORTGAGE LOAN DEBT (Details) (Parenthetical) - USD ($)
1 Months Ended 9 Months Ended
Jul. 31, 2021
Sep. 30, 2022
Short-Term Debt [Line Items]    
Repayments of First Mortgage Bond   $ 118,716
Maturity date June, 2027  
Debt instrument term 35 years  
Interest rate 2.38%  
First Mortgage Loan [Member]    
Short-Term Debt [Line Items]    
Mortgage one $ 2,065,969 2,961,167
Maturity date May 2024  
Second Mortgage [Member]    
Short-Term Debt [Line Items]    
Mortgage one $ 750,000 $ 3,289,595
Third Mortgage Loan [Member]    
Short-Term Debt [Line Items]    
Mortgage one $ 500,000  
Mortgage Loans [Member]    
Short-Term Debt [Line Items]    
Mortgage loan description [1]   The mortgage loan collateralized by this property is 80% guaranteed by the USDA and requires an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year.
USDA guaranteed rate   80.00%
Annual renewal fee payable   0.25%
[1] The Company refinanced all three mortgages in July 2021, that would have matured in June and July of 2021 amounting to $2,065,969, $750,000, and $500,000, to extend their maturity dates to June, 2027 for all three. Additionally, the Company has refinanced the primary mortgage at the Southern Hills Campus, for 35 years at 2.38%
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF OTHER DEBT (Details) - USD ($)
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]    
Debt, Principal Outstanding $ 1,025,000 $ 2,055,000
Other Debt [Member]    
Short-Term Debt [Line Items]    
Debt, Principal Outstanding 956,361 984,251
Goodwill Nursing Home [Member] | Other Debt [Member]    
Short-Term Debt [Line Items]    
Debt, Face Amount [1] 2,030,000  
Debt, Principal Outstanding [1] $ 741,000 741,000
Debt, Interest Rate [1] 13% Fixed  
Debt, Maturity Date [1] Dec. 31, 2019  
Goodwill Nursing Home - Related Party [Member] | Other Debt [Member]    
Short-Term Debt [Line Items]    
Debt, Face Amount [1] $ 150,000  
Debt, Principal Outstanding [1] $ 150,000 150,000
Debt, Interest Rate [1] 13% Fixed  
Debt, Maturity Date [1] Dec. 31, 2019  
Higher Call Nursing Center [Member] | Other Debt [Member]    
Short-Term Debt [Line Items]    
Debt, Face Amount $ 150,000  
Debt, Principal Outstanding $ 65,361 $ 93,251
Debt, Interest Rate 8% Fixed  
Debt, Maturity Date Apr. 01, 2024  
[1] The lease became effective on February 1, 2017, and the facility began generating rental revenue thereafter.
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS (Details) - USD ($)
9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]    
Debt, Principal Outstanding $ 1,025,000 $ 2,055,000
10% Senior Secured Promissory Note One [Member]    
Short-Term Debt [Line Items]    
Debt, Face Amount 1,670,000  
Debt, Principal Outstanding $ 1,025,000 1,305,000
Debt, Interest Rate 10.0% Fixed  
Debt, Maturity Date Jun. 30, 2024  
11% Senior Secured Promissory Notes Related Party [Member]    
Short-Term Debt [Line Items]    
Debt, Face Amount $ 975,000  
Debt, Principal Outstanding $ 750,000 $ 750,000
Debt, Interest Rate 10.0% Fixed  
Debt, Maturity Date Jun. 30, 2024  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.4
DEBT AND DEBT - RELATED PARTIES (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended
Jul. 31, 2021
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]      
Debt instrument term 35 years    
Debt instrument interest rate 2.38%    
Incremental increase in fair value of debt discount   $ 844,425  
Senior Secured Notes [Member]      
Debt Instrument [Line Items]      
Debt instrument term   1 year 8 months 1 day  
Debt maturity date   Oct. 31, 2021  
Debt instrument extended maturity date   Jun. 30, 2023  
Senior Secured Notes [Member] | Minimum [Member]      
Debt Instrument [Line Items]      
Debt instrument interest rate   10.00%  
Senior Secured Notes [Member] | Maximum [Member]      
Debt Instrument [Line Items]      
Debt instrument interest rate     11.00%
Fixed Rate [Member]      
Debt Instrument [Line Items]      
Debt weighted average interest rate   4.03%  
Debt instrument term   16 years 3 months 29 days  
Variable Rate [Member]      
Debt Instrument [Line Items]      
Debt weighted average interest rate   5.90%  
Debt instrument term   16 years 1 month 9 days  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY (Details) - Warrant [Member]
9 Months Ended
Sep. 30, 2022
$ / shares
shares
Accumulated Other Comprehensive Income (Loss) [Line Items]  
Number of Warrants, Beginning Balance | shares 206,000
Weighted Average Exercise Price, Beginning Balance | $ / shares $ 5
Number of Warrants, Exercised | shares
Weighted Average Exercise Price, Exercised | $ / shares
Number of Warrants, Expired | shares
Weighted Average Exercise Price, Expired | $ / shares
Number of Warrants, Ending Balance | shares 206,000
Weighted Average Exercise Price, Ending Balance | $ / shares $ 5
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.4
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Class of Stock [Line Items]      
Preferred stock, dividend paid $ 22,500 $ 30,000  
Warrant [Member]      
Class of Stock [Line Items]      
Warrants to purchase common stock 206,000   206,000
Weighted average exercise price $ 5.00   $ 5.00
Common stock warrants term 2 months 8 days   11 months 4 days
Aggregate intrinsic value of common stock warrants outstanding $ 360,052   $ 355,877
Dividend Declared [Member]      
Class of Stock [Line Items]      
Dividend, preferred stock 22,500 22,500  
Series D Preferred Stock [Member]      
Class of Stock [Line Items]      
Preferred stock, dividend paid $ 15,000 $ 30,000  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.4
OTHER CURRENT LIABILITY (Details Narrative) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Other Liabilities Disclosure [Abstract]    
Other current liability $ 931,446
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.4
RELATED PARTIES (Details Narrative) - Mr Clifford Neuman [Member] - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Related Party Transaction [Line Items]    
Due to related party $ 5,640 $ 21,571
Repayments of related party debt $ 64,433 $ 158,392
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF LEASING ARRANGEMENTS (Details) - Goodwill [Member]
9 Months Ended
Sep. 30, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Monthly lease income $ 48,125 [1]
Lease expiration date Feb. 01, 2027
Lease renewal option Term may be extended for one additional five-year term.
[1] The lease became effective on February 1, 2017, and the facility began generating rental revenue thereafter.
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.4
SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE (Details)
Sep. 30, 2022
USD ($)
Leases [Abstract]  
2022 $ 156,870
2023 635,026
2024 643,401
2025 651,954
2026 660,665
2027 and Thereafter 55,116
Total $ 2,803,032
XML 54 form10-q_htm.xml IDEA: XBRL DOCUMENT 0000727346 2022-01-01 2022-09-30 0000727346 2023-01-06 0000727346 2022-09-30 0000727346 2021-12-31 0000727346 us-gaap:SeriesAPreferredStockMember 2022-09-30 0000727346 us-gaap:SeriesAPreferredStockMember 2021-12-31 0000727346 us-gaap:SeriesDPreferredStockMember 2022-09-30 0000727346 us-gaap:SeriesDPreferredStockMember 2021-12-31 0000727346 us-gaap:SeriesAPreferredStockMember 2022-01-01 2022-09-30 0000727346 us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-12-31 0000727346 2021-01-01 2021-09-30 0000727346 2022-07-01 2022-09-30 0000727346 2021-07-01 2021-09-30 0000727346 GBCS:RentalMember 2022-01-01 2022-09-30 0000727346 GBCS:RentalMember 2021-01-01 2021-09-30 0000727346 GBCS:RentalMember 2022-07-01 2022-09-30 0000727346 GBCS:RentalMember 2021-07-01 2021-09-30 0000727346 us-gaap:HealthCareMember 2022-01-01 2022-09-30 0000727346 us-gaap:HealthCareMember 2021-01-01 2021-09-30 0000727346 us-gaap:HealthCareMember 2022-07-01 2022-09-30 0000727346 us-gaap:HealthCareMember 2021-07-01 2021-09-30 0000727346 GBCS:HealthcareGrantRevenueMember 2022-01-01 2022-09-30 0000727346 GBCS:HealthcareGrantRevenueMember 2021-01-01 2021-09-30 0000727346 GBCS:HealthcareGrantRevenueMember 2022-07-01 2022-09-30 0000727346 GBCS:HealthcareGrantRevenueMember 2021-07-01 2021-09-30 0000727346 GBCS:ManagementFeeRevenueMember 2022-01-01 2022-09-30 0000727346 GBCS:ManagementFeeRevenueMember 2021-01-01 2021-09-30 0000727346 GBCS:ManagementFeeRevenueMember 2022-07-01 2022-09-30 0000727346 GBCS:ManagementFeeRevenueMember 2021-07-01 2021-09-30 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0000727346 us-gaap:CommonStockMember 2021-12-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000727346 us-gaap:RetainedEarningsMember 2021-12-31 0000727346 us-gaap:NoncontrollingInterestMember 2021-12-31 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-03-31 0000727346 us-gaap:CommonStockMember 2022-03-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000727346 us-gaap:RetainedEarningsMember 2022-03-31 0000727346 us-gaap:NoncontrollingInterestMember 2022-03-31 0000727346 2022-03-31 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-06-30 0000727346 us-gaap:CommonStockMember 2022-06-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000727346 us-gaap:RetainedEarningsMember 2022-06-30 0000727346 us-gaap:NoncontrollingInterestMember 2022-06-30 0000727346 2022-06-30 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0000727346 us-gaap:CommonStockMember 2020-12-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000727346 us-gaap:RetainedEarningsMember 2020-12-31 0000727346 us-gaap:NoncontrollingInterestMember 2020-12-31 0000727346 2020-12-31 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-03-31 0000727346 us-gaap:CommonStockMember 2021-03-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000727346 us-gaap:RetainedEarningsMember 2021-03-31 0000727346 us-gaap:NoncontrollingInterestMember 2021-03-31 0000727346 2021-03-31 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-06-30 0000727346 us-gaap:CommonStockMember 2021-06-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000727346 us-gaap:RetainedEarningsMember 2021-06-30 0000727346 us-gaap:NoncontrollingInterestMember 2021-06-30 0000727346 2021-06-30 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0000727346 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000727346 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000727346 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000727346 2022-01-01 2022-03-31 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0000727346 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000727346 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000727346 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0000727346 2022-04-01 2022-06-30 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0000727346 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000727346 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000727346 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000727346 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000727346 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000727346 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000727346 2021-01-01 2021-03-31 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0000727346 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000727346 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000727346 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000727346 2021-04-01 2021-06-30 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000727346 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000727346 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000727346 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2022-09-30 0000727346 us-gaap:CommonStockMember 2022-09-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000727346 us-gaap:RetainedEarningsMember 2022-09-30 0000727346 us-gaap:NoncontrollingInterestMember 2022-09-30 0000727346 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000727346 us-gaap:SeriesDPreferredStockMember us-gaap:PreferredStockMember 2021-09-30 0000727346 us-gaap:CommonStockMember 2021-09-30 0000727346 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000727346 us-gaap:RetainedEarningsMember 2021-09-30 0000727346 us-gaap:NoncontrollingInterestMember 2021-09-30 0000727346 2021-09-30 0000727346 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-06-30 0000727346 srt:RestatementAdjustmentMember 2022-01-01 2022-06-30 0000727346 GBCS:AdjustedMember 2022-01-01 2022-06-30 0000727346 GBCS:RentalMember srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-06-30 0000727346 GBCS:RentalMember srt:RestatementAdjustmentMember 2022-01-01 2022-06-30 0000727346 GBCS:RentalMember GBCS:AdjustedMember 2022-01-01 2022-06-30 0000727346 us-gaap:HealthCareMember srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-06-30 0000727346 us-gaap:HealthCareMember srt:RestatementAdjustmentMember 2022-01-01 2022-06-30 0000727346 us-gaap:HealthCareMember GBCS:AdjustedMember 2022-01-01 2022-06-30 0000727346 GBCS:HealthcareGrantRevenueMember srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-06-30 0000727346 GBCS:HealthcareGrantRevenueMember srt:RestatementAdjustmentMember 2022-01-01 2022-06-30 0000727346 GBCS:HealthcareGrantRevenueMember GBCS:AdjustedMember 2022-01-01 2022-06-30 0000727346 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-03-31 0000727346 srt:RestatementAdjustmentMember 2022-01-01 2022-03-31 0000727346 GBCS:AdjustedMember 2022-01-01 2022-03-31 0000727346 us-gaap:HealthCareMember srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-03-31 0000727346 us-gaap:HealthCareMember srt:RestatementAdjustmentMember 2022-01-01 2022-03-31 0000727346 us-gaap:HealthCareMember GBCS:AdjustedMember 2022-01-01 2022-03-31 0000727346 srt:ScenarioPreviouslyReportedMember 2022-03-31 0000727346 srt:RestatementAdjustmentMember 2022-03-31 0000727346 GBCS:AdjustedMember 2022-03-31 0000727346 srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000727346 srt:RestatementAdjustmentMember 2021-01-01 2021-12-31 0000727346 GBCS:AdjustedMember 2021-01-01 2021-12-31 0000727346 us-gaap:HealthCareMember srt:ScenarioPreviouslyReportedMember 2021-01-01 2021-12-31 0000727346 us-gaap:HealthCareMember srt:RestatementAdjustmentMember 2021-01-01 2021-12-31 0000727346 us-gaap:HealthCareMember GBCS:AdjustedMember 2021-01-01 2021-12-31 0000727346 srt:ScenarioPreviouslyReportedMember 2022-06-30 0000727346 srt:RestatementAdjustmentMember 2022-06-30 0000727346 GBCS:AdjustedMember 2022-06-30 0000727346 2022-01-01 2022-06-30 0000727346 us-gaap:LandMember 2022-09-30 0000727346 us-gaap:LandMember 2021-12-31 0000727346 us-gaap:LandImprovementsMember 2022-09-30 0000727346 us-gaap:LandImprovementsMember 2021-12-31 0000727346 us-gaap:BuildingImprovementsMember 2022-09-30 0000727346 us-gaap:BuildingImprovementsMember 2021-12-31 0000727346 GBCS:FurnitureFixturesAndEquipmentMember 2022-09-30 0000727346 GBCS:FurnitureFixturesAndEquipmentMember 2021-12-31 0000727346 GBCS:StateandMunicipalMember 2022-09-30 0000727346 GBCS:StateandMunicipalMember 2021-12-31 0000727346 GBCS:SeniorSecuredPromissoryNotesMember 2022-09-30 0000727346 GBCS:SeniorSecuredPromissoryNotesMember 2021-12-31 0000727346 GBCS:SeniorSecuredPromissoryNotesRelatedPartiesMember 2022-09-30 0000727346 GBCS:SeniorSecuredPromissoryNotesRelatedPartiesMember 2021-12-31 0000727346 GBCS:FixedRateMortgageLoansMember 2022-09-30 0000727346 GBCS:FixedRateMortgageLoansMember 2021-12-31 0000727346 GBCS:VariableRateMortgageLoansMember 2022-09-30 0000727346 GBCS:VariableRateMortgageLoansMember 2021-12-31 0000727346 GBCS:OtherDebtSubordinatedSecuredMember 2022-09-30 0000727346 GBCS:OtherDebtSubordinatedSecuredMember 2021-12-31 0000727346 GBCS:OtherDebtSubordinatedSecuredRelatedPartiesMember 2022-09-30 0000727346 GBCS:OtherDebtSubordinatedSecuredRelatedPartiesMember 2021-12-31 0000727346 GBCS:OtherDebtSubordinatedSecuredSellerFinancingMember 2022-09-30 0000727346 GBCS:OtherDebtSubordinatedSecuredSellerFinancingMember 2021-12-31 0000727346 GBCS:FixedRateMember 2022-09-30 0000727346 GBCS:FixedRateMember 2022-01-01 2022-09-30 0000727346 GBCS:VariableRateMember 2022-09-30 0000727346 GBCS:VariableRateMember 2022-01-01 2022-09-30 0000727346 srt:MinimumMember GBCS:SeniorSecuredNotesMember 2022-09-30 0000727346 srt:MaximumMember GBCS:SeniorSecuredNotesMember 2021-12-31 0000727346 GBCS:SeniorSecuredNotesMember 2022-01-01 2022-09-30 0000727346 stpr:AR GBCS:MortgageLoansMember 2022-09-30 0000727346 stpr:AR GBCS:MortgageLoansMember 2021-12-31 0000727346 stpr:GA GBCS:MortgageLoansMember 2022-09-30 0000727346 stpr:GA GBCS:MortgageLoansMember 2021-12-31 0000727346 stpr:OH GBCS:MortgageLoansMember 2022-09-30 0000727346 stpr:OH GBCS:MortgageLoansMember 2021-12-31 0000727346 stpr:OK GBCS:MortgageLoansMember 2022-09-30 0000727346 stpr:OK GBCS:MortgageLoansMember 2021-12-31 0000727346 GBCS:MortgageLoansMember 2022-09-30 0000727346 GBCS:MortgageLoansMember 2021-12-31 0000727346 GBCS:MortgageLoansMember 2022-01-01 2022-09-30 0000727346 GBCS:FirstMortgageLoanMember 2022-01-01 2022-09-30 0000727346 us-gaap:SecondMortgageMember 2022-01-01 2022-09-30 0000727346 GBCS:FirstMortgageLoanMember 2021-07-01 2021-07-31 0000727346 us-gaap:SecondMortgageMember 2021-07-01 2021-07-31 0000727346 GBCS:ThirdMortgageLoanMember 2021-07-01 2021-07-31 0000727346 2021-07-01 2021-07-31 0000727346 2021-07-31 0000727346 GBCS:OtherDebtMember GBCS:GoodwillNursingHomeMember 2022-09-30 0000727346 GBCS:OtherDebtMember GBCS:GoodwillNursingHomeMember 2021-12-31 0000727346 GBCS:OtherDebtMember GBCS:GoodwillNursingHomeMember 2022-01-01 2022-09-30 0000727346 GBCS:OtherDebtMember GBCS:GoodwillNursingHomeOneMember 2022-09-30 0000727346 GBCS:OtherDebtMember GBCS:GoodwillNursingHomeOneMember 2021-12-31 0000727346 GBCS:OtherDebtMember GBCS:GoodwillNursingHomeOneMember 2022-01-01 2022-09-30 0000727346 GBCS:OtherDebtMember GBCS:HigherCallNursingCenterMember 2022-09-30 0000727346 GBCS:OtherDebtMember GBCS:HigherCallNursingCenterMember 2021-12-31 0000727346 GBCS:OtherDebtMember GBCS:HigherCallNursingCenterMember 2022-01-01 2022-09-30 0000727346 GBCS:OtherDebtMember 2022-09-30 0000727346 GBCS:OtherDebtMember 2021-12-31 0000727346 GBCS:TenPercentageSeniorSecuredPromissoryNoteOneMember 2022-09-30 0000727346 GBCS:TenPercentageSeniorSecuredPromissoryNoteOneMember 2021-12-31 0000727346 GBCS:TenPercentageSeniorSecuredPromissoryNoteOneMember 2022-01-01 2022-09-30 0000727346 GBCS:ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember 2022-09-30 0000727346 GBCS:ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember 2021-12-31 0000727346 GBCS:ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember 2022-01-01 2022-09-30 0000727346 us-gaap:SeriesDPreferredStockMember 2022-01-01 2022-09-30 0000727346 us-gaap:SeriesDPreferredStockMember 2021-01-01 2021-09-30 0000727346 us-gaap:DividendDeclaredMember 2022-01-01 2022-09-30 0000727346 us-gaap:DividendDeclaredMember 2021-01-01 2021-09-30 0000727346 us-gaap:WarrantMember 2022-09-30 0000727346 us-gaap:WarrantMember 2021-12-31 0000727346 us-gaap:WarrantMember 2022-01-01 2022-09-30 0000727346 us-gaap:WarrantMember 2021-01-01 2021-12-31 0000727346 GBCS:MrCliffordNeumanMember 2022-09-30 0000727346 GBCS:MrCliffordNeumanMember 2021-12-31 0000727346 GBCS:MrCliffordNeumanMember 2022-01-01 2022-09-30 0000727346 GBCS:MrCliffordNeumanMember 2021-01-01 2021-12-31 0000727346 us-gaap:GoodwillMember 2022-01-01 2022-09-30 iso4217:USD shares iso4217:USD shares pure GBCS:Integer 0000727346 false Q3 --12-31 10-Q true 2022-09-30 2022 false 0-15415 Selectis Health, Inc. UT 87-0340206 8480 E Orchard Rd Ste 4900 Greenwood Village CO 80111 720 680-0808 No Non-accelerated Filer true true false false Yes 3067059 1928472 3939445 3064919 3506719 462868 498015 24387 24387 5480646 7968566 831687 853656 36006716 37024592 1076908 1076908 43395957 46923722 2478953 4363917 21571 7500 7500 0 3234 150000 150000 1184 1714 2049750 6312562 931446 4686203 11786996 750000 750000 933737 452593 34528330 31054962 253899 229582 40218432 43821540 0 0 2.00 2.00 2000000 2000000 200500 200500 200500 200500 401000 401000 10.00 10.00 1000000 1000000 375000 375000 375000 375000 375000 375000 0.05 0.05 800000000 800000000 3054588 3054588 2998362 2998362 152728 150168 13793300 13494394 -11544503 -11318380 3177525 3102182 43395957 46923722 469938 933360 158875 155071 26438806 17431882 9135306 6939841 2891463 504550 287804 224143 224143 29800207 19093935 9581985 7319055 21192559 12613896 7227718 4413930 5329475 4732115 1970890 1721292 783524 28275 252050 12142 1348645 1286279 453608 435013 28654203 18660565 9904266 6582377 1146004 433370 -322281 736678 -46466 1438629 1680540 722226 486816 675598 135468 548933 53582 51856 450427 354710 -1349627 -906436 -668644 -789670 -203623 -473066 -990925 -52992 10650 -203623 -483716 -990925 -52992 22500 22500 7500 7500 -226123 -506216 -998425 -60492 -0.07 -0.18 -0.33 -0.02 -0.07 -0.18 -0.33 -0.02 3053970 2741186 3054588 2824560 3053970 2741186 3054588 2824560 200500 401000 375000 375000 2998362 150168 13494394 -11318380 3102182 7500 7500 56226 2560 252440 255000 46466 46466 37090 37090 200500 401000 375000 375000 3054588 152728 13793300 -11288790 3433238 7500 7500 750212 750212 200500 401000 375000 375000 3054588 152728 13793300 -10546078 4175950 7500 7500 -990925 -990925 200500 401000 375000 375000 3054588 152728 13793300 -11544503 3177525 200500 401000 375000 375000 2686638 134332 11540052 -9036400 -198045 3215939 7500 7500 248056 10650 258706 200500 401000 375000 375000 2686638 134332 11540052 -8795844 -187395 3467145 7500 7500 3000 150 18750 18900 2857 143 -143 -247395 187395 -60000 -678780 -678780 200500 401000 375000 375000 2692495 134625 11311264 -9482124 2739765 7500 7500 150000 7500 706125 713625 16667 833 -833 31200 1560 -1560 -52992 -52992 -52992 -52992 200500 401000 375000 375000 2890362 144518 12041996 -9542616 3392898 -203623 -473066 675598 40346 520221 1348645 1286279 157291 783524 28275 18900 341724 2535412 -616540 -853451 -2837981 248337 24317 7000 -650648 -1604764 330769 493689 -330769 -493689 9134102 1075491 8023719 22500 30000 713625 60000 46466 -1051525 1734008 -2032942 -364445 4793101 3978303 2760159 3613858 1438629 1680540 1928472 2791585 831687 822273 2760159 3613858 22500 22500 976 1560 581393 507433 <p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zdgK2ITc8w53" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_829_zPouGpfyfAG">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1.4pt; text-align: justify; text-indent: -0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1pt; text-align: justify; text-indent: -0.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization and Description of the Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 1pt; text-align: justify; text-indent: -0.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selectis Health, Inc (“Selectis” or “we” or the “Company”) owns and operates, through wholly-owned subsidiaries Assisted Living Facilities, Independent Living Facilities, and Skilled Nursing Facilities across the South and Southeastern portions of the US. In 2019 the Company shifted from leasing long-term care facilities to third-party, independent operators towards an owner operator model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Company changing its name to Selectis Health, Inc., the Company was known as Global Healthcare REIT, Inc. from September 30, 2013, to May 2021. Prior to this, the Company was known as Global Casinos, Inc. Global Casinos, Inc. operated two gaming casinos which were split-off and sold on September 30, 2013. Simultaneous with the split-off and sale of the gaming operations, the Company acquired West Paces Ferry Healthcare REIT, Inc. (“WPF”). WPF was merged into the Company in 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We acquire, develop, lease, manage, and dispose of healthcare real estate, provide financing to healthcare providers, and provide healthcare operations through our wholly-owned subsidiaries. Our portfolio is comprised of investments in the following three healthcare segments: (i) senior housing (including independent and assisted living), (ii) post-acute/skilled nursing, and (iii) bonds securing senior housing communities. We will make investments within our healthcare segments using the following six investment products: (i) direct ownership of properties, (ii) debt investments, (iii) developments and redevelopments, (iv) investment management, (v) the Housing and Economic Recovery Act of 2008 (“RIDEA”), which represents investments in senior housing operations utilizing the structure permitted by RIDEA and (xi) owning healthcare operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management’s Liquidity Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 27, 2014, FASB issued ASU 2014-05, <i>Disclosure of Uncertainties about an Entity’s ability to Continue as a Going Concern</i>, which requires management to assess a company’s ability to continue as a going concern within one year from financial statement issuance and to provide related footnote disclosures in certain circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2022, the Company had negative operating cash flows of $<span id="xdx_905_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn5n6_di_c20220101__20220930_zuqOdx6bbUB2">0.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and a net working capital of $<span id="xdx_902_ecustom--WorkingCapitalDeficit_iNI_pn5n6_di_c20220930_z7g3pEzIYmli">0.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Management believes that the Company has the ability to meet its obligations for the next twelve months from the date of these financial statements. This is, in part due to refinancing debt to more favorable terms, and the optimization of our operations in our current facilities. Based on management’s projections we expect to generate positive cash flows positive cash flows from its continued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The focus on opportunities within our current portfolio and future properties to acquire and operate, the settlement, refinance, and continued service of debt obligations, the potential funds generated from stock sales and other initiatives contributing to additional working capital should alleviate any substantial doubt about the Company’s ability to continue as a going concern as defined by ASU 2014-05. However, we cannot predict, with certainty, the outcome of our actions to generate liquidity and the failure to do so could negatively impact our future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -700000 -800000 <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zyJkX9uSi4O" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_825_zo1cGqwvcfZ6">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.7pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zAf6s7BgTdkb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zHGaH7Ay4Uca">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and in conjunction with the rules and regulations of the Securities Exchange Commission. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary to make the consolidated financial statements not misleading have been included. Operating results for the nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the entire year. The unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the board of directors of the Company approved a one-for-ten reverse stock split of the Company’s issued and outstanding shares of common stock. On September 21, 2021, the Company filed Amendment No. 1 to its Second Amended and Restated Articles of Incorporation reflecting the reverse split and name change. This took effect on September 22, 2021 upon approval from FINRA. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto, and elsewhere in this Form 10-Q, have been retroactively adjusted to give effect to the reverse stock split as if such reverse stock split occurred on the first day of the first period presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zbPxc51XKAyj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zLP104sMTtK6">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVv8Th2drgog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zVSsWQKDBJS">Recently Issued Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Financial Accounting Standards Board and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2022. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zGjk9WUBxsYk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z8HACmStKg3b">Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. </span>Certain intercompany revenues and expenses were included in revenue and general and administration expenses. These reclassifications had no effect on the previously reported net income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revisions to Previously Issued Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the six months ending June 30, 2022, the Company identified an error related to the accounting guidance for intercompany revenues and expenses. For the six months ending June 30, 2022 the Company recorded $869,249 of intercompany revenues to healthcare revenue and $869,249 of intercompany expenses in general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed the materiality of this error on prior period financial statements in accordance with the SEC Staff Accounting Bulletin Number 99, Materiality, and ASC 250-10, Accounting Changes and Error Corrections. The error did not have any effect on the Company’s previously reported Condensed Consolidated Statements of Cash Flows and Condensed Consolidated Statements of Shareholder’s Deficit. The Company determined that this error was not material to the financial statements for the six months ended June 30, 2022. The Company decided to correct this immaterial error as revision to previously issued financial statement and has revised the June 30, 2022 financial statements presented herein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ChangeInAccountingEstimateTextBlock_gL3CIAETB-RN_zWH4uTmSu9d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below tables summarize the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations for the six months ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zJ2BmHXp7xm7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF RESTATEMENT</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_z6MxRDsbmVLe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF RESTATEMENT (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zo0yStqS7aae" style="border-bottom: Black 1.5pt solid; text-align: center">As previously reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zlFnK70lgzAa" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630__srt--RestatementAxis__custom--AdjustedMember_zEr0uvmydCGf" style="border-bottom: Black 1.5pt solid; text-align: center">As revised</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="10" style="text-align: center">Six Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As previously reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As revised</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--RevenuesAbstract_zXCmaWAcPfwf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--RentalMember_ze2wUNhu9Z9d" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Rental Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">311,063</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">311,063</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zXq4EdiNanj2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,642,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,772,802</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthcareGrantRevenueMember_z6p6jz9Whqb3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Healthcare Grant Revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,603,659</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,603,659</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_zGom5usll4S9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,556,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,987,524</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpensesAbstract_iB_zQ0l3nHnYJl7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherCostAndExpenseOperating_i01_zttnirhwL0ti" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property Taxes, Insurance and Other Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,964,841</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,964,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_zPkRfNvLYKOc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and Administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,227,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,358,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ProvisionForDoubtfulAccounts_i01_zWO0r6OcTuZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for Bad Debts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,474</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationDepletionAndAmortization_i01_zSfGTAkr8MP" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">895,037</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">895,037</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_z4fc9qthUhj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Total Expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,619,186</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(869,249</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,749,937</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_zkJ5kXZSzUyd" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Income from Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zAxuWEwoDhHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other (Income) Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zqEZ2zp70Cr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss (Gain) on Extinguishment of Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,466</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InterestExpense_i01_zHc57tXO6xQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest Expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716,403</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--GainOnForgivenessOfPppLoan_i01_zOpIienisye2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gain on Forgiveness of PPP Loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_i01_zh106GS6CBah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81,886</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81,886</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--LeaseTerminationExpense_i01_zwGDaiCR1L19" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease Termination Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01T_zOzU9LlJtk8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Total Other (Income) Expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ProfitLoss_zWnccVCTxLic" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net Income (Loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zfMRs2lIEYo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the preparation of the nine months ending September 30, 2022, financial statements management became aware of misstatements in the financial statements of $<span id="xdx_908_ecustom--MisstatementAdjustmentErrorAmount_c20220101__20220331_zbuOymVzqbRb" title="Misstatement adjustment amount">191,589</span> and $<span id="xdx_909_ecustom--MisstatementAdjustmentErrorAmount_c20220101__20220630_zhdeJFEHMSLc" title="Misstatement adjustment amount">469,302</span> of healthcare revenue and accounts receivable reported during the three and six month periods ended March 31, 2022 and June 30, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that cash payments received from a Medicare B bad debt reimbursement program were recorded directly to revenue rather than a reduction to the account receivable account to which the receivables were recorded, causing both revenue and receivables to be overstated at each reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C0E_gL3CIAETB-RN_zI8brrK1AxW5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <div id="xdx_C0D_gL3CIAETB-RN_zExpmZxakwp8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_304_132_zElHP0xBAfnb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF RESTATEMENT (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z1SbzkqmHjF8" style="border-bottom: Black 1.5pt solid; text-align: center">Reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zfayNWhHwNwg" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220331__srt--RestatementAxis__custom--AdjustedMember_zTSVpaeIiGBl" style="border-bottom: Black 1.5pt solid; text-align: center">Adjusted</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjusted</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">P&amp;L Analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zcVtLx4nV6Y" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Total Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">10,091,006</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(191,589</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,899,417</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zloUldO4jjyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,367,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,176,265</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingIncome_zmsz7YVzE3j8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">615,396</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">423,807</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_zO2rplnmTLTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_z1ueYmpDi8Nb" style="vertical-align: bottom; background-color: White"> <td>EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zS1g6HO1U97l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>WASO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,052,769</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,052,769</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Balance Sheet Analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts Receivable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_ztDPtqoRPxEg" style="text-align: right" title="Accounts receivable">4,168,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_ze6YakUVyZK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accounts receivable">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_z1rOlgvfCh0l" style="text-align: right" title="Accounts receivable">3,976,683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zxJRNbxGp047" style="text-align: right" title="Current Assets">7,474,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_987_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_z7z4EMJKcv4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Current Assets">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zx88pE3hWUc7" style="text-align: right" title="Current Assets">7,282,945</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5l2LyIwHcbg" style="text-align: right" title="Assets">46,086,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_987_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zNQX1isfl77k" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Assets">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zp1PSm3007C9" style="text-align: right" title="Assets">45,894,462</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Working Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zesgVmXsdjMc" style="text-align: right" title="Working Capital">38,478,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98F_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zyZITZnBVOv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Working Capital">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zG2s4kQrSfBj" style="text-align: right" title="Working Capital">38,286,719</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zsz9dXGPfPtl" style="text-align: right" title="Accumulated Deficit">(11,089,701</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"/><td id="xdx_987_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zpriVaOMnO2g" style="text-align: right" title="Accumulated Deficit">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_z91vircFg0Df" style="text-align: right" title="Accumulated Deficit">(11,281,290</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zUCPQnwP1zGc" style="text-align: right" title="Total Equity">3,632,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98E_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zIVuLjVRjktf" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Total Equity">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zBQOcTiXSqZi" style="text-align: right" title="Total Equity">3,440,738</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zNq9HZBiArA7" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zaChOev8lacc" style="text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231__srt--RestatementAxis__custom--AdjustedMember_zismwMqI1EY6" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5fuOw490ogf" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_z87jMCx2IxV3" style="text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630__srt--RestatementAxis__custom--AdjustedMember_z9fy85EDxmsb" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="25" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three and six months ended June 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">P&amp;L analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z6jCwLyoSSEh" style="vertical-align: bottom; background-color: White"> <td style="width: 28%; text-align: left">Total Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">20,687,524</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">20,218,222</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,596,518</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p><span style="font-family: Times New Roman, Times, Serif"/></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,318,805</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zg7vqr4rUFy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,772,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,303,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,404,948</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(277,713</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,127,235</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--OperatingIncome_znzMzm1z3hg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,468,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,321,651</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,043,938</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_zQHxZ05l4Mcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">787,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,027,925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,212</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_zagAYXQ7cVG5" style="vertical-align: bottom; background-color: White"> <td>EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.25</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zASX0j4BJhLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>WASO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,998,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,998,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Balance Sheet analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts Receivable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5ZCFbRMxG41" style="text-align: right">5,167,862</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p id="xdx_981_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zJQHBqQA9hF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zQ3CuS5Y5uR6" style="text-align: right">4,698,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zVDnXzo5Pwy8" style="text-align: right">8,789,109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_988_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zH1oBjo1CFz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zSzQPYOOZvcl" style="text-align: right">8,319,807</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMiZgmZmtpC6" style="text-align: right">47,014,470</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_985_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zvbATEu7gj8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zD2uOg84SDT9" style="text-align: right">46,545,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Working Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z8FMR2THZSIc" style="text-align: right">32,534,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98F_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zkm5iUl2kNkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zio0gcX3KMB6" style="text-align: right">32,065,303</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbsDDMxIfLMf" style="text-align: right">(10,061,776</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zo0CNIMItFGk" style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zNaYjLttaYOk" style="text-align: right">(10,531,078</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zdLX2mevFDTf" style="text-align: right">4,660,252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98C_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zesYCrItTMO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zPA2uHgS4Byf" style="text-align: right">4,190,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_C08_gL3CIAETB-RN_znzaR29cVm7i"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zBF7qkE5sMB" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrbdoYC15cpk">Earnings per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings per share are based on the weighted-average number of shares of common stock outstanding. FASB ASC Topic 260, “Earnings per Share”, requires the Company to include additional shares in the computation of earnings per share, assuming dilution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted earnings per share are based on the assumption that all dilutive options and warrants were converted or exercised by applying the treasury stock method and that all convertible preferred stock were converted into common shares by applying the if-converted method. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period or at the time of issuance, if later, and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, the preferred dividends applicable to convertible preferred stock are added back to the numerator. The convertible preferred stock is assumed to have been converted at the beginning of the period or at time of issuance, if later, and the resulting common shares are included in the denominator.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We calculate basic earnings per share by dividing net income attributable to common stockholders (the “numerator”) by the weighted average number of common shares outstanding (the “denominator”) during the reporting period. Diluted earnings per share is calculated similarly but reflects the potential impact of outstanding options, warrants and other commitments to issue common stock, including shares issuable upon the conversion of convertible preferred stock outstanding, except where the impact would be anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zAD9RWhf78Pk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the computation of basic and diluted earnings per share:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z168DgKEXV18" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20220101__20220930_zSft5XSx4lMg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20210101__20210930_zY94qkh0ITu7" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20220701__20220930_zxCqKfiJgtZf" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20210701__20210930_zJY98EU51Fn5" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">Nine Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAbstract_iB_zMNtpmXSESbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Numerator for basic earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_zJWJ9lFSa77i" style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left">Net Income (Loss) Attributable to Selectis Health, Inc.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(203,623</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(483,716</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(990,925</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(52,992</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--PreferredStockDividendsAndOtherAdjustmentsBasic_i01_zyPu6UZj8qV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series D Preferred Dividends</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,500</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01T_pp0p0_zXL9iAqYTf86" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net Income (Loss) Attributable to Common Stockholders - Basic</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(226,123</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(506,216</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(998,425</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,492</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareDilutedAbstract_iB_zS6TWdjsokAl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator for diluted earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--NetIncomeLossAttributableToDilutedGross_i01_zTVtnu25PwG4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Net Income (Loss) Attributable to Common Stockholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(226,123</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(506,216</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(998,425</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(60,492</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--PreferredStockDividendsAndOtherAdjustmentsDiluted_i01N_di_zvvQ6u6yvyF5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Series D Preferred Dividends</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01T_z9vpBYTmLHkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Net Income (Loss) Attributable to Common Stockholders - Diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(483,716</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(990,925</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DenominatorForDilutedEarningsPerShareAbstract_iB_ztgtIrnAtOIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Denominator for basic earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zEl2hX1dsGdb" style="vertical-align: bottom; background-color: White"> <td>Weighted Average Common Shares Outstanding</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DenominatorForDilutedEarningsPerShareAbstract_iB_zJEyfUVlwG9k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Denominator for diluted earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingExceptEffectOfDilutiveSecurities_i01_zlA62q5D9Bp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Common Shares Outstanding - Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EffectOfDilutiveSecurities_i01_zIErhPNtt3Za" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ConversionOfPreferredShares_i01_zi8LPYerzim9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Conversion of preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ExerciseOfWarrants_i01_zNlenbXUY0A3" style="vertical-align: bottom; background-color: White"> <td>Exercise of warrants</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageCommonSharesOutstandingDilutedEffectOfDilutiveSecurities_i01_zkWwgC3JxcS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Common Shares Outstanding - Diluted</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasicAbstract_iB_z9U5PqS2SGYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income (Loss) per Share Attributable to Common Stockholders:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_i01_pid_z1R5tMTB78p5" style="vertical-align: bottom; background-color: White"> <td>Basic</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_i01_zOcWe8gjssYi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8AE_z5ugsbUnBdyg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zPYZ0YuP5Cz9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z52Uc7s5mYpl">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes the methods of fair value measurement as described in ASC 820 to value its financial assets and liabilities. As defined in ASC 820, fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Quoted market prices in active markets for identical assets or liabilities at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no financial assets or financial liabilities that are required to be measured at fair value on a recurring basis as of September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our consolidated balance sheets include the following financial instruments: cash and cash equivalents, accounts receivable, restricted cash, accounts payable, debt and lease security deposit. We consider the carrying values of our short-term financial instruments to approximate fair value because they generally expose the Company to limited credit risk, because of the short period of time between origination of the financial assets and liabilities and their expected settlement, or because of their proximity to acquisition date fair values. The carrying value of debt approximates fair value based on borrowing rates currently available for debt of similar terms and maturities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon acquisition of real estate properties, the Company determines the total purchase price of each property and allocates this price based on the fair value of the tangible assets and intangible assets, if any, acquired and any liabilities assumed based on Level 3 inputs. These Level 3 inputs can include comparable sales values, discount rates, and capitalization rates from a third-party appraisal or other market sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zAf6s7BgTdkb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zHGaH7Ay4Uca">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) for interim financial information and in conjunction with the rules and regulations of the Securities Exchange Commission. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary to make the consolidated financial statements not misleading have been included. Operating results for the nine months ended September 30, 2022, are not necessarily indicative of the results that may be expected for the entire year. The unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the board of directors of the Company approved a one-for-ten reverse stock split of the Company’s issued and outstanding shares of common stock. On September 21, 2021, the Company filed Amendment No. 1 to its Second Amended and Restated Articles of Incorporation reflecting the reverse split and name change. This took effect on September 22, 2021 upon approval from FINRA. Unless otherwise noted, impacted amounts and share information included in the financial statements and notes thereto, and elsewhere in this Form 10-Q, have been retroactively adjusted to give effect to the reverse stock split as if such reverse stock split occurred on the first day of the first period presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zbPxc51XKAyj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zLP104sMTtK6">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVv8Th2drgog" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zVSsWQKDBJS">Recently Issued Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Financial Accounting Standards Board and other entities issued new or modifications to, or interpretations of, existing accounting guidance during 2022. Management has carefully considered the new pronouncements that altered generally accepted accounting principles and does not believe that any other new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zGjk9WUBxsYk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z8HACmStKg3b">Reclassification</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. </span>Certain intercompany revenues and expenses were included in revenue and general and administration expenses. These reclassifications had no effect on the previously reported net income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Revisions to Previously Issued Financial Statements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the six months ending June 30, 2022, the Company identified an error related to the accounting guidance for intercompany revenues and expenses. For the six months ending June 30, 2022 the Company recorded $869,249 of intercompany revenues to healthcare revenue and $869,249 of intercompany expenses in general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company assessed the materiality of this error on prior period financial statements in accordance with the SEC Staff Accounting Bulletin Number 99, Materiality, and ASC 250-10, Accounting Changes and Error Corrections. The error did not have any effect on the Company’s previously reported Condensed Consolidated Statements of Cash Flows and Condensed Consolidated Statements of Shareholder’s Deficit. The Company determined that this error was not material to the financial statements for the six months ended June 30, 2022. The Company decided to correct this immaterial error as revision to previously issued financial statement and has revised the June 30, 2022 financial statements presented herein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ChangeInAccountingEstimateTextBlock_gL3CIAETB-RN_zWH4uTmSu9d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below tables summarize the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations for the six months ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zJ2BmHXp7xm7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF RESTATEMENT</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_z6MxRDsbmVLe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF RESTATEMENT (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zo0yStqS7aae" style="border-bottom: Black 1.5pt solid; text-align: center">As previously reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zlFnK70lgzAa" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630__srt--RestatementAxis__custom--AdjustedMember_zEr0uvmydCGf" style="border-bottom: Black 1.5pt solid; text-align: center">As revised</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="10" style="text-align: center">Six Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As previously reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As revised</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--RevenuesAbstract_zXCmaWAcPfwf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--RentalMember_ze2wUNhu9Z9d" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Rental Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">311,063</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">311,063</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zXq4EdiNanj2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,642,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,772,802</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthcareGrantRevenueMember_z6p6jz9Whqb3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Healthcare Grant Revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,603,659</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,603,659</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_zGom5usll4S9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,556,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,987,524</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpensesAbstract_iB_zQ0l3nHnYJl7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherCostAndExpenseOperating_i01_zttnirhwL0ti" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property Taxes, Insurance and Other Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,964,841</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,964,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_zPkRfNvLYKOc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and Administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,227,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,358,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ProvisionForDoubtfulAccounts_i01_zWO0r6OcTuZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for Bad Debts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,474</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationDepletionAndAmortization_i01_zSfGTAkr8MP" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">895,037</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">895,037</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_z4fc9qthUhj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Total Expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,619,186</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(869,249</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,749,937</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_zkJ5kXZSzUyd" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Income from Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zAxuWEwoDhHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other (Income) Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zqEZ2zp70Cr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss (Gain) on Extinguishment of Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,466</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InterestExpense_i01_zHc57tXO6xQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest Expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716,403</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--GainOnForgivenessOfPppLoan_i01_zOpIienisye2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gain on Forgiveness of PPP Loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_i01_zh106GS6CBah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81,886</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81,886</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--LeaseTerminationExpense_i01_zwGDaiCR1L19" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease Termination Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01T_zOzU9LlJtk8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Total Other (Income) Expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ProfitLoss_zWnccVCTxLic" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net Income (Loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zfMRs2lIEYo8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the preparation of the nine months ending September 30, 2022, financial statements management became aware of misstatements in the financial statements of $<span id="xdx_908_ecustom--MisstatementAdjustmentErrorAmount_c20220101__20220331_zbuOymVzqbRb" title="Misstatement adjustment amount">191,589</span> and $<span id="xdx_909_ecustom--MisstatementAdjustmentErrorAmount_c20220101__20220630_zhdeJFEHMSLc" title="Misstatement adjustment amount">469,302</span> of healthcare revenue and accounts receivable reported during the three and six month periods ended March 31, 2022 and June 30, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that cash payments received from a Medicare B bad debt reimbursement program were recorded directly to revenue rather than a reduction to the account receivable account to which the receivables were recorded, causing both revenue and receivables to be overstated at each reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_C0E_gL3CIAETB-RN_zI8brrK1AxW5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <div id="xdx_C0D_gL3CIAETB-RN_zExpmZxakwp8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_304_132_zElHP0xBAfnb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF RESTATEMENT (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z1SbzkqmHjF8" style="border-bottom: Black 1.5pt solid; text-align: center">Reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zfayNWhHwNwg" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220331__srt--RestatementAxis__custom--AdjustedMember_zTSVpaeIiGBl" style="border-bottom: Black 1.5pt solid; text-align: center">Adjusted</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjusted</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">P&amp;L Analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zcVtLx4nV6Y" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Total Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">10,091,006</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(191,589</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,899,417</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zloUldO4jjyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,367,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,176,265</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingIncome_zmsz7YVzE3j8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">615,396</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">423,807</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_zO2rplnmTLTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_z1ueYmpDi8Nb" style="vertical-align: bottom; background-color: White"> <td>EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zS1g6HO1U97l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>WASO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,052,769</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,052,769</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Balance Sheet Analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts Receivable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_ztDPtqoRPxEg" style="text-align: right" title="Accounts receivable">4,168,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_ze6YakUVyZK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accounts receivable">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_z1rOlgvfCh0l" style="text-align: right" title="Accounts receivable">3,976,683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zxJRNbxGp047" style="text-align: right" title="Current Assets">7,474,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_987_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_z7z4EMJKcv4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Current Assets">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zx88pE3hWUc7" style="text-align: right" title="Current Assets">7,282,945</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5l2LyIwHcbg" style="text-align: right" title="Assets">46,086,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_987_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zNQX1isfl77k" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Assets">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zp1PSm3007C9" style="text-align: right" title="Assets">45,894,462</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Working Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zesgVmXsdjMc" style="text-align: right" title="Working Capital">38,478,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98F_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zyZITZnBVOv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Working Capital">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zG2s4kQrSfBj" style="text-align: right" title="Working Capital">38,286,719</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zsz9dXGPfPtl" style="text-align: right" title="Accumulated Deficit">(11,089,701</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"/><td id="xdx_987_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zpriVaOMnO2g" style="text-align: right" title="Accumulated Deficit">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_z91vircFg0Df" style="text-align: right" title="Accumulated Deficit">(11,281,290</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zUCPQnwP1zGc" style="text-align: right" title="Total Equity">3,632,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98E_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zIVuLjVRjktf" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Total Equity">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zBQOcTiXSqZi" style="text-align: right" title="Total Equity">3,440,738</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zNq9HZBiArA7" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zaChOev8lacc" style="text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231__srt--RestatementAxis__custom--AdjustedMember_zismwMqI1EY6" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5fuOw490ogf" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_z87jMCx2IxV3" style="text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630__srt--RestatementAxis__custom--AdjustedMember_z9fy85EDxmsb" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="25" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three and six months ended June 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">P&amp;L analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z6jCwLyoSSEh" style="vertical-align: bottom; background-color: White"> <td style="width: 28%; text-align: left">Total Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">20,687,524</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">20,218,222</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,596,518</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p><span style="font-family: Times New Roman, Times, Serif"/></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,318,805</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zg7vqr4rUFy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,772,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,303,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,404,948</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(277,713</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,127,235</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--OperatingIncome_znzMzm1z3hg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,468,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,321,651</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,043,938</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_zQHxZ05l4Mcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">787,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,027,925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,212</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_zagAYXQ7cVG5" style="vertical-align: bottom; background-color: White"> <td>EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.25</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zASX0j4BJhLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>WASO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,998,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,998,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Balance Sheet analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts Receivable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5ZCFbRMxG41" style="text-align: right">5,167,862</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p id="xdx_981_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zJQHBqQA9hF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zQ3CuS5Y5uR6" style="text-align: right">4,698,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zVDnXzo5Pwy8" style="text-align: right">8,789,109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_988_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zH1oBjo1CFz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zSzQPYOOZvcl" style="text-align: right">8,319,807</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMiZgmZmtpC6" style="text-align: right">47,014,470</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_985_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zvbATEu7gj8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zD2uOg84SDT9" style="text-align: right">46,545,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Working Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z8FMR2THZSIc" style="text-align: right">32,534,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98F_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zkm5iUl2kNkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zio0gcX3KMB6" style="text-align: right">32,065,303</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbsDDMxIfLMf" style="text-align: right">(10,061,776</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zo0CNIMItFGk" style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zNaYjLttaYOk" style="text-align: right">(10,531,078</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zdLX2mevFDTf" style="text-align: right">4,660,252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98C_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zesYCrItTMO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zPA2uHgS4Byf" style="text-align: right">4,190,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> </div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span id="xdx_C08_gL3CIAETB-RN_znzaR29cVm7i"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89F_eus-gaap--ChangeInAccountingEstimateTextBlock_gL3CIAETB-RN_zWH4uTmSu9d2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below tables summarize the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations for the six months ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_8B4_zJ2BmHXp7xm7" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE OF RESTATEMENT</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_z6MxRDsbmVLe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF RESTATEMENT (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zo0yStqS7aae" style="border-bottom: Black 1.5pt solid; text-align: center">As previously reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zlFnK70lgzAa" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630__srt--RestatementAxis__custom--AdjustedMember_zEr0uvmydCGf" style="border-bottom: Black 1.5pt solid; text-align: center">As revised</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="10" style="text-align: center">Six Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As previously reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As revised</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--RevenuesAbstract_zXCmaWAcPfwf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--RentalMember_ze2wUNhu9Z9d" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Rental Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">311,063</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">311,063</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zXq4EdiNanj2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,642,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,772,802</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--HealthcareGrantRevenueMember_z6p6jz9Whqb3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Healthcare Grant Revenue</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,603,659</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,603,659</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_zGom5usll4S9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Total Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,556,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,987,524</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpensesAbstract_iB_zQ0l3nHnYJl7" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherCostAndExpenseOperating_i01_zttnirhwL0ti" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property Taxes, Insurance and Other Operating</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,964,841</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,964,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_zPkRfNvLYKOc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and Administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,227,834</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(869,249</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,358,585</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ProvisionForDoubtfulAccounts_i01_zWO0r6OcTuZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for Bad Debts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,474</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">531,474</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationDepletionAndAmortization_i01_zSfGTAkr8MP" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and Amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">895,037</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">895,037</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingExpenses_i01T_z4fc9qthUhj7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Total Expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,619,186</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(869,249</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,749,937</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingIncomeLoss_iT_zkJ5kXZSzUyd" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Income from Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zAxuWEwoDhHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other (Income) Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zqEZ2zp70Cr7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss (Gain) on Extinguishment of Debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,466</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InterestExpense_i01_zHc57tXO6xQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest Expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">716,403</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--GainOnForgivenessOfPppLoan_i01_zOpIienisye2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gain on Forgiveness of PPP Loan</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0850">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherNonoperatingIncomeExpense_i01_zh106GS6CBah" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81,886</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81,886</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--LeaseTerminationExpense_i01_zwGDaiCR1L19" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Lease Termination Expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpense_i01T_zOzU9LlJtk8c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Total Other (Income) Expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">680,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ProfitLoss_zWnccVCTxLic" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net Income (Loss)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td></tr> </table> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended March 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_304_132_zElHP0xBAfnb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF RESTATEMENT (Details)"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z1SbzkqmHjF8" style="border-bottom: Black 1.5pt solid; text-align: center">Reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zfayNWhHwNwg" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220331__srt--RestatementAxis__custom--AdjustedMember_zTSVpaeIiGBl" style="border-bottom: Black 1.5pt solid; text-align: center">Adjusted</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended March 31, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Reported</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustments</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjusted</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">P&amp;L Analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zcVtLx4nV6Y" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Total Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">10,091,006</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(191,589</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">9,899,417</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zloUldO4jjyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,367,854</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,176,265</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingIncome_zmsz7YVzE3j8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">615,396</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">423,807</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_zO2rplnmTLTe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,090</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_z1ueYmpDi8Nb" style="vertical-align: bottom; background-color: White"> <td>EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zS1g6HO1U97l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>WASO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,052,769</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,052,769</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Balance Sheet Analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts Receivable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_ztDPtqoRPxEg" style="text-align: right" title="Accounts receivable">4,168,272</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p id="xdx_984_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_ze6YakUVyZK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Accounts receivable">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_z1rOlgvfCh0l" style="text-align: right" title="Accounts receivable">3,976,683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zxJRNbxGp047" style="text-align: right" title="Current Assets">7,474,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_987_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_z7z4EMJKcv4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Current Assets">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AssetsCurrent_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zx88pE3hWUc7" style="text-align: right" title="Current Assets">7,282,945</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5l2LyIwHcbg" style="text-align: right" title="Assets">46,086,051</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_987_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zNQX1isfl77k" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Assets">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Assets_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zp1PSm3007C9" style="text-align: right" title="Assets">45,894,462</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Working Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zesgVmXsdjMc" style="text-align: right" title="Working Capital">38,478,308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98F_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zyZITZnBVOv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Working Capital">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--WorkingCapital_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zG2s4kQrSfBj" style="text-align: right" title="Working Capital">38,286,719</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zsz9dXGPfPtl" style="text-align: right" title="Accumulated Deficit">(11,089,701</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"/><td id="xdx_987_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zpriVaOMnO2g" style="text-align: right" title="Accumulated Deficit">(191,589</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_z91vircFg0Df" style="text-align: right" title="Accumulated Deficit">(11,281,290</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zUCPQnwP1zGc" style="text-align: right" title="Total Equity">3,632,327</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98E_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zIVuLjVRjktf" style="font: 10pt Times New Roman, Times, Serif; margin: 0" title="Total Equity">(191,589</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockholdersEquity_iI_c20220331__srt--RestatementAxis__custom--AdjustedMember_zBQOcTiXSqZi" style="text-align: right" title="Total Equity">3,440,738</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below table summarizes the effect of the revisions on the affected line items within the Condensed Consolidated Statement of Operations and Condensed Consolidated Balance Sheet for the period ended June 30, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zNq9HZBiArA7" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20210101__20211231__srt--RestatementAxis__srt--RestatementAdjustmentMember_zaChOev8lacc" style="text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210101__20211231__srt--RestatementAxis__custom--AdjustedMember_zismwMqI1EY6" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20220101__20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5fuOw490ogf" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_z87jMCx2IxV3" style="text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220630__srt--RestatementAxis__custom--AdjustedMember_z9fy85EDxmsb" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="25" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three and six months ended June 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">YTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Reported</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Revision adjustment</td><td style="text-align: center; padding-bottom: 1.5pt"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">QTD Adjusted</td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">P&amp;L analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_z6jCwLyoSSEh" style="vertical-align: bottom; background-color: White"> <td style="width: 28%; text-align: left">Total Revenue</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">20,687,524</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">20,218,222</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,596,518</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p><span style="font-family: Times New Roman, Times, Serif"/></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,318,805</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__us-gaap--HealthCareMember_zg7vqr4rUFy4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Healthcare Revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,772,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,303,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,404,948</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(277,713</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,127,235</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--OperatingIncome_znzMzm1z3hg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,937,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,468,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,321,651</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,043,938</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_zQHxZ05l4Mcf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,256,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">787,302</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,027,925</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(277,713</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,212</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_zagAYXQ7cVG5" style="vertical-align: bottom; background-color: White"> <td>EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.25</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zASX0j4BJhLe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>WASO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,998,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,998,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,627</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,627</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Balance Sheet analysis</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accounts Receivable</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z5ZCFbRMxG41" style="text-align: right">5,167,862</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><p id="xdx_981_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zJQHBqQA9hF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AccountsReceivableNetCurrent_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zQ3CuS5Y5uR6" style="text-align: right">4,698,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zVDnXzo5Pwy8" style="text-align: right">8,789,109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_988_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zH1oBjo1CFz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AssetsCurrent_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zSzQPYOOZvcl" style="text-align: right">8,319,807</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total Assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zMiZgmZmtpC6" style="text-align: right">47,014,470</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_985_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zvbATEu7gj8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Assets_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zD2uOg84SDT9" style="text-align: right">46,545,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Working Capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z8FMR2THZSIc" style="text-align: right">32,534,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98F_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zkm5iUl2kNkl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--WorkingCapital_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zio0gcX3KMB6" style="text-align: right">32,065,303</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zbsDDMxIfLMf" style="text-align: right">(10,061,776</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zo0CNIMItFGk" style="text-align: right">(469,302</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zNaYjLttaYOk" style="text-align: right">(10,531,078</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total Equity</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zdLX2mevFDTf" style="text-align: right">4,660,252</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p id="xdx_98C_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__srt--RestatementAdjustmentMember_zesYCrItTMO3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">(469,302</p></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockholdersEquity_iI_c20220630__srt--RestatementAxis__custom--AdjustedMember_zPA2uHgS4Byf" style="text-align: right">4,190,950</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table>   311063 311063 18642051 -869249 17772802 2603659 2603659 21556773 -869249 20987524 13964841 13964841 4227834 -869249 3358585 531474 531474 895037 895037 19619186 -869249 18749937 1937587 1937587 46466 46466 716403 716403 -81886 -81886 680983 680983 1256604 1256604 191589 469302 10091006 -191589 9899417 9367854 -191589 9176265 615396 -191589 423807 228679 -191589 37090 0.07 0.01 3052769 3052769 4168272 -191589 3976683 7474534 -191589 7282945 46086051 -191589 45894462 38478308 -191589 38286719 -11089701 -191589 -11281290 3632327 -191589 3440738 20687524 -469302 20218222 10596518 -277713 10318805 17772802 -469302 17303500 8404948 -277713 8127235 1937587 -469302 1468285 1321651 -277713 1043938 1256604 -469302 787302 1027925 -277713 750212 0.42 0.26 0.34 0.25 2998361 2998361 3054627 3054627 5167862 -469302 4698560 8789109 -469302 8319807 47014470 -469302 46545168 32534605 -469302 32065303 -10061776 -469302 -10531078 4660252 -469302 4190950 <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zBF7qkE5sMB" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrbdoYC15cpk">Earnings per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic earnings per share are based on the weighted-average number of shares of common stock outstanding. FASB ASC Topic 260, “Earnings per Share”, requires the Company to include additional shares in the computation of earnings per share, assuming dilution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted earnings per share are based on the assumption that all dilutive options and warrants were converted or exercised by applying the treasury stock method and that all convertible preferred stock were converted into common shares by applying the if-converted method. Under the treasury stock method, options and warrants are assumed to be exercised at the beginning of the period or at the time of issuance, if later, and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Under the if-converted method, the preferred dividends applicable to convertible preferred stock are added back to the numerator. The convertible preferred stock is assumed to have been converted at the beginning of the period or at time of issuance, if later, and the resulting common shares are included in the denominator.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We calculate basic earnings per share by dividing net income attributable to common stockholders (the “numerator”) by the weighted average number of common shares outstanding (the “denominator”) during the reporting period. Diluted earnings per share is calculated similarly but reflects the potential impact of outstanding options, warrants and other commitments to issue common stock, including shares issuable upon the conversion of convertible preferred stock outstanding, except where the impact would be anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zAD9RWhf78Pk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the computation of basic and diluted earnings per share:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z168DgKEXV18" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20220101__20220930_zSft5XSx4lMg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20210101__20210930_zY94qkh0ITu7" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20220701__20220930_zxCqKfiJgtZf" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20210701__20210930_zJY98EU51Fn5" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">Nine Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAbstract_iB_zMNtpmXSESbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Numerator for basic earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_zJWJ9lFSa77i" style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left">Net Income (Loss) Attributable to Selectis Health, Inc.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(203,623</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(483,716</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(990,925</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(52,992</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--PreferredStockDividendsAndOtherAdjustmentsBasic_i01_zyPu6UZj8qV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series D Preferred Dividends</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,500</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01T_pp0p0_zXL9iAqYTf86" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net Income (Loss) Attributable to Common Stockholders - Basic</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(226,123</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(506,216</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(998,425</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,492</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareDilutedAbstract_iB_zS6TWdjsokAl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator for diluted earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--NetIncomeLossAttributableToDilutedGross_i01_zTVtnu25PwG4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Net Income (Loss) Attributable to Common Stockholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(226,123</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(506,216</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(998,425</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(60,492</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--PreferredStockDividendsAndOtherAdjustmentsDiluted_i01N_di_zvvQ6u6yvyF5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Series D Preferred Dividends</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01T_z9vpBYTmLHkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Net Income (Loss) Attributable to Common Stockholders - Diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(483,716</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(990,925</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DenominatorForDilutedEarningsPerShareAbstract_iB_ztgtIrnAtOIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Denominator for basic earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zEl2hX1dsGdb" style="vertical-align: bottom; background-color: White"> <td>Weighted Average Common Shares Outstanding</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DenominatorForDilutedEarningsPerShareAbstract_iB_zJEyfUVlwG9k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Denominator for diluted earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingExceptEffectOfDilutiveSecurities_i01_zlA62q5D9Bp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Common Shares Outstanding - Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EffectOfDilutiveSecurities_i01_zIErhPNtt3Za" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ConversionOfPreferredShares_i01_zi8LPYerzim9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Conversion of preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ExerciseOfWarrants_i01_zNlenbXUY0A3" style="vertical-align: bottom; background-color: White"> <td>Exercise of warrants</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageCommonSharesOutstandingDilutedEffectOfDilutiveSecurities_i01_zkWwgC3JxcS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Common Shares Outstanding - Diluted</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasicAbstract_iB_z9U5PqS2SGYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income (Loss) per Share Attributable to Common Stockholders:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_i01_pid_z1R5tMTB78p5" style="vertical-align: bottom; background-color: White"> <td>Basic</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_i01_zOcWe8gjssYi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8AE_z5ugsbUnBdyg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zAD9RWhf78Pk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the computation of basic and diluted earnings per share:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z168DgKEXV18" style="display: none">SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20220101__20220930_zSft5XSx4lMg" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20210101__20210930_zY94qkh0ITu7" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20220701__20220930_zxCqKfiJgtZf" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" id="xdx_49F_20210701__20210930_zJY98EU51Fn5" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="text-align: center">Nine Months Ended</td><td> </td><td> </td> <td colspan="6" style="text-align: center">Three Months Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasicAbstract_iB_zMNtpmXSESbd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Numerator for basic earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_i01_zJWJ9lFSa77i" style="vertical-align: bottom; background-color: White"> <td style="width: 44%; text-align: left">Net Income (Loss) Attributable to Selectis Health, Inc.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(203,623</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(483,716</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(990,925</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(52,992</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--PreferredStockDividendsAndOtherAdjustmentsBasic_i01_zyPu6UZj8qV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Series D Preferred Dividends</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,500</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,500</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_i01T_pp0p0_zXL9iAqYTf86" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net Income (Loss) Attributable to Common Stockholders - Basic</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(226,123</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(506,216</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(998,425</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,492</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--EarningsPerShareDilutedAbstract_iB_zS6TWdjsokAl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Numerator for diluted earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--NetIncomeLossAttributableToDilutedGross_i01_zTVtnu25PwG4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Net Income (Loss) Attributable to Common Stockholders</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(226,123</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(506,216</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(998,425</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(60,492</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--PreferredStockDividendsAndOtherAdjustmentsDiluted_i01N_di_zvvQ6u6yvyF5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Series D Preferred Dividends</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_i01T_z9vpBYTmLHkb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Net Income (Loss) Attributable to Common Stockholders - Diluted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(203,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(483,716</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(990,925</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(52,992</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DenominatorForDilutedEarningsPerShareAbstract_iB_ztgtIrnAtOIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Denominator for basic earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_zEl2hX1dsGdb" style="vertical-align: bottom; background-color: White"> <td>Weighted Average Common Shares Outstanding</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--DenominatorForDilutedEarningsPerShareAbstract_iB_zJEyfUVlwG9k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Denominator for diluted earnings per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WeightedAverageNumberOfDilutedSharesOutstandingExceptEffectOfDilutiveSecurities_i01_zlA62q5D9Bp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Common Shares Outstanding - Basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--EffectOfDilutiveSecurities_i01_zIErhPNtt3Za" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ConversionOfPreferredShares_i01_zi8LPYerzim9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Conversion of preferred shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1064">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--ExerciseOfWarrants_i01_zNlenbXUY0A3" style="vertical-align: bottom; background-color: White"> <td>Exercise of warrants</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageCommonSharesOutstandingDilutedEffectOfDilutiveSecurities_i01_zkWwgC3JxcS3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Common Shares Outstanding - Diluted</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,053,970</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,741,186</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,054,588</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,824,560</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EarningsPerShareBasicAbstract_iB_z9U5PqS2SGYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Income (Loss) per Share Attributable to Common Stockholders:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasic_i01_pid_z1R5tMTB78p5" style="vertical-align: bottom; background-color: White"> <td>Basic</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--EarningsPerShareDiluted_i01_zOcWe8gjssYi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Diluted</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.07</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.18</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.33</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.02</td><td style="text-align: left">)</td></tr> </table> -203623 -483716 -990925 -52992 -22500 -22500 -7500 -7500 -226123 -506216 -998425 -60492 -226123 -506216 -998425 -60492 -22500 -22500 -7500 -7500 -203623 -483716 -990925 -52992 3053970 2741186 3054588 2824560 3053970 2741186 3054588 2824560 3053970 2741186 3054588 2824560 -0.07 -0.18 -0.33 -0.02 -0.07 -0.18 -0.33 -0.02 <p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zPYZ0YuP5Cz9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z52Uc7s5mYpl">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes the methods of fair value measurement as described in ASC 820 to value its financial assets and liabilities. As defined in ASC 820, fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 – Quoted market prices in active markets for identical assets or liabilities at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 – Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable and can be corroborated by observable market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 – Inputs reflecting management’s best estimates and assumptions of what market participants would use in pricing assets or liabilities at the measurement date. The inputs are unobservable in the market and significant to the valuation of the instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no financial assets or financial liabilities that are required to be measured at fair value on a recurring basis as of September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our consolidated balance sheets include the following financial instruments: cash and cash equivalents, accounts receivable, restricted cash, accounts payable, debt and lease security deposit. We consider the carrying values of our short-term financial instruments to approximate fair value because they generally expose the Company to limited credit risk, because of the short period of time between origination of the financial assets and liabilities and their expected settlement, or because of their proximity to acquisition date fair values. The carrying value of debt approximates fair value based on borrowing rates currently available for debt of similar terms and maturities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon acquisition of real estate properties, the Company determines the total purchase price of each property and allocates this price based on the fair value of the tangible assets and intangible assets, if any, acquired and any liabilities assumed based on Level 3 inputs. These Level 3 inputs can include comparable sales values, discount rates, and capitalization rates from a third-party appraisal or other market sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zEQgHAhLHlB6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. <span id="xdx_823_zwkjxwr2kgda">PROPERTY AND EQUIPMENT, NET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKwYm3jizqh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross carrying amount and accumulated depreciation of the Company’s property and equipment as of September 30, 2022, and December 31, 2021, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zkKQ6xewl8q" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220930_z8yJh8SYSAF1" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20211231_zbXXpjCpozMj" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zT0BDKgXcWnd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Land</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,778,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,778,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandImprovementsMember_zo28jWTNqY0i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Land Improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">329,055</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">329,055</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zBw78VQatdsf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Buildings and Improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,230,535</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,574,401</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureFixturesAndEquipmentMember_zpioVzvWyqc3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture, Fixtures and Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,436,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,322,297</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzK3P_zKxoz1yqlD7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and Equipment, gross</p></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,774,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,004,003</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzK3P_zB6e4OLLKwRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,768,056</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,419,411</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzK3P_z26rLZpfP7i5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><p style="margin: 0">Property and Equipment, net</p></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">36,006,716</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,024,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220930_zHMmo2Emmcm1" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20210101__20210930_zsnrbCFW56X8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: right">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--Depreciation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Depreciation Expense (excluding Intangible Assets)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,348,645</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,286,279</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zzfl6aAyNf4k" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zKwYm3jizqh7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The gross carrying amount and accumulated depreciation of the Company’s property and equipment as of September 30, 2022, and December 31, 2021, are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zkKQ6xewl8q" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220930_z8yJh8SYSAF1" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20211231_zbXXpjCpozMj" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zT0BDKgXcWnd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Land</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,778,250</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,778,250</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandImprovementsMember_zo28jWTNqY0i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Land Improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">329,055</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">329,055</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zBw78VQatdsf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Buildings and Improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43,230,535</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,574,401</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureFixturesAndEquipmentMember_zpioVzvWyqc3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture, Fixtures and Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,436,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,322,297</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzK3P_zKxoz1yqlD7d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Property and Equipment, gross</p></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,774,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,004,003</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzK3P_zB6e4OLLKwRe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,768,056</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,419,411</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzK3P_z26rLZpfP7i5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><p style="margin: 0">Property and Equipment, net</p></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">36,006,716</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,024,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220930_zHMmo2Emmcm1" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20210101__20210930_zsnrbCFW56X8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: right">For the Nine Months Ended September 30,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--Depreciation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Depreciation Expense (excluding Intangible Assets)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,348,645</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">1,286,279</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1778250 1778250 329055 329055 43230535 44574401 2436932 2322297 47774772 49004003 11768056 10419411 36006716 37024592 1348645 1286279 <p id="xdx_80C_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zJSt2PfWLMQl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. <span id="xdx_82B_zuEw6im3m0Eh">INVESTMENTS IN DEBT SECURITIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--MarketableSecuritiesTextBlock_zvFiZJNNdsk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2022 and December 31, 2021, the Company held investments in debt securities that were classified as held-to-maturity and carried at amortized costs. Held-to-maturity securities consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_ziBJfmnDGvvi" style="display: none">SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">  </td><td style="width: 18%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">States and Municipalities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--TradingSecurities_iI_pp0p0_c20220930__us-gaap--InformationByCategoryOfDebtSecurityAxis__custom--StateandMunicipalMember_z1jkTcJeFeL9" style="text-align: right" title="Held-to-maturity securities">24,387</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--TradingSecurities_iI_pp0p0_c20211231__us-gaap--InformationByCategoryOfDebtSecurityAxis__custom--StateandMunicipalMember_zNyCffE3ohl7" style="text-align: right" title="Held-to-maturity securities">24,387</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zxfZjje7HKA3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual maturity of held-to-maturity securities at September 30, 2022, is $<span id="xdx_909_eus-gaap--DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_iI_c20220930_zLMghsz0m062" title="Contractual maturity of held-to-maturity securities">24,387</span>, all due in one year or less, and total value of securities at their respective maturity dates is $<span id="xdx_909_eus-gaap--HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue_iI_pp0p0_c20211231_z1ol327mL3yh" title="Held-to-maturity fair value">24,387</span>. Actual maturities may differ from contractual maturities because some borrowers have the right to call or prepay obligations with or without call or prepayment penalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_897_eus-gaap--MarketableSecuritiesTextBlock_zvFiZJNNdsk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September 30, 2022 and December 31, 2021, the Company held investments in debt securities that were classified as held-to-maturity and carried at amortized costs. Held-to-maturity securities consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_ziBJfmnDGvvi" style="display: none">SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">  </td><td style="width: 18%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">States and Municipalities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--TradingSecurities_iI_pp0p0_c20220930__us-gaap--InformationByCategoryOfDebtSecurityAxis__custom--StateandMunicipalMember_z1jkTcJeFeL9" style="text-align: right" title="Held-to-maturity securities">24,387</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--TradingSecurities_iI_pp0p0_c20211231__us-gaap--InformationByCategoryOfDebtSecurityAxis__custom--StateandMunicipalMember_zNyCffE3ohl7" style="text-align: right" title="Held-to-maturity securities">24,387</td><td style="text-align: left"> </td></tr> </table> 24387 24387 24387 24387 <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zKygsgcDuIk2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. <span id="xdx_82C_zCNNOJNpGmt9">DEBT AND DEBT - RELATED PARTIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zYklQFAT1l8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the Company’s debt outstanding as of September 30, 2022, and December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z4dAeRGGkWG9" style="display: none">SCHEDULE OF DEBT INSTRUMENTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220930_zU9EKAYZXLG6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_z0u4YlTzl27f" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_404_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredPromissoryNotesMember_zNPnv16U8tCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Senior Secured Promissory Notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,025,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,305,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredPromissoryNotesRelatedPartiesMember_zTo8Q4bRLhEa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Senior Secured Promissory Notes - Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--FixedRateMortgageLoansMember_zCDKjYvHkcO" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fixed-Rate Mortgage Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,695,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,407,503</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--VariableRateMortgageLoansMember_zTUc2m1gGdbj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Variable-Rate Mortgage Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,919,504</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,063,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--OtherDebtSubordinatedSecuredMember_zEhqSOJ4HLN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Other Debt, Subordinated Secured</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">741,000</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">741,000</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--OtherDebtSubordinatedSecuredRelatedPartiesMember_zwtn4X9VBBXl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other Debt, Subordinated Secured - Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--OtherDebtSubordinatedSecuredSellerFinancingMember_zeqWW8bQbK6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other Debt, Subordinated Secured - Seller Financing</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,361</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,251</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_maDIUDPzQ6l_zWEVa7wJwSQb" style="vertical-align: bottom; background-color: White"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Instrument, Gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,346,641</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,510,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iNI_pp0p0_di_msDIUDPzQ6l_zRbm372zQnH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unamortized Discount and Debt Issuance Costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(868,561</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,243,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DebtLongtermAndShorttermCombinedNetAmount_iTI_pp0p0_mtDIUDPzQ6l_zE3NQpOY7FV3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Instrument, Net of Discount</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,478,080</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,267,524</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">As presented in the Consolidated Balance Sheets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtCurrent_iI_pp0p0_zNnGelYEb3a3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current Maturities of Long Term Debt, Net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,049,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,312,562</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_pp0p0_z37ypNh7r4g7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term debt – Related Parties, Net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_zUtH9Go3imDc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt, Net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,528,330</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,054,962</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableRelatedPartiesNoncurrent_iI_pp0p0_zLpgt0dxECbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debt – Related Parties, Net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_z0ALQ8kztaQe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The weighted average interest rate and term of our fixed rate debt are <span id="xdx_90E_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_uPure_c20220930__us-gaap--VariableRateAxis__custom--FixedRateMember_zYmM58PDVgLi" title="Debt weighted average interest rate">4.03%</span> and <span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20220101__20220930__us-gaap--VariableRateAxis__custom--FixedRateMember_zsdjo7HRykib" title="Debt instrument term">16.33</span> years, respectively, as of September 30, 2022. The weighted average interest rate and term of our variable rate debt are <span id="xdx_907_eus-gaap--DebtWeightedAverageInterestRate_iI_pid_uPure_c20220930__us-gaap--VariableRateAxis__custom--VariableRateMember_zHoWWhOyKYf1" title="Debt weighted average interest rate">5.90%</span> and <span id="xdx_901_eus-gaap--DebtInstrumentTerm_dtY_c20220101__20220930__us-gaap--VariableRateAxis__custom--VariableRateMember_zizruyGQQ4hj" title="Debt instrument term">16.11</span> years, respectively, as of September 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Senior and Senior Secured Promissory Notes</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, and December 31, 2021, the senior secured notes are subject to annual interest ranging from <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220930__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--RangeAxis__srt--MinimumMember_zus6OzNfUBz" title="Debt instrument interest rate">10%</span> to <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember__srt--RangeAxis__srt--MaximumMember_zgLUeXnQjK5h" title="Debt instrument interest rate">11%</span> and initially matured on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zCyrmPOQ7ju" title="Debt maturity date">October 31, 2021</span>. These notes were extended to <span id="xdx_907_ecustom--DebtInstrumentExtendedMaturityDate_dd_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zWyE8xPAZI89" title="Debt instrument extended maturity date">June 30, 2023</span> and as consideration the Company modified the outstanding warrants to extend the life and additional <span id="xdx_900_eus-gaap--DebtInstrumentTerm_dtY_c20220101__20220930__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zVcg5GEhI8E8" title="Debt instrument term">1.67</span> years. As a result of the warrant modification, the Company recorded the incremental increase in fair value of $<span id="xdx_900_ecustom--IncrementalIncreaseInFairValueOfDebtDiscount_iI_c20220930_zWH8L5eCgNf1" title="Incremental increase in fair value of debt discount">844,425</span> as a debt discount which will be amortized over the new life of the loans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"/> <p style="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Mortgage Loans and Lines of Credit Secured by Real Estate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mortgage loans and other debts such as line of credit here are collateralized by all assets of each nursing home property and an assignment of its rents. Collateral for certain mortgage loans includes the personal guarantee of Christopher Brogdon, formerly but no longer a related party, or corporate guarantees. Mortgage loans for the periods presented consisted of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfParticipatingMortgageLoansTextBlock_zyyCkrDEQIjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_z8mEWxLget29" style="display: none">SCHEDULE OF MORTGAGE LOAN DEBT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Face</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Principal Outstanding as of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">State</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Properties</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: justify"><span style="font-size: 10pt">Arkansas<sup id="xdx_F4C_z2jv8nKtjzCa">(1)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--NumberOfRealEstateProperties_iI_pid_uInteger_c20220930__srt--StatementGeographicalAxis__stpr--AR__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDEp_zHWdX5W7zZUf" style="width: 12%; text-align: right" title="Number of Properties">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__srt--StatementGeographicalAxis__stpr--AR__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDEp_z08bWhu8Ryqf" style="width: 12%; text-align: right" title="Face Amount">5,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20220930__srt--StatementGeographicalAxis__stpr--AR__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDEp_z23LVblcnqpi" style="width: 16%; text-align: right" title="Long-term Debt, Gross">3,937,978</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__stpr--AR__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDEp_zIDrNmft0Hai" style="width: 16%; text-align: right" title="Long-term Debt, Gross">4,058,338</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-size: 10pt">Georgia<sup id="xdx_F45_zLZTWkqbBcv6">(2)</sup></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NumberOfRealEstateProperties_iI_uInteger_c20220930__srt--StatementGeographicalAxis__stpr--GA__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDIp_zuWy214nxRk5" style="text-align: right" title="Number of Properties">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--GA__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDIp_zxKqOs3h9Dx1" title="Face Amount">17,765,992</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--GA__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDIp_zhZxrpTp6Sz4" title="Long-term Debt, Gross">16,156,093</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20211231__srt--StatementGeographicalAxis__stpr--GA__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDIp_zDOMarFMABO6" title="Long-term Debt, Gross">16,581,232</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Ohio</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--NumberOfRealEstateProperties_iI_uInteger_c20220930__srt--StatementGeographicalAxis__stpr--OH__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_ztMepXVUU637" title="Number of Properties">1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--OH__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_z96Uv0WCQST4" title="Face Amount">3,000,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--OH__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zFCsFz6FG1gj" title="Long-term Debt, Gross">2,728,599</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20211231__srt--StatementGeographicalAxis__stpr--OH__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zSu5sXtOSQ07" title="Long-term Debt, Gross">2,728,599</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Oklahoma<sup id="xdx_F4A_zno764gVLewb">(3)</sup></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--NumberOfRealEstateProperties_iI_uInteger_c20220930__srt--StatementGeographicalAxis__stpr--OK__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zVY5DiWLWhL" title="Number of Properties">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--OK__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zUBgaLT9INI4" title="Face Amount">13,331,325</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--OK__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zGOjes6Z9JB6" title="Long-term Debt, Gross">12,792,194</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_c20211231__srt--StatementGeographicalAxis__stpr--OK__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zb8G2DVI7wae" title="Long-term Debt, Gross">12,895,890</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 11pt; text-align: right"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--NumberOfRealEstateProperties_iI_uInteger_c20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zeqk6bpbayil" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Properties">13</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zBAVDavYpYJ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Face Amount">39,097,317</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zPSmyRTjc1r9" title="Long-term Debt, Gross">35,614,825</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zVXih4XDFA14" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term Debt, Gross">36,264,059</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td id="xdx_F06_zOoPz8SgRRrf" style="text-align: justify; width: 0.25in">(1)</td><td id="xdx_F16_zFPHIEQsrM58" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_ecustom--MortgageLoanDescription_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zQmFxe1xizo1" title="Mortgage loan description">The mortgage loan collateralized by this property is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_ecustom--UsdaGuaranteedRate_pid_uPure_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zcYKTyjJZOUi" title="USDA guaranteed rate">80%</span> guaranteed by the USDA and requires an annual renewal fee payable in the amount of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--AnnualRenewalFeePayable_pid_uPure_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zxpL65REdIWb" title="Annual renewal fee payable">0.25%</span> of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year.</span> Guarantors under the mortgage loan include Christopher Brogdon. Mr. Brogdon has assumed operations of the facility and is making payments of principal and interest on the loan on our behalf in lieu of paying rent on the facility to us. During the nine months ended September 30, 2022, the Company recognized other income of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--RepaymentsOfFirstMortgageBond_pp0p0_c20220101__20220930_z1M9xxWRhuUb">118,716 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for repayments on the loan.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td><td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td id="xdx_F09_zvU8a5qQlW79" style="text-align: justify">(2)</td><td id="xdx_F1B_zDJhcSZQT398" style="text-align: justify">The Company has refinanced two of its mortgages that would have matured in June and October of 2021 amounting to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ProceedsFromMortgageDeposits_pp0p0_c20220101__20220930__us-gaap--FinancialInstrumentAxis__custom--FirstMortgageLoanMember_ztBHrpmnDUF9" title="Proceeds from refinance">2,961,167</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--ProceedsFromMortgageDeposits_c20220101__20220930__us-gaap--FinancialInstrumentAxis__us-gaap--SecondMortgageMember_zcdcVSv5QZcc" title="Proceeds from refinance">3,289,595</span>, to extend their maturity dates to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_c20210701__20210731__us-gaap--FinancialInstrumentAxis__custom--FirstMortgageLoanMember_zLtd3gt2gbyk" title="Maturity date">May 2024</span> for both.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td><td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td id="xdx_F02_z0JRDKeJihL2" style="text-align: justify">(3)</td><td id="xdx_F1C_z6xZgNJbvtFb" style="text-align: justify">The Company refinanced all three mortgages in July 2021, that would have matured in June and July of 2021 amounting to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ProceedsFromMortgageDeposits_pp0p0_c20210701__20210731__us-gaap--FinancialInstrumentAxis__custom--FirstMortgageLoanMember_zXl7pDAsMSN6" title="Mortgage one">2,065,969</span>, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ProceedsFromMortgageDeposits_pp0p0_c20210701__20210731__us-gaap--FinancialInstrumentAxis__us-gaap--SecondMortgageMember_z8Jk5CBsZFqa" title="Mortgage one">750,000</span>, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ProceedsFromMortgageDeposits_pp0p0_c20210701__20210731__us-gaap--FinancialInstrumentAxis__custom--ThirdMortgageLoanMember_zSxty8JchB17" title="Mortgage one">500,000</span>, to extend their maturity dates to<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDateDescription_c20210701__20210731_zXSwCysexJN2" title="Maturity date"> June, 2027</span> for all three. Additionally, the Company has refinanced the primary mortgage at the Southern Hills Campus, for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentTerm_dtY_c20210701__20210731_zwBEbPzf4kzf" title="Debt instrument term">35</span> years at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210731_zIcIOhZobyaf" title="Interest rate">2.38%</span></td></tr></table> <p id="xdx_8AF_zQow3suAnL5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Subordinated, Corporate and Other Debt</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other debt due at September 30, 2022 and December 31, 2021 includes unsecured notes payable issued to entities controlled by the Company used to facilitate the acquisition of the nursing home properties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89C_ecustom--ScheduleOfOtherDebtTableTextBlock_zWn5yDnPYH77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zcON4drNoda6" style="display: none">SCHEDULE OF OTHER DEBT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Principal Outstanding at</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Stated Interest</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Property</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Face Amount</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Rate</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Maturity Date</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F47_zZoosFwqoS18" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-left: -10pt; width: 21%; text-align: left">Goodwill Nursing Home <sup id="xdx_F4E_ztn9fzo6WVi">(1)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_znebFn2owKak" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Debt, Face Amount">2,030,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zmUL1T5rGoWk" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Debt, Principal Outstanding">741,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zGr3KJkqPiXi" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Debt, Principal Outstanding">741,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 13%"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zuXiYTCUcfz3" title="Debt, Interest Rate">13% Fixed</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 15%"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_z1KfuC2s4CSj" title="Debt, Maturity Date">December 31, 2019</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td id="xdx_F42_zgZvBHUc0E0c" style="font: 10pt Times New Roman, Times, Serif">Goodwill Nursing Home - Related Party <sup>(1)</sup></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zNT0dwpyKUag" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Face Amount">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zUpezIxsyWFk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zZqRclflpRM" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zkfCGfdX2AG5" title="Debt, Interest Rate">13% Fixed</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zsZaqD70ga7j" title="Debt, Maturity Date">December 31, 2019</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F47_z2ws2hE8AQZ9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Higher Call Nursing Center <sup>(2)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_zpq9tGtqHHid" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Debt, Face Amount">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_z8OLfkGUgWDa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">65,361</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_zDWl7A246nn7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">93,251</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_zg2v0VaRNPo1" title="Debt, Interest Rate">8% Fixed</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_zeV4bAIf2n59" title="Debt, Maturity Date">April 1, 2024</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z2y6SKxKgEG5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">956,361</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z5p800WanCZj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">984,251</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p id="xdx_8A2_zV8HulbVj3s4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate debt at September 30, 2022, and December 31, 2021 includes unsecured notes and notes secured by all assets of the Company not serving as collateral for other notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89C_eus-gaap--ScheduleOfDebtTableTextBlock_ziSCMjo9nmHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zsq6zDwYMHJ9" style="display: none">SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Principal Outstanding at</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center">Stated Interest</td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Series</td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Face Amount</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid">December 31,2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Rate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Maturity Date</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 21%">10% Senior Secured Promissory Notes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_zJRBCHw2pAe1" style="width: 10%; text-align: right" title="Debt, Face Amount">1,670,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_zpABAlh3tCHf" style="width: 15%; text-align: right" title="Debt, Principal Outstanding">1,025,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_z3AgiE88N1Dd" style="width: 15%; text-align: right" title="Debt, Principal Outstanding">1,305,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 13%"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_z4oUSlINyvkl" title="Debt, Interest Rate">10.0% Fixed</span></td><td style="width: 1%"> </td> <td style="text-align: center; width: 15%"><span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_zAhFXelEwED4" title="Debt, Maturity Date">June 30, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">11% Senior Secured Promissory Notes – Related Party</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zeF8pTtv9776" style="padding-bottom: 1.5pt; text-align: right" title="Debt, Face Amount">975,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zrA8F59xjKdb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt, Principal Outstanding">750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zTuUACQLUmjd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt, Principal Outstanding">750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zVJZmITp8JDc" title="Debt, Interest Rate">10.0% Fixed</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zh5GBT5Z6vv9" title="Debt, Maturity Date">June 30, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20220930_zmnS9YxOKY14" style="border-bottom: Black 2.5pt double; text-align: right" title="Debt, Principal Outstanding">1,025,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20211231_zMCiT4NQsQ9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Debt, Principal Outstanding">2,055,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8AA_zJ8ESpNxZxKh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_894_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zYklQFAT1l8c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the Company’s debt outstanding as of September 30, 2022, and December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z4dAeRGGkWG9" style="display: none">SCHEDULE OF DEBT INSTRUMENTS</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220930_zU9EKAYZXLG6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20211231_z0u4YlTzl27f" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_404_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredPromissoryNotesMember_zNPnv16U8tCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Senior Secured Promissory Notes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,025,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,305,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredPromissoryNotesRelatedPartiesMember_zTo8Q4bRLhEa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Senior Secured Promissory Notes - Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--FixedRateMortgageLoansMember_zCDKjYvHkcO" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fixed-Rate Mortgage Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,695,361</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,407,503</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--VariableRateMortgageLoansMember_zTUc2m1gGdbj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Variable-Rate Mortgage Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,919,504</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,063,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--OtherDebtSubordinatedSecuredMember_zEhqSOJ4HLN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left">Other Debt, Subordinated Secured</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">741,000</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0">741,000</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--OtherDebtSubordinatedSecuredRelatedPartiesMember_zwtn4X9VBBXl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other Debt, Subordinated Secured - Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_hus-gaap--LongtermDebtTypeAxis__custom--OtherDebtSubordinatedSecuredSellerFinancingMember_zeqWW8bQbK6d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other Debt, Subordinated Secured - Seller Financing</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">65,361</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,251</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iI_pp0p0_maDIUDPzQ6l_zWEVa7wJwSQb" style="vertical-align: bottom; background-color: White"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Instrument, Gross</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,346,641</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,510,595</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iNI_pp0p0_di_msDIUDPzQ6l_zRbm372zQnH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Unamortized Discount and Debt Issuance Costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(868,561</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,243,071</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DebtLongtermAndShorttermCombinedNetAmount_iTI_pp0p0_mtDIUDPzQ6l_zE3NQpOY7FV3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Instrument, Net of Discount</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,478,080</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,267,524</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">As presented in the Consolidated Balance Sheets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtCurrent_iI_pp0p0_zNnGelYEb3a3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current Maturities of Long Term Debt, Net</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,049,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,312,562</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_pp0p0_z37ypNh7r4g7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short term debt – Related Parties, Net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LongTermDebtNoncurrent_iI_pp0p0_zUtH9Go3imDc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Debt, Net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,528,330</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,054,962</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--NotesPayableRelatedPartiesNoncurrent_iI_pp0p0_zLpgt0dxECbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Debt – Related Parties, Net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">750,000</td><td style="text-align: left"> </td></tr> </table> 1025000 1305000 750000 750000 30695361 31407503 4919504 5063841 741000 741000 150000 150000 65361 93251 38346641 39510595 868561 1243071 37478080 38267524 2049750 6312562 150000 150000 34528330 31054962 750000 750000 0.0403 P16Y3M29D 0.0590 P16Y1M9D 0.10 0.11 2021-10-31 2023-06-30 P1Y8M1D 844425 <p id="xdx_89A_eus-gaap--ScheduleOfParticipatingMortgageLoansTextBlock_zyyCkrDEQIjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_z8mEWxLget29" style="display: none">SCHEDULE OF MORTGAGE LOAN DEBT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Total Face</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Principal Outstanding as of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">State</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Properties</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: justify"><span style="font-size: 10pt">Arkansas<sup id="xdx_F4C_z2jv8nKtjzCa">(1)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--NumberOfRealEstateProperties_iI_pid_uInteger_c20220930__srt--StatementGeographicalAxis__stpr--AR__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDEp_zHWdX5W7zZUf" style="width: 12%; text-align: right" title="Number of Properties">1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__srt--StatementGeographicalAxis__stpr--AR__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDEp_z08bWhu8Ryqf" style="width: 12%; text-align: right" title="Face Amount">5,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20220930__srt--StatementGeographicalAxis__stpr--AR__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDEp_z23LVblcnqpi" style="width: 16%; text-align: right" title="Long-term Debt, Gross">3,937,978</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20211231__srt--StatementGeographicalAxis__stpr--AR__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDEp_zIDrNmft0Hai" style="width: 16%; text-align: right" title="Long-term Debt, Gross">4,058,338</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-size: 10pt">Georgia<sup id="xdx_F45_zLZTWkqbBcv6">(2)</sup></span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--NumberOfRealEstateProperties_iI_uInteger_c20220930__srt--StatementGeographicalAxis__stpr--GA__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDIp_zuWy214nxRk5" style="text-align: right" title="Number of Properties">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--GA__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDIp_zxKqOs3h9Dx1" title="Face Amount">17,765,992</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--GA__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDIp_zhZxrpTp6Sz4" title="Long-term Debt, Gross">16,156,093</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20211231__srt--StatementGeographicalAxis__stpr--GA__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDIp_zDOMarFMABO6" title="Long-term Debt, Gross">16,581,232</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Ohio</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--NumberOfRealEstateProperties_iI_uInteger_c20220930__srt--StatementGeographicalAxis__stpr--OH__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_ztMepXVUU637" title="Number of Properties">1</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--OH__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_z96Uv0WCQST4" title="Face Amount">3,000,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--OH__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zFCsFz6FG1gj" title="Long-term Debt, Gross">2,728,599</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentCarryingAmount_iI_c20211231__srt--StatementGeographicalAxis__stpr--OH__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zSu5sXtOSQ07" title="Long-term Debt, Gross">2,728,599</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-size: 10pt">Oklahoma<sup id="xdx_F4A_zno764gVLewb">(3)</sup></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--NumberOfRealEstateProperties_iI_uInteger_c20220930__srt--StatementGeographicalAxis__stpr--OK__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zVY5DiWLWhL" title="Number of Properties">6</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--OK__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zUBgaLT9INI4" title="Face Amount">13,331,325</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220930__srt--StatementGeographicalAxis__stpr--OK__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zGOjes6Z9JB6" title="Long-term Debt, Gross">12,792,194</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--DebtInstrumentCarryingAmount_iI_c20211231__srt--StatementGeographicalAxis__stpr--OK__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zb8G2DVI7wae" title="Long-term Debt, Gross">12,895,890</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 11pt; text-align: right"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--NumberOfRealEstateProperties_iI_uInteger_c20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zeqk6bpbayil" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Properties">13</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zBAVDavYpYJ9" style="border-bottom: Black 2.5pt double; text-align: right" title="Face Amount">39,097,317</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentCarryingAmount_iI_c20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zPSmyRTjc1r9" title="Long-term Debt, Gross">35,614,825</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zVXih4XDFA14" style="border-bottom: Black 2.5pt double; text-align: right" title="Long-term Debt, Gross">36,264,059</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top"> <td id="xdx_F06_zOoPz8SgRRrf" style="text-align: justify; width: 0.25in">(1)</td><td id="xdx_F16_zFPHIEQsrM58" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_ecustom--MortgageLoanDescription_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_fKDMp_zQmFxe1xizo1" title="Mortgage loan description">The mortgage loan collateralized by this property is <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_ecustom--UsdaGuaranteedRate_pid_uPure_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zcYKTyjJZOUi" title="USDA guaranteed rate">80%</span> guaranteed by the USDA and requires an annual renewal fee payable in the amount of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_ecustom--AnnualRenewalFeePayable_pid_uPure_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--MortgageLoansMember_zxpL65REdIWb" title="Annual renewal fee payable">0.25%</span> of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year.</span> Guarantors under the mortgage loan include Christopher Brogdon. Mr. Brogdon has assumed operations of the facility and is making payments of principal and interest on the loan on our behalf in lieu of paying rent on the facility to us. During the nine months ended September 30, 2022, the Company recognized other income of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--RepaymentsOfFirstMortgageBond_pp0p0_c20220101__20220930_z1M9xxWRhuUb">118,716 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for repayments on the loan.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td><td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td id="xdx_F09_zvU8a5qQlW79" style="text-align: justify">(2)</td><td id="xdx_F1B_zDJhcSZQT398" style="text-align: justify">The Company has refinanced two of its mortgages that would have matured in June and October of 2021 amounting to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--ProceedsFromMortgageDeposits_pp0p0_c20220101__20220930__us-gaap--FinancialInstrumentAxis__custom--FirstMortgageLoanMember_ztBHrpmnDUF9" title="Proceeds from refinance">2,961,167</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--ProceedsFromMortgageDeposits_c20220101__20220930__us-gaap--FinancialInstrumentAxis__us-gaap--SecondMortgageMember_zcdcVSv5QZcc" title="Proceeds from refinance">3,289,595</span>, to extend their maturity dates to <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_c20210701__20210731__us-gaap--FinancialInstrumentAxis__custom--FirstMortgageLoanMember_zLtd3gt2gbyk" title="Maturity date">May 2024</span> for both.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td><td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td id="xdx_F02_z0JRDKeJihL2" style="text-align: justify">(3)</td><td id="xdx_F1C_z6xZgNJbvtFb" style="text-align: justify">The Company refinanced all three mortgages in July 2021, that would have matured in June and July of 2021 amounting to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_909_eus-gaap--ProceedsFromMortgageDeposits_pp0p0_c20210701__20210731__us-gaap--FinancialInstrumentAxis__custom--FirstMortgageLoanMember_zXl7pDAsMSN6" title="Mortgage one">2,065,969</span>, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--ProceedsFromMortgageDeposits_pp0p0_c20210701__20210731__us-gaap--FinancialInstrumentAxis__us-gaap--SecondMortgageMember_z8Jk5CBsZFqa" title="Mortgage one">750,000</span>, and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_eus-gaap--ProceedsFromMortgageDeposits_pp0p0_c20210701__20210731__us-gaap--FinancialInstrumentAxis__custom--ThirdMortgageLoanMember_zSxty8JchB17" title="Mortgage one">500,000</span>, to extend their maturity dates to<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90C_eus-gaap--DebtInstrumentMaturityDateDescription_c20210701__20210731_zXSwCysexJN2" title="Maturity date"> June, 2027</span> for all three. Additionally, the Company has refinanced the primary mortgage at the Southern Hills Campus, for <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90E_eus-gaap--DebtInstrumentTerm_dtY_c20210701__20210731_zwBEbPzf4kzf" title="Debt instrument term">35</span> years at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIE1PUlRHQUdFIExPQU4gREVCVCAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210731_zIcIOhZobyaf" title="Interest rate">2.38%</span></td></tr></table> 1 5000000 3937978 4058338 5 17765992 16156093 16581232 1 3000000 2728599 2728599 6 13331325 12792194 12895890 13 39097317 35614825 36264059 The mortgage loan collateralized by this property is 80% guaranteed by the USDA and requires an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year. 0.80 0.0025 118716 2961167 3289595 May 2024 2065969 750000 500000 June, 2027 P35Y 0.0238 <p id="xdx_89C_ecustom--ScheduleOfOtherDebtTableTextBlock_zWn5yDnPYH77" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zcON4drNoda6" style="display: none">SCHEDULE OF OTHER DEBT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Principal Outstanding at</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">Stated Interest</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Property</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Face Amount</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">September 30, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2021</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Rate</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Maturity Date</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F47_zZoosFwqoS18" style="font: 10pt Times New Roman, Times, Serif; vertical-align: middle; padding-left: -10pt; width: 21%; text-align: left">Goodwill Nursing Home <sup id="xdx_F4E_ztn9fzo6WVi">(1)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_znebFn2owKak" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Debt, Face Amount">2,030,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zmUL1T5rGoWk" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Debt, Principal Outstanding">741,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zGr3KJkqPiXi" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Debt, Principal Outstanding">741,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 13%"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zuXiYTCUcfz3" title="Debt, Interest Rate">13% Fixed</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 15%"><span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_z1KfuC2s4CSj" title="Debt, Maturity Date">December 31, 2019</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td id="xdx_F42_zgZvBHUc0E0c" style="font: 10pt Times New Roman, Times, Serif">Goodwill Nursing Home - Related Party <sup>(1)</sup></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zNT0dwpyKUag" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Face Amount">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zUpezIxsyWFk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zZqRclflpRM" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zkfCGfdX2AG5" title="Debt, Interest Rate">13% Fixed</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--GoodwillNursingHomeOneMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDEp_zsZaqD70ga7j" title="Debt, Maturity Date">December 31, 2019</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td id="xdx_F47_z2ws2hE8AQZ9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">Higher Call Nursing Center <sup>(2)</sup></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_zpq9tGtqHHid" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right" title="Debt, Face Amount">150,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_z8OLfkGUgWDa" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">65,361</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_985_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_zDWl7A246nn7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">93,251</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_zg2v0VaRNPo1" title="Debt, Interest Rate">8% Fixed</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HigherCallNursingCenterMember__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_fKDIp_zeV4bAIf2n59" title="Debt, Maturity Date">April 1, 2024</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z2y6SKxKgEG5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">956,361</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--OtherDebtMember_z5p800WanCZj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Debt, Principal Outstanding">984,251</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> 2030000 741000 741000 13% Fixed 2019-12-31 150000 150000 150000 13% Fixed 2019-12-31 150000 65361 93251 8% Fixed 2024-04-01 956361 984251 <p id="xdx_89C_eus-gaap--ScheduleOfDebtTableTextBlock_ziSCMjo9nmHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zsq6zDwYMHJ9" style="display: none">SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Principal Outstanding at</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center">Stated Interest</td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Series</td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Face Amount</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid">December 31,2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Rate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center">Maturity Date</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 21%">10% Senior Secured Promissory Notes</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_zJRBCHw2pAe1" style="width: 10%; text-align: right" title="Debt, Face Amount">1,670,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_zpABAlh3tCHf" style="width: 15%; text-align: right" title="Debt, Principal Outstanding">1,025,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_z3AgiE88N1Dd" style="width: 15%; text-align: right" title="Debt, Principal Outstanding">1,305,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 13%"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_z4oUSlINyvkl" title="Debt, Interest Rate">10.0% Fixed</span></td><td style="width: 1%"> </td> <td style="text-align: center; width: 15%"><span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--TenPercentageSeniorSecuredPromissoryNoteOneMember_zAhFXelEwED4" title="Debt, Maturity Date">June 30, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">11% Senior Secured Promissory Notes – Related Party</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zeF8pTtv9776" style="padding-bottom: 1.5pt; text-align: right" title="Debt, Face Amount">975,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--NotesPayable_iI_pp0p0_c20220930__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zrA8F59xjKdb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt, Principal Outstanding">750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--NotesPayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zTuUACQLUmjd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Debt, Principal Outstanding">750,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateTerms_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zVJZmITp8JDc" title="Debt, Interest Rate">10.0% Fixed</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20220101__20220930__us-gaap--DebtInstrumentAxis__custom--ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember_zh5GBT5Z6vv9" title="Debt, Maturity Date">June 30, 2024</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesPayable_iI_pp0p0_c20220930_zmnS9YxOKY14" style="border-bottom: Black 2.5pt double; text-align: right" title="Debt, Principal Outstanding">1,025,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayable_iI_pp0p0_c20211231_zMCiT4NQsQ9a" style="border-bottom: Black 2.5pt double; text-align: right" title="Debt, Principal Outstanding">2,055,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> 1670000 1025000 1305000 10.0% Fixed 2024-06-30 975000 750000 750000 10.0% Fixed 2024-06-30 1025000 2055000 <p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zMv8bPTMgXO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify"><b>6. <span id="xdx_826_zJgNPrGyzQR3">STOCKHOLDERS’ EQUITY</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: justify"><b>Preferred Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September 30, 2022 and 2021, the Company paid $<span id="xdx_905_eus-gaap--PaymentsOfDividendsPreferredStockAndPreferenceStock_pp0p0_c20220101__20220930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_z8octkVQKn4i" title="Preferred stock, dividend paid">15,000</span> and $<span id="xdx_90D_eus-gaap--PaymentsOfDividendsPreferredStockAndPreferenceStock_pp0p0_c20210101__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember_zrRdXMleCe06" title="Preferred stock, dividend paid">30,000</span> respectively for Series D preferred stock dividends. Dividends of $<span id="xdx_906_eus-gaap--DividendsPreferredStock_c20220101__20220930__us-gaap--DividendsAxis__us-gaap--DividendDeclaredMember_z3zf3QgVRMzh" title="Dividend, preferred stock"><span id="xdx_909_eus-gaap--DividendsPreferredStock_c20210101__20210930__us-gaap--DividendsAxis__us-gaap--DividendDeclaredMember_zF78aw8mowL3" title="Dividend, preferred stock">22,500</span></span> were declared during the nine months ended September 30, 2022 and September 30, 2021. All quarterly dividends previously declared have been paid.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the nine months ended September 30, 2022, the Company did not issue nor did it pay dividends on common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, and December 31, 2021, the Company had <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVREfevyzJ9c" title="Warrants to purchase common stock"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zb0aaIUg2ZOd" title="Warrants to purchase common stock">206,000</span></span>, of outstanding warrants to purchase common stock at a weighted average exercise price of $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzyqWyN60yld" title="Weighted average exercise price"><span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzck6Zdx6Pb4" title="Weighted average exercise price">5.00</span></span>, respectively, and weighted average remaining term of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhWrTF17VATg" title="Common stock warrants term">0.19</span> years and <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zreCHbTFzUv9" title="Common stock warrants term">0.93</span> years, respectively. The aggregate intrinsic value of common stock warrants outstanding as of September 30, 2022, and December 31, 2021 was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGARYy4pLRHb" title="Aggregate intrinsic value of common stock warrants outstanding">360,052</span> and $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmIEzYzrcMCd" title="Aggregate intrinsic value of common stock warrants outstanding">355,877</span>, respectively. Activity for the nine months ended September 30, 2022, related to common stock warrants is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zgikzVJc6yne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zRWM7NgtvGsf" style="display: none">SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Beginning Balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZI4c2zAC35l" style="width: 14%; text-align: right" title="Number of Warrants, Beginning Balance">206,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbQZEO7rRgnh" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvuRLAMz0M" style="text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zywlbHRlnWVe" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsT1E3mGlMXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKxvqPwnsjHj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">         <span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCTRTZleKHM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Ending Balance">206,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8QI88vJqcP3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance">5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zosw0xHEN1hk" style="margin: 0pt 0"> </p> 15000 30000 22500 22500 206000 206000 5.00 5.00 P0Y2M8D P0Y11M4D 360052 355877 <p id="xdx_89B_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zgikzVJc6yne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zRWM7NgtvGsf" style="display: none">SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">September 30, 2022</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Number of</td><td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center">Weighted Average</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Beginning Balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZI4c2zAC35l" style="width: 14%; text-align: right" title="Number of Warrants, Beginning Balance">206,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbQZEO7rRgnh" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Beginning Balance">5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvuRLAMz0M" style="text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zywlbHRlnWVe" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsT1E3mGlMXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKxvqPwnsjHj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Expired">         <span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Ending Balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCTRTZleKHM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Ending Balance">206,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8QI88vJqcP3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Ending Balance">5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 206000 5 206000 5 <p id="xdx_80E_eus-gaap--OtherLiabilitiesDisclosureTextBlock_zYjVLJfJV7bh" style="font: 11pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"><b>7. <span id="xdx_82F_zhRFvcBOYDW6">OTHER CURRENT LIABILITY</span></b></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2021 the Company received an overpayment from Medicare of $<span id="xdx_908_eus-gaap--OtherLiabilitiesCurrent_iI_c20211231_zpSGm3EFaw7e" title="Other current liability">931,446</span>. Beginning in February, 2022 payments were recouped to satisfy the overpayment. As of September 30, 2022, this liability has been satisfied.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 931446 <p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zs33YdxQTPs3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. <span id="xdx_827_z8NNSaQXG2C7">RELATED PARTIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clifford Neuman, a former member of the Company’s Board of Directors, provided legal services to the Company. As of September 30, 2022, and December 31, 2021, the Company owed Mr. Neuman for legal services rendered $<span id="xdx_901_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrCliffordNeumanMember_zHZ0P8Ph2Irf" title="Due to related party">5,640</span> and $<span id="xdx_905_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrCliffordNeumanMember_zYmdaMCRqnTb" title="Due to related party">21,571</span>, respectively. During the nine months ended September 30, 2022 the Company has paid Mr. Neuman $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrCliffordNeumanMember_zZKGyerY8Wwh" title="Repayments of related party debt">64,433</span> for legal services. During the year ended December 31, 2021 the Company paid Mr. Neuman $<span id="xdx_906_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrCliffordNeumanMember_zW1B8qomGoLj" title="Repayments of related party debt">158,392</span> for legal services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 5640 21571 64433 158392 <p id="xdx_806_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zu3Ye8b2uLHi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. <span id="xdx_825_zqt21TyqM223">FACILITY LEASES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_891_ecustom--ScheduleOfLeasingArrangementsTableTextBlock_zgftsdxT6jbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our leasing arrangements related to the Company’s healthcare facilities at September 30, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zZL2TElz6WO" style="display: none">SCHEDULE OF LEASING ARRANGEMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center">Monthly Lease</td><td style="font-size: 10pt"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Facility</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><span style="font-size: 10pt">Income <sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Lease Expiration</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Renewal Option if any</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 14%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Goodwill <sup id="xdx_F45_zUf8qCy6oTqg">(1)</sup></span></td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeasesIncomeStatementLeaseRevenue_c20220101__20220930__us-gaap--TypeOfArrangementAxis__us-gaap--GoodwillMember_fKDEp_zpUdbpwexvzj" style="width: 14%; font-size: 10pt; text-align: right" title="Monthly lease income">48,125</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 16%; font-size: 10pt; text-align: center"><span id="xdx_90B_eus-gaap--LeaseExpirationDate1_c20220101__20220930__us-gaap--TypeOfArrangementAxis__us-gaap--GoodwillMember_zTDOxxBscSBf" title="Lease expiration date">February 1, 2027</span></td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 48%; font-size: 10pt; text-align: center"><span id="xdx_90B_ecustom--LeaseRenewalOption_c20220101__20220930__us-gaap--TypeOfArrangementAxis__us-gaap--GoodwillMember_zPKGw6mzqrVb" title="Lease renewal option">Term may be extended for one additional five-year term.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td id="xdx_F00_zpPSVqzYHuDa" style="text-align: justify; width: 0.25in">(1)</td> <td id="xdx_F10_zBZQvMiCdBVj" style="text-align: justify">The lease became effective on February 1, 2017, and the facility began generating rental revenue thereafter.</td></tr> </table> <p id="xdx_8A0_zSfeM74FAWp4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zURgek5q65yk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future cash payments for rent to be received during the initial terms of the leases for the next five years and thereafter are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zjGlRUNqI3Fg" style="display: none">SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Years Ending September 30,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220930_zGox8ssrGISc" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzKQr_zBy49aBkYtXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; font-size: 10pt; text-align: center">2022</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">156,870</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzKQr_z7jddwu0bvte" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: center">2023</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">635,026</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzKQr_zLmkvfDUE5fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: center">2024</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">643,401</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzKQr_zS5VI18m5GO5" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: center">2025</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">651,954</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzKQr_zF9rkOBsQNri" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: center">2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">660,665</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter_iI_pp0p0_maLOLLPzKQr_zCY63oekLi2f" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: center; padding-bottom: 1.5pt">2027 and Thereafter</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">55,116</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzKQr_zSTnNSiTwjE7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: center">Total</td><td style="padding-bottom: 2.5pt; font-size: 10pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,803,032</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0pt; margin-bottom: 0pt"/> <p id="xdx_8AD_zONOgOLi4C0d" style="margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_891_ecustom--ScheduleOfLeasingArrangementsTableTextBlock_zgftsdxT6jbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes our leasing arrangements related to the Company’s healthcare facilities at September 30, 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_zZL2TElz6WO" style="display: none">SCHEDULE OF LEASING ARRANGEMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: center">Monthly Lease</td><td style="font-size: 10pt"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Facility</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><span style="font-size: 10pt">Income <sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Lease Expiration</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Renewal Option if any</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 14%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Goodwill <sup id="xdx_F45_zUf8qCy6oTqg">(1)</sup></span></td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeasesIncomeStatementLeaseRevenue_c20220101__20220930__us-gaap--TypeOfArrangementAxis__us-gaap--GoodwillMember_fKDEp_zpUdbpwexvzj" style="width: 14%; font-size: 10pt; text-align: right" title="Monthly lease income">48,125</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 16%; font-size: 10pt; text-align: center"><span id="xdx_90B_eus-gaap--LeaseExpirationDate1_c20220101__20220930__us-gaap--TypeOfArrangementAxis__us-gaap--GoodwillMember_zTDOxxBscSBf" title="Lease expiration date">February 1, 2027</span></td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 48%; font-size: 10pt; text-align: center"><span id="xdx_90B_ecustom--LeaseRenewalOption_c20220101__20220930__us-gaap--TypeOfArrangementAxis__us-gaap--GoodwillMember_zPKGw6mzqrVb" title="Lease renewal option">Term may be extended for one additional five-year term.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td id="xdx_F00_zpPSVqzYHuDa" style="text-align: justify; width: 0.25in">(1)</td> <td id="xdx_F10_zBZQvMiCdBVj" style="text-align: justify">The lease became effective on February 1, 2017, and the facility began generating rental revenue thereafter.</td></tr> </table> 48125 2027-02-01 Term may be extended for one additional five-year term. <p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zURgek5q65yk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future cash payments for rent to be received during the initial terms of the leases for the next five years and thereafter are as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zjGlRUNqI3Fg" style="display: none">SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center">Years Ending September 30,</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220930_zGox8ssrGISc" style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzKQr_zBy49aBkYtXc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 82%; font-size: 10pt; text-align: center">2022</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">156,870</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzKQr_z7jddwu0bvte" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: center">2023</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">635,026</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzKQr_zLmkvfDUE5fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: center">2024</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">643,401</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzKQr_zS5VI18m5GO5" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: center">2025</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">651,954</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_maLOLLPzKQr_zF9rkOBsQNri" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: center">2026</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">660,665</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter_iI_pp0p0_maLOLLPzKQr_zCY63oekLi2f" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: center; padding-bottom: 1.5pt">2027 and Thereafter</td><td style="font-size: 10pt; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">55,116</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzKQr_zSTnNSiTwjE7" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: center">Total</td><td style="padding-bottom: 2.5pt; font-size: 10pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,803,032</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0pt; margin-bottom: 0pt"/> 156870 635026 643401 651954 660665 55116 2803032 <p id="xdx_808_eus-gaap--LegalMattersAndContingenciesTextBlock_ztZO7IKB8Uzi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>9. <span id="xdx_828_zDuai0pSBti3">LEGAL PROCEEDINGS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and/or its affiliated subsidiaries are or were involved in the following litigation:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Bailey v. GL Nursing, LLC, et. Al in the Circuit Court of Lonoke County, Arkansas, 23<sup>rd</sup> Circuit, </i>43CV-19-151.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2019, the Company’s wholly-owned subsidiary was named as a co-defendant in the action arising out of a claimed personal injury suffered by the plaintiff while a resident of the skilled nursing home owned, but not operated, by GL Nursing. As of this date, we have engaged legal counsel, but no further information is known regarding the merits of the claim. After initial inquiry, it does not appear that the lease operator of the facility had in effect general liability insurance covering the GL Nursing, as landlord, as required by the operating lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we simply were the owners of the property and not the operators, we believe that primary responsibility, if any, falls with the operator at the time. Under the terms of the lease, the operator has a duty to indemnify the Company, a claim which we intend to assert.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While it is too early to assess the Company’s exposure, we believe at this time that the likelihood of an adverse outcome is remote.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Thomas v. Edwards Redeemer Property Holdings, LLC, et.al., </i>District Court for Oklahoma County, Oklahoma, Case No. CJ 2016-2160.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This action arises from a personal injury claim brought by heirs of a former resident of our Edwards Redeemer facility, filed in April 2016. We are entitled to indemnification from the lease operator and should be covered under the lease operator’s general liability policy. As we are not the operators of the facility and believe we have indemnity coverage, we believe we have no exposure. The lease operator’s insurance carrier is providing a defense and indemnity and, as a result, we believe the likelihood of a material adverse result is remote.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Edwards Redeemer Property Holdings LLC v. Edwards Redeemer Healthcare &amp; Rehab, LLC, </i>District Court of Oklahoma County, State of Oklahoma, Case No. CJ-19-5883.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This action was brought by us against the former lease operator for breaching the lease agreement, removing all the patients, and closing the facility. On October 17, 2019, the Court entered an Order Appointing a Receiver. We have entered into a Settlement Agreement and Release with the Receiver and an Operations Transfer Agreement pursuant to which our newly formed subsidiary will acquire the assets and operations of the facility. In March 2021, the Court approved the Settlement Agreement and Operations Transfer Agreement, the skilled nursing license was assigned to the Company’s wholly-owned subsidiary Park Place Health, LLC and the Company reopened the facility under the name Park Place Health. This matter is considered resolved.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Oliphant v. Global Eastman, LLC, et.al., State Court of Cobb County, State of Georgia, </i>Civil Action No. 20-A-3983</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This is a personal injury lawsuit against various defendants arising out of the death of a patient of the Eastman Healthcare &amp; Rehab Center (the “Facility”). At all relevant times, the Facility was owned by the Company’s wholly owned subsidiary Dodge NH, LLC and leased to Eastman Health &amp; Rehab LLC, an affiliate of Cadence Healthcare, as lease operator. Neither the Company nor any affiliate of the Company had any involvement in patient care at the time of the incident for which complaint was made. The Company relies upon well-settled Georgia law that a landlord has no liability for patient care. The landlord is Dodge NH, LLC. Global Eastman, LLC was not formed as a legal entity during the period of the incident and did not assume the past liabilities as part of the OTA with the receivership of Eastman Healthcare &amp; Rehab LLC which was effective July 1, 2020. Global Eastman LLC was formed on November 21, 2019. Plaintiff has dismissed these claims with prejudice, and the Company has filed a Motion to be awarded attorney’s fees and costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In the matter of Austin.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 23, 2020, we received written notice from an attorney of the intent to assert an action for damages against Dodge NH, LLC, which is our subsidiary that owns the nursing facility in Eastman Georgia. The action arises from the shooting death outside of the facility of a woman that worked for our cleaning contractor that cleaned the nursing home. The woman was shot by her former boyfriend who then committed suicide. The incident occurred in December 2019 when the facility was operated by a third-party operator who was in receivership. We do not believe there is any basis in law or fact to hold the owner of the real estate liable, and as a result management has concluded that the likelihood of a material adverse result is remote.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In re: Providence HR, LLC v. CRM of Warrenton, LLC, United States Bankruptcy Court, Middle District of Georgia, Macon Division, Case No. 21-50201</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In re: ALT/WARR, LLC v. CRM of Sparta, LLC, United States Bankruptcy Court, Middle District of Georgia, Macon Division, Case No. 21-50200</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These are companion cases arising out of the Company’s election to terminate the operating leases on the Company’s two facilities in Warrenton and Sparta, Georgia. The Company served a Notice of Termination on each facility and in response the lease operators filed voluntary petitions under Chapter 11 of the US Bankruptcy Code. The Company filed Motions for Relief from Stay which was heard by the Court on March 22, 2021. By Order of the Court, the hearing was continued to May 25, 2021. The Court entered an interim Order requiring the lease operators to comply with their leases, including payment of rent, pending the next hearing. In June 2021, the Court entered an Order approving a Lease Termination Agreement, Operations Transfer Agreement and Interim Management Agreement which had been negotiated by the Company and the two operating tenants, CRM of Warrenton, LLC and CRM of Sparta, LLC. The Lease Termination Agreement and Operations Transfer Agreement became effective upon the granting of a new License by the State of Georgia for the Warrenton and Sparta facilities to two newly formed wholly owned operating subsidiaries of the Company: Selectis Sparta, LLC and Selectis Warrenton, LLC.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>High Street Nursing, LLC v. Ohio Department of Health, Court of Common Pleas, Franklin County, Ohio, Case No. 21 CV 6559.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company brought this action through its wholly owned subsidiary High Street Nursing, LLC (“High Street”) against the Ohio Department of Health (ODH) to prevent the Department of Health from revoking the state issued license covering the Meadowview skilled nursing facility located in Seville, Ohio. The facility is owned by High Street and was leased to a third-party operator who abandoned the facility. The Department of Health is trying to revoke the license of the former operator and has refused our request to transfer the license to a new operator controlled by the Company. Our Motion for Temporary Injunction was denied by the Court. We have subsequently filed a Motion for Preliminary and Permanent Injunction which is pending. Our claims against the Department of Health are based upon our property interests in the facility and raise issues of unlawful condemnation and eminent domain. No prediction can be made regarding the outcome of this matter; but the Company will pursue the ODH to the fullest extent.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>In the Matter of Hunter</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received a spoliation letter from an attorney dated October 8, 2021, advising of the intent to assert a personal injury claim against our operating subsidiary Glen Eagle Health &amp; Rehab, LLC which operates our skilled nursing facility in Abbeville, Georgia. We have been provided no further information, but after reviewing the information we believe at this time that the likelihood of an adverse outcome is remote.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Edwards Redeemer Property Holdings, LLC, et.al. v. Buildstrong Roofing and Construction, Inc.,et.al. District Court of and for Tulsa County, Oklahoma, Case No. CJ-202</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Company brought this action against a contractor that performed work at our Park Place facility in Oklahoma City and our Southern Hills SNF in Tulsa. The claims are based upon negligence and breach of contract for subpar work due to defects in materials, workmanship and Buildstrong not providing services for which they received payment. The case is pending.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tara Gaspar, et.al v. GL Nursing, LLC, et.al., Circuit Court of Lonoke County, Arkansas, Civil Division, Case. No. 43CV-21-864.</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This case is a personal injury action in which our subsidiary GL Nursing, LLC was joined as a defendant because it is the owner of the property leased to an operating tenant. The action is based upon quality of care over which we had no control. We believe that our risk of a material adverse outcome is remote.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_z3qQWizTzoU2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>10. <span id="xdx_822_zuMJngNYgFEb">SUBSEQUENT EVENTS</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 4, 2022, the Company changed its independent registered public accountants by engaging Marcum LLP as the company’s independent registered public accounting firm for the year ended December 31, 2022. Marcum LLP will also review the Company’s interim report as of and for the period ended September 30, 2022. Haynie &amp; Company had previously served as the Company’s independent registered public accountants for the year ended December 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 17, 2022, Clifford Neuman resigned as a director and Andy Sink was appointed to fill the vacancy created by Mr. Neuman’s resignation. It was determined that Mr. Neuman did not qualify as an “independent” director within the meaning of Nasdaq regulations; and Mr. Neuman agreed to resign from the Board to facilitate the Company’s efforts to up list to the Nasdaq Stock Market.</p> The mortgage loan collateralized by this property is 80% guaranteed by the USDA and requires an annual renewal fee payable in the amount of 0.25% of the USDA guaranteed portion of the outstanding principal balance as of December 31 of each year. Guarantors under the mortgage loan include Christopher Brogdon. Mr. Brogdon has assumed operations of the facility and is making payments of principal and interest on the loan on our behalf in lieu of paying rent on the facility to us. During the nine months ended September 30, 2022, the Company recognized other income of $118,716 for repayments on the loan. The Company has refinanced two of its mortgages that would have matured in June and October of 2021 amounting to $2,961,167 and $3,289,595, to extend their maturity dates to May 2024 for both. The Company refinanced all three mortgages in July 2021, that would have matured in June and July of 2021 amounting to $2,065,969, $750,000, and $500,000, to extend their maturity dates to June, 2027 for all three. Additionally, the Company has refinanced the primary mortgage at the Southern Hills Campus, for 35 years at 2.38% The lease became effective on February 1, 2017, and the facility began generating rental revenue thereafter. EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 233 219 1 true 49 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://selectis.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://selectis.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://selectis.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://selectis.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) Sheet http://selectis.com/role/StatementsOfChangesInEquity Condensed Consolidated Statements of Changes in Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://selectis.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://selectis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://selectis.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://selectis.com/role/PropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 9 false false R10.htm 00000010 - Disclosure - INVESTMENTS IN DEBT SECURITIES Sheet http://selectis.com/role/InvestmentsInDebtSecurities INVESTMENTS IN DEBT SECURITIES Notes 10 false false R11.htm 00000011 - Disclosure - DEBT AND DEBT - RELATED PARTIES Sheet http://selectis.com/role/DebtAndDebt-RelatedParties DEBT AND DEBT - RELATED PARTIES Notes 11 false false R12.htm 00000012 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://selectis.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 12 false false R13.htm 00000013 - Disclosure - OTHER CURRENT LIABILITY Sheet http://selectis.com/role/OtherCurrentLiability OTHER CURRENT LIABILITY Notes 13 false false R14.htm 00000014 - Disclosure - RELATED PARTIES Sheet http://selectis.com/role/RelatedParties RELATED PARTIES Notes 14 false false R15.htm 00000015 - Disclosure - FACILITY LEASES Sheet http://selectis.com/role/FacilityLeases FACILITY LEASES Notes 15 false false R16.htm 00000016 - Disclosure - LEGAL PROCEEDINGS Sheet http://selectis.com/role/LegalProceedings LEGAL PROCEEDINGS Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://selectis.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://selectis.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://selectis.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://selectis.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://selectis.com/role/PropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://selectis.com/role/PropertyAndEquipmentNet 20 false false R21.htm 00000021 - Disclosure - INVESTMENTS IN DEBT SECURITIES (Tables) Sheet http://selectis.com/role/InvestmentsInDebtSecuritiesTables INVESTMENTS IN DEBT SECURITIES (Tables) Tables http://selectis.com/role/InvestmentsInDebtSecurities 21 false false R22.htm 00000022 - Disclosure - DEBT AND DEBT - RELATED PARTIES (Tables) Sheet http://selectis.com/role/DebtAndDebt-RelatedPartiesTables DEBT AND DEBT - RELATED PARTIES (Tables) Tables http://selectis.com/role/DebtAndDebt-RelatedParties 22 false false R23.htm 00000023 - Disclosure - STOCKHOLDERS??? EQUITY (Tables) Sheet http://selectis.com/role/StockholdersEquityTables STOCKHOLDERS??? EQUITY (Tables) Tables http://selectis.com/role/StockholdersEquity 23 false false R24.htm 00000024 - Disclosure - FACILITY LEASES (Tables) Sheet http://selectis.com/role/FacilityLeasesTables FACILITY LEASES (Tables) Tables http://selectis.com/role/FacilityLeases 24 false false R25.htm 00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://selectis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://selectis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF RESTATEMENT (Details) Sheet http://selectis.com/role/ScheduleOfRestatementDetails SCHEDULE OF RESTATEMENT (Details) Details 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE (Details) Sheet http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE (Details) Details 27 false false R28.htm 00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://selectis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://selectis.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) Sheet http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) Details 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES (Details) Sheet http://selectis.com/role/ScheduleOfInvestmentsInMarketableSecuritiesDetails SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES (Details) Details 30 false false R31.htm 00000031 - Disclosure - INVESTMENTS IN DEBT SECURITIES (Details Narrative) Sheet http://selectis.com/role/InvestmentsInDebtSecuritiesDetailsNarrative INVESTMENTS IN DEBT SECURITIES (Details Narrative) Details http://selectis.com/role/InvestmentsInDebtSecuritiesTables 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF DEBT INSTRUMENTS (Details) Sheet http://selectis.com/role/ScheduleOfDebtInstrumentsDetails SCHEDULE OF DEBT INSTRUMENTS (Details) Details 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF MORTGAGE LOAN DEBT (Details) Sheet http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails SCHEDULE OF MORTGAGE LOAN DEBT (Details) Details 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF MORTGAGE LOAN DEBT (Details) (Parenthetical) Sheet http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical SCHEDULE OF MORTGAGE LOAN DEBT (Details) (Parenthetical) Details 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF OTHER DEBT (Details) Sheet http://selectis.com/role/ScheduleOfOtherDebtDetails SCHEDULE OF OTHER DEBT (Details) Details 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS (Details) Notes http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS (Details) Details 36 false false R37.htm 00000037 - Disclosure - DEBT AND DEBT - RELATED PARTIES (Details Narrative) Sheet http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative DEBT AND DEBT - RELATED PARTIES (Details Narrative) Details http://selectis.com/role/DebtAndDebt-RelatedPartiesTables 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY (Details) Sheet http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY (Details) Details 38 false false R39.htm 00000039 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://selectis.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://selectis.com/role/StockholdersEquityTables 39 false false R40.htm 00000040 - Disclosure - OTHER CURRENT LIABILITY (Details Narrative) Sheet http://selectis.com/role/OtherCurrentLiabilityDetailsNarrative OTHER CURRENT LIABILITY (Details Narrative) Details http://selectis.com/role/OtherCurrentLiability 40 false false R41.htm 00000041 - Disclosure - RELATED PARTIES (Details Narrative) Sheet http://selectis.com/role/RelatedPartiesDetailsNarrative RELATED PARTIES (Details Narrative) Details http://selectis.com/role/RelatedParties 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF LEASING ARRANGEMENTS (Details) Sheet http://selectis.com/role/ScheduleOfLeasingArrangementsDetails SCHEDULE OF LEASING ARRANGEMENTS (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE (Details) Sheet http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE (Details) Details 43 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm gbcs-20220930.xsd gbcs-20220930_cal.xml gbcs-20220930_def.xml gbcs-20220930_lab.xml gbcs-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 738, "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 233, "dts": { "calculationLink": { "local": [ "gbcs-20220930_cal.xml" ] }, "definitionLink": { "local": [ "gbcs-20220930_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "gbcs-20220930_lab.xml" ] }, "presentationLink": { "local": [ "gbcs-20220930_pre.xml" ] }, "schema": { "local": [ "gbcs-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 383, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 112, "http://selectis.com/20220930": 37, "http://xbrl.sec.gov/dei/2022": 4, "total": 153 }, "keyCustom": 37, "keyStandard": 182, "memberCustom": 26, "memberStandard": 23, "nsprefix": "GBCS", "nsuri": "http://selectis.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://selectis.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - INVESTMENTS IN DEBT SECURITIES", "menuCat": "Notes", "order": "10", "role": "http://selectis.com/role/InvestmentsInDebtSecurities", "shortName": "INVESTMENTS IN DEBT SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - DEBT AND DEBT - RELATED PARTIES", "menuCat": "Notes", "order": "11", "role": "http://selectis.com/role/DebtAndDebt-RelatedParties", "shortName": "DEBT AND DEBT - RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "12", "role": "http://selectis.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - OTHER CURRENT LIABILITY", "menuCat": "Notes", "order": "13", "role": "http://selectis.com/role/OtherCurrentLiability", "shortName": "OTHER CURRENT LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - RELATED PARTIES", "menuCat": "Notes", "order": "14", "role": "http://selectis.com/role/RelatedParties", "shortName": "RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - FACILITY LEASES", "menuCat": "Notes", "order": "15", "role": "http://selectis.com/role/FacilityLeases", "shortName": "FACILITY LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - LEGAL PROCEEDINGS", "menuCat": "Notes", "order": "16", "role": "http://selectis.com/role/LegalProceedings", "shortName": "LEGAL PROCEEDINGS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "17", "role": "http://selectis.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "18", "role": "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingEstimateTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "19", "role": "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingEstimateTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://selectis.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "menuCat": "Tables", "order": "20", "role": "http://selectis.com/role/PropertyAndEquipmentNetTables", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - INVESTMENTS IN DEBT SECURITIES (Tables)", "menuCat": "Tables", "order": "21", "role": "http://selectis.com/role/InvestmentsInDebtSecuritiesTables", "shortName": "INVESTMENTS IN DEBT SECURITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - DEBT AND DEBT - RELATED PARTIES (Tables)", "menuCat": "Tables", "order": "22", "role": "http://selectis.com/role/DebtAndDebt-RelatedPartiesTables", "shortName": "DEBT AND DEBT - RELATED PARTIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)", "menuCat": "Tables", "order": "23", "role": "http://selectis.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "GBCS:ScheduleOfLeasingArrangementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - FACILITY LEASES (Tables)", "menuCat": "Tables", "order": "24", "role": "http://selectis.com/role/FacilityLeasesTables", "shortName": "FACILITY LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "GBCS:ScheduleOfLeasingArrangementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "25", "role": "http://selectis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "-5", "lang": null, "name": "GBCS:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherCostAndExpenseOperating", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF RESTATEMENT (Details)", "menuCat": "Details", "order": "26", "role": "http://selectis.com/role/ScheduleOfRestatementDetails", "shortName": "SCHEDULE OF RESTATEMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ChangeInAccountingEstimateTextBlock", "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-06-30_srt_ScenarioPreviouslyReportedMember", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE (Details)", "menuCat": "Details", "order": "27", "role": "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails", "shortName": "SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "lang": null, "name": "GBCS:PreferredStockDividendsAndOtherAdjustmentsBasic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31", "decimals": "0", "first": true, "lang": null, "name": "GBCS:MisstatementAdjustmentErrorAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-03-31", "decimals": "0", "first": true, "lang": null, "name": "GBCS:MisstatementAdjustmentErrorAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)", "menuCat": "Details", "order": "29", "role": "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "GBCS:DebtDiscountOfRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://selectis.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "GBCS:DebtDiscountOfRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_custom_StateandMunicipalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES (Details)", "menuCat": "Details", "order": "30", "role": "http://selectis.com/role/ScheduleOfInvestmentsInMarketableSecuritiesDetails", "shortName": "SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_custom_StateandMunicipalMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - INVESTMENTS IN DEBT SECURITIES (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://selectis.com/role/InvestmentsInDebtSecuritiesDetailsNarrative", "shortName": "INVESTMENTS IN DEBT SECURITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SCHEDULE OF DEBT INSTRUMENTS (Details)", "menuCat": "Details", "order": "32", "role": "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails", "shortName": "SCHEDULE OF DEBT INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfParticipatingMortgageLoansTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_custom_MortgageLoansMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "Integer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - SCHEDULE OF MORTGAGE LOAN DEBT (Details)", "menuCat": "Details", "order": "33", "role": "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails", "shortName": "SCHEDULE OF MORTGAGE LOAN DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfParticipatingMortgageLoansTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_custom_MortgageLoansMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "Integer", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "link:footnote", "td", "tr", "table", "us-gaap:ScheduleOfParticipatingMortgageLoansTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfFirstMortgageBond", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF MORTGAGE LOAN DEBT (Details) (Parenthetical)", "menuCat": "Details", "order": "34", "role": "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical", "shortName": "SCHEDULE OF MORTGAGE LOAN DEBT (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "link:footnote", "td", "tr", "table", "us-gaap:ScheduleOfParticipatingMortgageLoansTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfFirstMortgageBond", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF OTHER DEBT (Details)", "menuCat": "Details", "order": "35", "role": "http://selectis.com/role/ScheduleOfOtherDebtDetails", "shortName": "SCHEDULE OF OTHER DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "GBCS:ScheduleOfOtherDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_custom_OtherDebtMember", "decimals": "0", "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS (Details)", "menuCat": "Details", "order": "36", "role": "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails", "shortName": "SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_custom_TenPercentageSeniorSecuredPromissoryNoteOneMember", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "td", "tr", "table", "us-gaap:ScheduleOfParticipatingMortgageLoansTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-07-012021-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - DEBT AND DEBT - RELATED PARTIES (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative", "shortName": "DEBT AND DEBT - RELATED PARTIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "lang": null, "name": "GBCS:IncrementalIncreaseInFairValueOfDebtDiscount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY (Details)", "menuCat": "Details", "order": "38", "role": "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails", "shortName": "SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://selectis.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://selectis.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-09-30", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilitiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - OTHER CURRENT LIABILITY (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://selectis.com/role/OtherCurrentLiabilityDetailsNarrative", "shortName": "OTHER CURRENT LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_custom_MrCliffordNeumanMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - RELATED PARTIES (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://selectis.com/role/RelatedPartiesDetailsNarrative", "shortName": "RELATED PARTIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30_custom_MrCliffordNeumanMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "GBCS:ScheduleOfLeasingArrangementsTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-09-30_us-gaap_GoodwillMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF LEASING ARRANGEMENTS (Details)", "menuCat": "Details", "order": "42", "role": "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails", "shortName": "SCHEDULE OF LEASING ARRANGEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "GBCS:ScheduleOfLeasingArrangementsTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-012022-09-30_us-gaap_GoodwillMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesIncomeStatementLeaseRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE (Details)", "menuCat": "Details", "order": "43", "role": "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails", "shortName": "SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesAPreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://selectis.com/role/StatementsOfChangesInEquity", "shortName": "Condensed Consolidated Statements of Changes in Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-01-012021-03-31_us-gaap_RetainedEarningsMember", "decimals": "0", "lang": null, "name": "us-gaap:DividendsPreferredStockStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-07-012022-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://selectis.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": "0", "lang": null, "name": "GBCS:OtherIncomeFromPartialSettlementOfDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://selectis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://selectis.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - PROPERTY AND EQUIPMENT, NET", "menuCat": "Notes", "order": "9", "role": "http://selectis.com/role/PropertyAndEquipmentNet", "shortName": "PROPERTY AND EQUIPMENT, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-01-01to2022-09-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 49, "tag": { "GBCS_AdjustedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjusted [Member]", "label": "Adjusted [Member]" } } }, "localname": "AdjustedMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "domainItemType" }, "GBCS_AnnualRenewalFeePayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual renewal fee payable.", "label": "Annual renewal fee payable" } } }, "localname": "AnnualRenewalFeePayable", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "percentItemType" }, "GBCS_CashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless exercise of warrants.", "label": "Cashless Exercise of Warrants" } } }, "localname": "CashlessExerciseOfWarrants", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "GBCS_CashlessExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cashless exercise of warrants shares.", "label": "Cashless Exercise of Warrants, shares" } } }, "localname": "CashlessExerciseOfWarrantsShares", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "GBCS_ConversionOfPreferredShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of preferred shares.", "label": "Conversion of preferred shares" } } }, "localname": "ConversionOfPreferredShares", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "sharesItemType" }, "GBCS_DebtDiscountOfRelatedParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt discount of related parties .", "label": "Debt discount of related parties" } } }, "localname": "DebtDiscountOfRelatedParties", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "GBCS_DebtInstrumentExtendedMaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument extended maturity date.", "label": "Debt instrument extended maturity date" } } }, "localname": "DebtInstrumentExtendedMaturityDate", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "dateItemType" }, "GBCS_DebtLongtermAndShorttermCombinedNetAmount": { "auth_ref": [], "calculation": { "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt long term and short term combined net amount.", "label": "DebtLongtermAndShorttermCombinedNetAmount", "totalLabel": "Debt Instrument, Net of Discount" } } }, "localname": "DebtLongtermAndShorttermCombinedNetAmount", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "GBCS_DenominatorForDilutedEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominator for diluted earnings per share [Abstract]", "label": "Denominator for diluted earnings per share:" } } }, "localname": "DenominatorForDilutedEarningsPerShareAbstract", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "stringItemType" }, "GBCS_DividendsDeclaredOnSeriesDPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Dividends declared on series D preferred stock.", "label": "Dividends Declared on Series D Preferred Stock" } } }, "localname": "DividendsDeclaredOnSeriesDPreferredStock", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "GBCS_EffectOfDilutiveSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effect of dilutive securities.", "label": "Effect of dilutive securities:" } } }, "localname": "EffectOfDilutiveSecurities", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "sharesItemType" }, "GBCS_ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eleven Percentage Senior Secured Promissory Notes Related Party [Member]", "label": "11% Senior Secured Promissory Notes Related Party [Member]" } } }, "localname": "ElevenPercentageSeniorSecuredPromissoryNotesRelatedPartyMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "domainItemType" }, "GBCS_ExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of warrants.", "label": "Exercise of warrants" } } }, "localname": "ExerciseOfWarrants", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "sharesItemType" }, "GBCS_FinancingOfInsurancePremiums": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing of insurance premiums.", "label": "Financing of Insurance Premiums" } } }, "localname": "FinancingOfInsurancePremiums", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "GBCS_FirstMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Mortgage Loan [Member]", "label": "First Mortgage Loan [Member]" } } }, "localname": "FirstMortgageLoanMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GBCS_FixedRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed Rate [Member]", "label": "Fixed Rate [Member]" } } }, "localname": "FixedRateMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GBCS_FixedRateMortgageLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fixed Rate Mortgage Loans [Member]" } } }, "localname": "FixedRateMortgageLoansMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "GBCS_FurnitureFixturesAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Furniture Fixtures And Equipment [Member]" } } }, "localname": "FurnitureFixturesAndEquipmentMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "GBCS_GainOnForgivenessFromPaycheckProtectionProgramLoan": { "auth_ref": [], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://selectis.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on forgiveness from PPP Loan.", "label": "GainOnForgivenessFromPaycheckProtectionProgramLoan", "negatedLabel": "Gain on Forgiveness of PPP Loan", "negatedTerseLabel": "Gain on Forgiveness from PPP Loan" } } }, "localname": "GainOnForgivenessFromPaycheckProtectionProgramLoan", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "GBCS_GainOnForgivenessOfPppLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on forgiveness of Loan.", "label": "Gain on Forgiveness of PPP Loan" } } }, "localname": "GainOnForgivenessOfPppLoan", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "GBCS_GoodwillNursingHomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Nursing Home [Member]", "label": "Goodwill Nursing Home [Member]" } } }, "localname": "GoodwillNursingHomeMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfOtherDebtDetails" ], "xbrltype": "domainItemType" }, "GBCS_GoodwillNursingHomeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill Nursing Home - Related Party [Member]", "label": "Goodwill Nursing Home - Related Party [Member]" } } }, "localname": "GoodwillNursingHomeOneMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfOtherDebtDetails" ], "xbrltype": "domainItemType" }, "GBCS_HealthcareGrantRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Healthcare Grant Revenue [Member]", "label": "Healthcare Grant Revenue [Member]" } } }, "localname": "HealthcareGrantRevenueMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "GBCS_HigherCallNursingCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Higher Call Nursing Center [Member]", "label": "Higher Call Nursing Center [Member]" } } }, "localname": "HigherCallNursingCenterMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfOtherDebtDetails" ], "xbrltype": "domainItemType" }, "GBCS_IncrementalIncreaseInFairValueOfDebtDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Incremental increase in fair value of debt discount.", "label": "Incremental increase in fair value of debt discount" } } }, "localname": "IncrementalIncreaseInFairValueOfDebtDiscount", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GBCS_InformationByCategoryOfDebtSecurityDomain": { "auth_ref": [], "localname": "InformationByCategoryOfDebtSecurityDomain", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfInvestmentsInMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "GBCS_IssuanceOfCommonStockForCashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock for cashless exercise of warrants.", "label": "Issuance of common stock for cashless exercise of warrants" } } }, "localname": "IssuanceOfCommonStockForCashlessExerciseOfWarrants", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "GBCS_LeaseRenewalOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Renewal Option.", "label": "Lease renewal option" } } }, "localname": "LeaseRenewalOption", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails" ], "xbrltype": "stringItemType" }, "GBCS_LeaseTerminationExpense": { "auth_ref": [], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease termination expense.", "label": "Lease Termination Expense" } } }, "localname": "LeaseTerminationExpense", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "GBCS_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter": { "auth_ref": [], "calculation": { "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due year four and thereafter.", "label": "2027 and Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereAfter", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails" ], "xbrltype": "monetaryItemType" }, "GBCS_ManagementFeeRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management Fee Revenue [Member]", "label": "Management Fee Revenue [Member]" } } }, "localname": "ManagementFeeRevenueMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "GBCS_MisstatementAdjustmentErrorAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Misstaement adjustment error amount.", "label": "Misstatement adjustment amount" } } }, "localname": "MisstatementAdjustmentErrorAmount", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "GBCS_MortgageLoanDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage loan description.", "label": "Mortgage loan description" } } }, "localname": "MortgageLoanDescription", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "stringItemType" }, "GBCS_MortgageLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage Loans [Member]", "label": "Mortgage Loans [Member]" } } }, "localname": "MortgageLoansMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails", "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GBCS_MrCliffordNeumanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Clifford Neuman [Member]", "label": "Mr Clifford Neuman [Member]" } } }, "localname": "MrCliffordNeumanMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GBCS_NetIncomeLossAttributableToDilutedGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net income loss attributable to diluted gross.", "label": "Net Income (Loss) Attributable to Common Stockholders" } } }, "localname": "NetIncomeLossAttributableToDilutedGross", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "monetaryItemType" }, "GBCS_OperatingIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating income.", "label": "Operating Income" } } }, "localname": "OperatingIncome", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "GBCS_OtherDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the amount of long-term and short-term debt outstanding, less the amount of unamortized discount, as of the indicated date.", "label": "Other Debt [Member]" } } }, "localname": "OtherDebtMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfOtherDebtDetails" ], "xbrltype": "domainItemType" }, "GBCS_OtherDebtSubordinatedSecuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Debt Sub ordinated Secured [Member]", "label": "Other Debt Sub ordinated Secured [Member]" } } }, "localname": "OtherDebtSubordinatedSecuredMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "GBCS_OtherDebtSubordinatedSecuredRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Debt Subordinated Secured Related Parties [Member]" } } }, "localname": "OtherDebtSubordinatedSecuredRelatedPartiesMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "GBCS_OtherDebtSubordinatedSecuredSellerFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Debt Subordinated Secured Seller Financing [Member]" } } }, "localname": "OtherDebtSubordinatedSecuredSellerFinancingMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "GBCS_OtherIncomeFromPartialSettlementOfDebt": { "auth_ref": [], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other income from partial settlement of debt.", "label": "OtherIncomeFromPartialSettlementOfDebt", "negatedLabel": "Other Income from Partial Settlement of Debt" } } }, "localname": "OtherIncomeFromPartialSettlementOfDebt", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "GBCS_PreferredStockDividendsAndOtherAdjustmentsBasic": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock dividends and other adjustments basic.", "label": "Series D Preferred Dividends" } } }, "localname": "PreferredStockDividendsAndOtherAdjustmentsBasic", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "monetaryItemType" }, "GBCS_PreferredStockDividendsAndOtherAdjustmentsDiluted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock dividends and other adjustments diluted.", "label": "PreferredStockDividendsAndOtherAdjustmentsDiluted", "negatedLabel": "Series D Preferred Dividends" } } }, "localname": "PreferredStockDividendsAndOtherAdjustmentsDiluted", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "monetaryItemType" }, "GBCS_ProceedsFromDebtDiscountWarrantsRelatedParties": { "auth_ref": [], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Discount - Warrants RP.", "label": "Debt Discount \u2013 Warrants RP" } } }, "localname": "ProceedsFromDebtDiscountWarrantsRelatedParties", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "GBCS_RentalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rental [Member]", "label": "Rental [Member]" } } }, "localname": "RentalMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "GBCS_ScheduleOfLeasingArrangementsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Leasing Arrangements [Table Text Block]", "label": "SCHEDULE OF LEASING ARRANGEMENTS" } } }, "localname": "ScheduleOfLeasingArrangementsTableTextBlock", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/FacilityLeasesTables" ], "xbrltype": "textBlockItemType" }, "GBCS_ScheduleOfOtherDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Other Debt [Table Text Block]", "label": "SCHEDULE OF OTHER DEBT" } } }, "localname": "ScheduleOfOtherDebtTableTextBlock", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "GBCS_SeniorSecuredNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Secured Notes [Member]", "label": "Senior Secured Notes [Member]" } } }, "localname": "SeniorSecuredNotesMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GBCS_SeniorSecuredPromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Secured Promissory Notes [Member]" } } }, "localname": "SeniorSecuredPromissoryNotesMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "GBCS_SeniorSecuredPromissoryNotesRelatedPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Senior Secured Promissory Notes Related Parties [Member]" } } }, "localname": "SeniorSecuredPromissoryNotesRelatedPartiesMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "GBCS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of non options equity instruments outstanding.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "GBCS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price for warrant.", "label": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "GBCS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of non options equity instruments exercises.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "GBCS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price of non options equity instruments expirations.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails" ], "xbrltype": "perShareItemType" }, "GBCS_StateandMunicipalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State and Municipal [Member]", "label": "State and Municipal [Member]" } } }, "localname": "StateandMunicipalMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfInvestmentsInMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "GBCS_StockIssuedDuringPeriodSharesIssuedForLossOnForgivenessOfDebtNet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss on Forgiveness of Debt, net", "label": "Loss on Forgiveness of Debt" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForLossOnForgivenessOfDebtNet", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "GBCS_TenPercentageSeniorSecuredPromissoryNoteOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "10% Senior Secured Promissory Note One [Member]", "label": "10% Senior Secured Promissory Note One [Member]" } } }, "localname": "TenPercentageSeniorSecuredPromissoryNoteOneMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "domainItemType" }, "GBCS_ThirdMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Mortgage Loan [Member]", "label": "Third Mortgage Loan [Member]" } } }, "localname": "ThirdMortgageLoanMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "domainItemType" }, "GBCS_UsdaGuaranteedRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "USDA guaranteed rate.", "label": "USDA guaranteed rate" } } }, "localname": "UsdaGuaranteedRate", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "percentItemType" }, "GBCS_VariableRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate [Member]", "label": "Variable Rate [Member]" } } }, "localname": "VariableRateMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "GBCS_VariableRateMortgageLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Variable Rate Mortgage Loans [Member]" } } }, "localname": "VariableRateMortgageLoansMember", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "GBCS_WeightedAverageCommonSharesOutstandingDilutedEffectOfDilutiveSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average common shares outstanding diluted effect of dilutive securities", "label": "Weighted Average Common Shares Outstanding - Diluted" } } }, "localname": "WeightedAverageCommonSharesOutstandingDilutedEffectOfDilutiveSecurities", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "sharesItemType" }, "GBCS_WeightedAverageNumberOfDilutedSharesOutstandingExceptEffectOfDilutiveSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of diluted shares outstanding except effect of dilutive securities.", "label": "Weighted Average Common Shares Outstanding - Basic" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstandingExceptEffectOfDilutiveSecurities", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "sharesItemType" }, "GBCS_WorkingCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Working capital.", "label": "Working Capital" } } }, "localname": "WorkingCapital", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "GBCS_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Working capital deficit.", "label": "Working capital deficit", "negatedLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://selectis.com/20220930", "presentation": [ "http://selectis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r458", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://selectis.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r234", "r235", "r236", "r237", "r299", "r374", "r393", "r420", "r421", "r436", "r439", "r445", "r515", "r531", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r234", "r235", "r236", "r237", "r299", "r374", "r393", "r420", "r421", "r436", "r439", "r445", "r515", "r531", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r212", "r375", "r437", "r443", "r511", "r512", "r518", "r538" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r212", "r375", "r437", "r443", "r511", "r512", "r518", "r538" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r234", "r235", "r236", "r237", "r297", "r299", "r301", "r302", "r303", "r350", "r374", "r393", "r420", "r421", "r436", "r439", "r445", "r510", "r515", "r532", "r533", "r534", "r535", "r536" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r234", "r235", "r236", "r237", "r297", "r299", "r301", "r302", "r303", "r350", "r374", "r393", "r420", "r421", "r436", "r439", "r445", "r510", "r515", "r532", "r533", "r534", "r535", "r536" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r164", "r165", "r166", "r175", "r176", "r195", "r319", "r320", "r487", "r488", "r489", "r490", "r492", "r495", "r496" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r129", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r195", "r222", "r223", "r308", "r318", "r319", "r320", "r321", "r332", "r334", "r335", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r129", "r164", "r165", "r166", "r168", "r169", "r170", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r180", "r195", "r222", "r223", "r308", "r318", "r319", "r320", "r321", "r332", "r334", "r335", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403" ], "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r129", "r164", "r166", "r168", "r169", "r170", "r171", "r179", "r195", "r308", "r318", "r319", "r320", "r332", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r491", "r492", "r493", "r494", "r495", "r505", "r506", "r522", "r526", "r527" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r213", "r214", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r438", "r444", "r518" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r213", "r214", "r406", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r438", "r444", "r518" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails" ], "xbrltype": "stringItemType" }, "stpr_AR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ARKANSAS" } } }, "localname": "AR", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails" ], "xbrltype": "domainItemType" }, "stpr_GA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GEORGIA" } } }, "localname": "GA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails" ], "xbrltype": "domainItemType" }, "stpr_OH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OHIO" } } }, "localname": "OH", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails" ], "xbrltype": "domainItemType" }, "stpr_OK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OKLAHOMA" } } }, "localname": "OK", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r12", "r99", "r100", "r482" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable \u2013 Related Parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r216", "r217" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net of allowance", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r56", "r135" ], "calculation": { "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r147", "r148", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r442" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r304", "r305", "r306", "r484", "r485", "r486", "r521" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Purchase of Non-Controlling Interest" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by (Used in) Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r271", "r330", "r434", "r435", "r477" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Deferred Loan Costs and Debt Discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r102", "r116", "r137", "r162", "r203", "r206", "r210", "r220", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r247", "r248", "r310", "r314", "r322", "r442", "r513", "r514", "r529" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r131", "r143", "r162", "r220", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r247", "r248", "r310", "r314", "r322", "r442", "r513", "r514", "r529" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets", "verboseLabel": "Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r404", "r405", "r442", "r469" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r36", "r41", "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Total Cash and Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r36", "r41", "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and Cash Equivalents and Restricted Cash at End of the Period", "periodStartLabel": "Cash and Cash Equivalents and Restricted Cash at Beginning of the Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r36", "r92" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Decrease in Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Schedule of Non-Cash Investing and Financing Activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTextBlock": { "auth_ref": [ "r167", "r174" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting change in accounting estimate.", "label": "SCHEDULE OF RESTATEMENT" } } }, "localname": "ChangeInAccountingEstimateTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r140", "r141", "r142", "r162", "r184", "r185", "r192", "r194", "r197", "r198", "r220", "r238", "r241", "r242", "r243", "r247", "r248", "r277", "r278", "r281", "r285", "r292", "r322", "r422", "r467", "r479", "r497" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/BalanceSheetsParenthetical", "http://selectis.com/role/StatementsOfChangesInEquity", "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r107", "r121" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r484", "r485", "r521" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r68" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r442" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock - $0.05 Par Value; 800,000,000 Shares Authorized, 3,054,588 and 2,998,362 Shares Issued and Outstanding at September 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r87", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r64", "r160", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r265", "r272", "r273", "r275" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "DEBT AND DEBT - RELATED PARTIES" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r1", "r2", "r3", "r103", "r104", "r115", "r163", "r249", "r250", "r251", "r252", "r253", "r255", "r261", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r331", "r431", "r432", "r433", "r434", "r435", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails", "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical", "http://selectis.com/role/ScheduleOfOtherDebtDetails", "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r3", "r104", "r115", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r94", "r97", "r249", "r331", "r432", "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Face Amount", "verboseLabel": "Debt, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails", "http://selectis.com/role/ScheduleOfOtherDebtDetails", "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r19", "r250" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate", "verboseLabel": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt, Interest Rate" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfOtherDebtDetails", "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r144", "r431", "r523" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt, Maturity Date", "verboseLabel": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfOtherDebtDetails", "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r21", "r163", "r249", "r250", "r251", "r252", "r253", "r255", "r261", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r331", "r431", "r432", "r433", "r434", "r435", "r480" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails", "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical", "http://selectis.com/role/ScheduleOfOtherDebtDetails", "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r21", "r69", "r72", "r73", "r74", "r93", "r94", "r97", "r114", "r163", "r249", "r250", "r251", "r252", "r253", "r255", "r261", "r262", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r274", "r331", "r431", "r432", "r433", "r434", "r435", "r480" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r93", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Long term debt, net of discount, current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r93", "r97" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Long term debt, net of discount, non current" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "auth_ref": [ "r93", "r94", "r95", "r96", "r97", "r516" ], "calculation": { "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails": { "order": 2.0, "parentTag": "GBCS_DebtLongtermAndShorttermCombinedNetAmount", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount (premium).", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "negatedLabel": "Unamortized Discount and Debt Issuance Costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "calculation": { "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails": { "order": 1.0, "parentTag": "GBCS_DebtLongtermAndShorttermCombinedNetAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt Instrument, Gross" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": { "auth_ref": [ "r507" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Investments in Debt Securities", "verboseLabel": "Contractual maturity of held-to-maturity securities" } } }, "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/InvestmentsInDebtSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt weighted average interest rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r39", "r54" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation Expense (excluding Intangible Assets)" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r39", "r202" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://selectis.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation", "verboseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfCashFlows", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendDeclaredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution of earnings in the form of cash, property or capital stock declared by the board of directors to be distributed to shareholders.", "label": "Dividend Declared [Member]" } } }, "localname": "DividendDeclaredMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock.", "label": "Dividends [Axis]" } } }, "localname": "DividendsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock." } } }, "localname": "DividendsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r75", "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividend, preferred stock" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical", "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPreferredStockStock": { "auth_ref": [ "r75", "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.", "label": "Dividends, Preferred Stock, Stock", "negatedLabel": "Series D Preferred Dividends" } } }, "localname": "DividendsPreferredStockStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r106", "r123", "r240", "r241", "r242", "r246", "r247", "r248", "r339", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r152", "r170", "r171", "r173", "r174", "r175", "r181", "r184", "r192", "r193", "r194", "r195", "r320", "r321", "r389", "r392", "r426" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic", "verboseLabel": "EPS" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails", "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss per Share Attributable to Common Stockholders:", "verboseLabel": "Net Income (Loss) per Share Attributable to Common Stockholders:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Common Shares Outstanding:" } } }, "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r152", "r170", "r171", "r173", "r174", "r175", "r184", "r192", "r193", "r194", "r195", "r320", "r321", "r389", "r392", "r426" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator for diluted earnings per share:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r48", "r49" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r68", "r128", "r147", "r148", "r149", "r164", "r165", "r166", "r169", "r176", "r179", "r196", "r221", "r294", "r304", "r305", "r306", "r307", "r308", "r319", "r323", "r324", "r325", "r326", "r327", "r328", "r335", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails", "http://selectis.com/role/StatementsOfChangesInEquity", "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r218", "r219", "r224", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r274", "r290", "r316", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r429", "r501", "r502", "r503", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r39", "r62", "r63" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Loss (Gain) on Extinguishment of Debt", "negatedLabel": "Loss (Gain) on Extinguishment of Debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r136", "r233", "r388", "r430", "r442", "r508", "r509" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HealthCareMember": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Service provided for prevention, maintenance, diagnosis or treatment of physical and mental health.", "label": "Health Care [Member]" } } }, "localname": "HealthCareMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue": { "auth_ref": [ "r52", "r111", "r500", "r537" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date.", "label": "Held-to-maturity fair value" } } }, "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/InvestmentsInDebtSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r38" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in Operating Assets and Liabilities, Net of Assets and Liabilities Acquired:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r38" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid Expenses and Other Assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r38" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts and Rents Receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "auth_ref": [ "r38" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in security deposits.", "label": "Lease Security Deposits" } } }, "localname": "IncreaseDecreaseInSecurityDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InformationByCategoryOfDebtSecurityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.", "label": "Debt Security Category [Axis]" } } }, "localname": "InformationByCategoryOfDebtSecurityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfInvestmentsInMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r95", "r110", "r150", "r201", "r329" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r154", "r157", "r158" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash Paid for Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r53", "r101", "r112", "r125", "r423" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "INVESTMENTS IN DEBT SECURITIES" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/InvestmentsInDebtSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "FACILITY LEASES" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/FacilityLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "LEGAL PROCEEDINGS" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/LegalProceedings" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF FUTURE CASH PAYMENTS FOR RENT RECEIVED DURING INITIAL TERM OF LEASE" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/FacilityLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r333" ], "calculation": { "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r333" ], "calculation": { "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r333" ], "calculation": { "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r333" ], "calculation": { "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r333" ], "calculation": { "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r525" ], "calculation": { "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfFutureCashPaymentsForRentReceivedDuringInitialTermOfLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r15", "r162", "r220", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r247", "r248", "r311", "r314", "r315", "r322", "r427", "r513", "r529", "r530" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities [Default Label]", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r105", "r119", "r442", "r481", "r504", "r524" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r132", "r162", "r220", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r247", "r248", "r311", "r314", "r315", "r322", "r442", "r513", "r529", "r530" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current Maturities of Long Term Debt, Net of Discount of $1,184 and $1,714, respectively", "verboseLabel": "Current Maturities of Long Term Debt, Net" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r139" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Debt, Net of discount of $933,737 and $452,593, respectively", "verboseLabel": "Debt, Net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r21", "r60" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "SCHEDULE OF INVESTMENTS IN MARKETABLE SECURITIES" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/InvestmentsInDebtSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r156" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash (Used in) Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r156" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r36", "r37", "r40" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash Used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r40", "r109", "r124", "r130", "r145", "r146", "r149", "r162", "r168", "r170", "r171", "r173", "r174", "r178", "r179", "r190", "r203", "r205", "r209", "r211", "r220", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r247", "r248", "r321", "r322", "r428", "r513" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income", "totalLabel": "Net Loss Attributable to Selectis Health, Inc.", "verboseLabel": "Net Income (Loss) Attributable to Selectis Health, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails", "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r88", "r90", "r145", "r146", "r178", "r179", "r474" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net Loss Attributable to Noncontrolling Interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r170", "r171", "r173", "r174", "r181", "r182", "r191", "r194", "r203", "r205", "r209", "r211", "r428" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Loss Attributable to Common Stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r183", "r186", "r187", "r188", "r189", "r191", "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net Income (Loss) Attributable to Common Stockholders - Diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r85", "r294", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total Other Expense", "totalLabel": "Total Other (Income) Expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (Income) Expense" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r3", "r104", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Debt, Principal Outstanding" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfOtherDebtDetails", "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r11", "r99", "r482" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Short term debt \u2013 Related Parties, Net of discount of $0 and $3,234, respectively", "verboseLabel": "Short term debt \u2013 Related Parties, Net" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesNoncurrent": { "auth_ref": [ "r22", "r98", "r482" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).", "label": "Debt- Related Parties", "verboseLabel": "Debt \u2013 Related Parties, Net" } } }, "localname": "NotesPayableRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Properties" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r203", "r205", "r209", "r211", "r428" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (Loss) from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesIncomeStatementLeaseRevenue": { "auth_ref": [ "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of revenue recognized for the period from operating leases, including minimum lease revenue, contingent revenue, percentage revenue and sublease revenue.", "label": "Monthly lease income" } } }, "localname": "OperatingLeasesIncomeStatementLeaseRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r0", "r46", "r50", "r91" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r27" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Property Taxes, Insurance and Other Operating" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r16", "r442" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Current Liability", "verboseLabel": "Other current liability" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/OtherCurrentLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "OTHER CURRENT LIABILITY" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/OtherCurrentLiability" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Income", "negatedLabel": "Other Income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": { "auth_ref": [ "r476" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.", "label": "Payments for Repurchase of Redeemable Noncontrolling Interest", "negatedLabel": "Purchase of Non-Controlling Interest" } } }, "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock": { "auth_ref": [ "r34" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.", "label": "Preferred stock, dividend paid", "negatedLabel": "Dividends Paid on Preferred Stock" } } }, "localname": "PaymentsOfDividendsPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows", "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r31" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital Expenditures for Property and Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockDividendsAndOtherAdjustments": { "auth_ref": [ "r47", "r499" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.", "label": "Preferred Stock Dividends and Other Adjustments", "negatedLabel": "Series D Preferred Dividends" } } }, "localname": "PreferredStockDividendsAndOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r4", "r277" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r4", "r277" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r4", "r442" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock value:" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r473" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expenses and Other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r32" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from stock offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r33" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "Proceeds from Issuance of Debt, Non-Related Party" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMortgageDeposits": { "auth_ref": [ "r475" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow received in association with a commitment to issue a mortgage.", "label": "Mortgage one" } } }, "localname": "ProceedsFromMortgageDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r130", "r145", "r146", "r155", "r162", "r168", "r178", "r179", "r203", "r205", "r209", "r211", "r220", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r247", "r248", "r309", "r312", "r313", "r321", "r322", "r390", "r428", "r440", "r441", "r474", "r513" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://selectis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss)", "totalLabel": "Net Loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfCashFlows", "http://selectis.com/role/StatementsOfChangesInEquity", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r58", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r55", "r134" ], "calculation": { "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and Equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r57", "r120", "r391", "r442" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and Equipment, Net", "totalLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r153", "r225" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://selectis.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for Bad Debts", "verboseLabel": "Provision for Bad Debt" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfCashFlows", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r298", "r338", "r339" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfOtherDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r298", "r338", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r528" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/RelatedPartiesDetailsNarrative", "http://selectis.com/role/ScheduleOfOtherDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r336", "r337", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTIES" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/RelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfFirstMortgageBond": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument issued, secured by a first mortgage deed of trust, containing a pledge of real property. The lender has the highest claim on the property in case of default.", "label": "Repayments of First Mortgage Bond" } } }, "localname": "RepaymentsOfFirstMortgageBond", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r35" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Payments on Debt, Non-Related Party" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of related party debt" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r41", "r45", "r133" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "periodEndLabel": "Restricted Cash" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r407", "r470", "r478" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r75", "r118", "r398", "r403", "r442" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r128", "r164", "r165", "r166", "r169", "r176", "r179", "r221", "r304", "r305", "r306", "r307", "r308", "r319", "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r199", "r200", "r204", "r207", "r208", "r212", "r213", "r215", "r295", "r296", "r375" ], "calculation": { "http://selectis.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total Revenue", "verboseLabel": "Healthcare Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r151", "r162", "r199", "r200", "r204", "r207", "r208", "r212", "r213", "r215", "r220", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r247", "r248", "r322", "r390", "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "verboseLabel": "Total Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r21", "r69", "r72", "r73", "r74", "r93", "r94", "r97", "r114", "r432", "r434", "r483" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "SCHEDULE OF DEBT INSTRUMENTS" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "SCHEDULE OF UNSECURED NOTES AND NOTES SECURED BY ALL ASSETS" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r498" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "SCHEDULE OF BASIC AND DILUTED EARNING PER SHARE" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfParticipatingMortgageLoansTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the terms and amounts of participation in loan arrangements.", "label": "SCHEDULE OF MORTGAGE LOAN DEBT" } } }, "localname": "ScheduleOfParticipatingMortgageLoansTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails", "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical", "http://selectis.com/role/ScheduleOfOtherDebtDetails", "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r65", "r66", "r67", "r69", "r70", "r71", "r72", "r73", "r74", "r75", "r140", "r141", "r142", "r197", "r277", "r278", "r279", "r281", "r285", "r290", "r292", "r436", "r467", "r479" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r76", "r78" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF COMMON STOCK WARRANTS ACTIVITY" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecondMortgageMember": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Loan secured by real property that is lower or subordinate to other loans on such property in the event of default by the borrower.", "label": "Second Mortgage [Member]" } } }, "localname": "SecondMortgageMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SecurityDepositLiability": { "auth_ref": [ "r122" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.", "label": "Lease Security Deposit" } } }, "localname": "SecurityDepositLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r471", "r472", "r517" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/BalanceSheetsParenthetical", "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [ "r471", "r472", "r517" ], "lang": { "en-us": { "role": { "documentation": "Series D preferred stock.", "label": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/BalanceSheetsParenthetical", "http://selectis.com/role/StatementsOfChangesInEquity", "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r38" ], "calculation": { "http://selectis.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock Based Compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Number of Warrants, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Number of Warrants, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Warrants, Ending Balance", "periodStartLabel": "Number of Warrants, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Aggregate intrinsic value of common stock warrants outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Common stock warrants term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetails", "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical", "http://selectis.com/role/ScheduleOfOtherDebtDetails", "http://selectis.com/role/ScheduleOfUnsecuredNotesAndNotesSecuredByAllAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r46", "r159" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r140", "r141", "r142", "r162", "r184", "r185", "r192", "r194", "r197", "r198", "r220", "r238", "r241", "r242", "r243", "r247", "r248", "r277", "r278", "r281", "r285", "r292", "r322", "r422", "r467", "r479", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/BalanceSheetsParenthetical", "http://selectis.com/role/StatementsOfChangesInEquity", "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r25", "r68", "r128", "r147", "r148", "r149", "r164", "r165", "r166", "r169", "r176", "r179", "r196", "r221", "r294", "r304", "r305", "r306", "r307", "r308", "r319", "r323", "r324", "r325", "r326", "r327", "r328", "r335", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails", "http://selectis.com/role/StatementsOfChangesInEquity", "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/BalanceSheetsParenthetical", "http://selectis.com/role/ScheduleOfInvestmentsInMarketableSecuritiesDetails", "http://selectis.com/role/StatementsOfChangesInEquity", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r164", "r165", "r166", "r196", "r375" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/BalanceSheetsParenthetical", "http://selectis.com/role/ScheduleOfInvestmentsInMarketableSecuritiesDetails", "http://selectis.com/role/StatementsOfChangesInEquity", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r42", "r43", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Issuance of common stock for cashless exercise of options" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r24", "r68", "r69", "r75", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common shares issued for debt, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r4", "r5", "r68", "r75" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock for cash, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r68", "r75" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Share Based Compensation - Restricted Stock Awards, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r4", "r5", "r68", "r75", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Cashless Exercise of Stock Options, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r25", "r68", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Common shares issued for debt" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r4", "r5", "r68", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock for cash" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r4", "r5", "r68", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Share Based Compensation \u2013 Restricted Stock Awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r25", "r68", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Cashless Exercise of Stock Options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r51", "r442", "r481", "r504", "r524" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Total Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfRestatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r85", "r86", "r89", "r128", "r129", "r148", "r164", "r165", "r166", "r169", "r176", "r221", "r294", "r304", "r305", "r306", "r307", "r308", "r319", "r323", "r324", "r328", "r335", "r395", "r396", "r481", "r504", "r524" ], "calculation": { "http://selectis.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Selectis Health, Inc. Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets", "http://selectis.com/role/StatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r77", "r161", "r278", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r294", "r317" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure of Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r108", "r138", "r424" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Held-to-maturity securities" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfInvestmentsInMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r218", "r219", "r274", "r290", "r316", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r501", "r502", "r503", "r539", "r540", "r541", "r542", "r543", "r544", "r545" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfMortgageLoanDebtDetailsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfLeasingArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/DebtAndDebt-RelatedPartiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfCommonStockWarrantsActivityDetails", "http://selectis.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r183", "r194" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r181", "r194" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "WASO", "terseLabel": "Weighted Average Common Shares Outstanding", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://selectis.com/role/ScheduleOfBasicAndDilutedEarningPerShareDetails", "http://selectis.com/role/ScheduleOfRestatementDetails", "http://selectis.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "https://asc.fasb.org/topic&trid=2208923", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r447": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r448": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r449": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r451": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r452": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r453": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r454": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r455": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r456": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r457": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r458": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r459": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r461": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r462": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r463": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r464": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r465": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r466": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99377297&loc=d3e10013-112621", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 61 0001493152-23-000793-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-000793-xbrl.zip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�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